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ABSTRACT 
Hyperlipidaemia describes increased plasma concentrations of cholesterol 
and/ or triglyceride and may arise from primary, often inherited defects in 
lipoprotein metabolism or appear secondary to systemic disease. The aim of 
this study was to characterise the abnormalities of lipoprotein metabolism 
responsible for hyperlipidaemia in the dog, to establish their effect upon the 
health of the individual, and to evaluate approaches to therapy. 
A combined ultracentrifugation/precipitation technique for the 
measurement of very low density lipoproteins (VLDL) , low density lipoproteins 
(LDL) and high density lipoproteins (HDL) was adapted and validated for use 
with canine plasma. Alternative methods of analysis were evaluated, but none 
of the commercially available precipitation reagents for the measurement of 
human lipoproteins were found to be suitable for use in the dog. Lipoprotein 
electrophoresis was useful in the investigation of hyperlipidaemic patients by 
allowing the identification of other lipoprotein classes, namely chylomicrons, 
HDLI and {3-VLDL. 
The effects of age, breed, sex and health status on lipoprotein 
concentrations in the dog were established. The HDL concentration was 
greater in entire females than males and certain disease processes were found 
to display characteristic lipoprotein abnormalities. Dogs with diabetes mellitus 
and hypothyroidism presented with defects in the metabolism of LDL and HDL 
and triglyceride-rich lipoproteins, while hyperadrenocorticism, obstructive 
jaundice and protein-losing nephropathies were predominantly associated with 
abnormalities of cholesterol metabolism. A decreased lipoprotein lipase 
activity was partially responsible for the hyperlipidaemia in hypothyroid dogs. 
Overt hyperlipidaemia was not identified in obese dogs, but aberrations of 
triglyceride metabolism were identified by kinetic analysis and found to be a 
result of decreased lipoprotein lipase activity. Impaired triglyceride clearance 
in the postprandial period may therefore predispose obese dogs to the 
development of acute pancreatitis. 
The lipoprotein abnormalities underlying idiopathic hyperlipidaemia 
were heterogeneous. Dogs with hypertriglyceridaemia presented with clinical 
signs believed to be precipitated by the hyperlipidaemia which resolved with 
reduction of the plasma lipid concentrations. Restriction of the dietary fat 
intake was successful in reducing the hyperlipidaemia in most animals, 
however, in some cases the hypertriglyceridaemia was found to be less 
responsive and required additional therapy with omega-3 fatty acids. 
It is concluded that the investigation of hyperlipidaemia, including 
quantitative and qualitative lipoprotein analysis, measurement of the activity of 
lipoprotein lipase and, where necessary, the performance of an intravenous fat 
tolerance test will allow the identification of underlying defects of lipoprotein 
metabolism and a rational approach to their therapy. 
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CHAPTER I 
INTRODUCTION 
CHAPTER I 
This thesis concerns the aetiology, characterisation and management of 
abnormalities of lipid metabolism in the dog. In this introduction an account of 
lipid metabolism, based on observations in man and the dog, is followed by a 
review of the literature regardin[ the clinical presentations of canine 
hyperlipidaemia. Lastly the aims of this study are defined. 
1. LIPIDS: THE REQUIREMENT FOR LIFE 
Lipids are water-insoluble biomolecules that are essential for normal 
physiological function. The neutral fats, or triglycerides, are the most abundant 
and are formed by the esterification of one molecule of glycerol with three fatty 
acids. Accumulation of triglycerides in cellular cytoplasm, particularly in 
adipocytes, provides an essential reserve of chemical energy for tissue 
requirements. The transfer of these stores in the form of non-esterified fatty 
acids (NEF A) to other tissues for oxidation provides a means of supplying 
energy according to cellular demand. 
The polar lipids, including cholesterol and phospholipids are major 
components of cellular membranes. Cholesterol appears to regulate and 
stabilise the fluidity of the outer cell membrane, thus determining its 
permeability (Brown and Goldstein 1986). In addition, this sterol is an 
essential precursor of steroid hormones, vitamins and bile acids. 
Cholesterol may exist in the free or esterified form and is formed by a 
complex process including the condensation of three units of acetyl Co-A to 
mevalonic acid, a reaction which is catalysed by the enzyme 3-hydroxy,3-
methylglutaryl-coenzyme A reductase (HMG-CoA reductase, EC 1.1.1.34). 
This is the rate-limiting step in cholesterol synthesis and is subject to a number 
of influencing factors, including the free cellular concentration. Since the liver 
produces approximately 50% of the body's cholesterol pool, it follows that the 
delivery of dietary cholesterol to the hepatocytes has a major regulatory effect 
on cholesterol synthesis. 
16 
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The phospholipids are derived from glycerol and contain both 
hydrophobic and hydrophilic regions, making them ideally suited to their role 
as the major components of membranes. One group of phospholipids, the 
lecithins, are found in both cell mtmbranes and extracellular fluid and are 
important in the esterification of cholesterol catalysed by the enzyme 
lecithin:cholesterol acyl transferase (LeAT). 
2. LIPOPROTEIN STRUCTURE AND FUNCTION 
It is necessary to transfer insoluble lipid substances through the aqueous phase 
of the plasma to their site of utilisation or storage. This is best achieved by the 
formation of lipid-protein complexes which act as vehicles for the transport of 
triglycerides, cholesterol and cholesteryl esters. Lipoproteins are composed of 
a surface coat, containing phospholipid, cholesterol and apolipoproteins (apo), 
surrounding a hydrophobic lipid centre containing triglycerides and cholesteryl 
esters. The apolipoproteins are specific proteins which direct the lipoproteins 
to their sites of metabolism by acting as ligands for cell surface receptors and as 
cofactors in the enzymatic hydrolysis of triglyceride and esterification of 
cholesterol. There are a number of discrete populations of lipoproteins which 
may be classified on the basis of their size, hydrated density, lipid and 
apolipoprotein composition, and electrophoretic mobility. The classes 
recognised in the dog are chylomicrons, very low density lipoproteins (VLDL), 
low density lipoproteins (LDL) and high density lipoproteins (HDL). The 
characteristics of these classes have been described by Mahley and Weisgraber 
(1974) (Fig. la. and lb.). 
17 
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Figure la. The physical characteristics of canine plasma lipoproteins. 
Lipoprotein 
Chylomicron 
VLDL 
LDL 
HDLI 
HDL2 
Diameter 
nm 
75-200 
26-80 
16-25 
10-35 
5-9 
Density 
g/ml 
<0.960 
0.930-1.006 
1.019-1.087 
1.025-1.100 
1.100-1.210 
Electrophoretic 
mobility 
ongm 
pre{3 
{3 
Ql2 
Qll 
Figure lb. The approximate lipid and protein compositions of canine plasma 
lipoproteins. 
Percentage of particle mass 
Lipoprotein Trig Chol PL Protein Apolipoproteins 
Chylomicron 90 3 5 2 B48, A, C, E 
VLDL 62 12 14 12 B lDO , C, E 
LDL 30 22 24 24 B 100 
36 40 23 E,A,C 
21 35 43 A,C,E 
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Each lipoprotein species has a specific function and co-ordinated 
interaction between lipoprotein populations and tissues ensures the efficient 
transport of lipid in response to physiologic demands. The chylomicrons, 
VLDL and LDL of the dog resemble those of man (Mahley and Weisgraber 
1974), while the subpopulations of HDL identified in the dog are peculiar to 
that species. LDL is quantitatively the most important cholesterol carrier in 
human plasma but the majority of cholesteryl esters in canine plasma are 
transported within HDL (Solyorn, Bradford and Furman 1971; Mahley and 
Weisgraber 1974). The following sections review the current understanding of 
the fate and function of the lipoprotein populations in the healthy individual, 
based on observations made in both man and the dog. 
2.1. Exogenous Lipid Transport 
As a carnivorous species, the natural diet of the dog has a high fat content, the 
majority of which is in the form of triglyceride with a small quantity of esterifed 
cholesterol and phospholipids. In the small intestine these lipids interact with 
bile acids to form micelles, creating an emulsion in the intestinal lumen. 
Pancreatic lipase is then responsible for the hydrolysis of triglycerides to 
monoacylglycerol and fatty acids, which are transported to the absorptive sites 
of the intestinal mucosa. Within the lumenal cells, the absorbed glyceride is re-
esterified and packaged into chylomicrons with the cholesterol, phospholipids 
and apolipoproteins A-I, A-II, A-IV and B (Durrington 1989). ApoB exists in 
two forms: apoB 100 which is synthesised by the liver and apoB 48 which is 
produced by the intestine and is the major structural component of 
chylomicrons. Following secretion from the lumenal cells, the chylomicrons 
enter the intestinal lacteals and lymphatics where they transfer to the thoracic 
duct and finally the circulation. Chylomicron synthesis and the secretion of 
apoB 48 therefore accompanies fat absorption and this lipoprotein class is 
detected in plasma during the postprandial period. 
19 
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Mter entering the circulation the chylomicrons deliver their core lipid to 
tissues by two mechanisms. On entering the plasma, apoC-II, apoC-III and 
apoE are transferred from HDL to the chylomicron surface. The acquisition of 
apoC-II, activates the enzyme lipoprotein lipase which hydrolyses the core 
triglycerides, liberating fatty acids for uptake by the peripheral tissues (Ben-
Aviram, Ben-Zeev, Lee, Haaga, Shively, Goers, Pederson, Reeve and Schotz 
1986). Lipoprotein lipase is bound to the endothelium of cardiac and skeletal 
muscle, and adipose tissue, where it regulates the provision of fatty acids for 
oxidation or storage, respectively. The activity of the enzyme is modulated by 
apoC-III, ensuring a regulated delivery of fatty acids to these tissues. The 
lipolytic process eviscerates the chylomicron particle and renders some of the 
surface layer (phospholipid, free cholesterol, apoA-I, apoA-II) redundant. This 
material is transferred back to HDL. Mter approximately 75% of the core 
triglyceride is hydrolysed, apoC-II is lost from the lipoprotein and lipolysis 
ceases, leaving the chylomicron remnant relatively deficient in triglyceride and 
enriched in cholesteryl ester (Mahley and Innerarity 1983). 
Removal of the chylomicron from the circulation is a function of the 
apoE receptor on hepatic parenchymal cell membranes (Bergman, Havel, 
Wolfe and Bohmer 1971; Sherrill, Innerarity and Mahley 1980). Delipidation 
of the chylomicron particle appears to result in a configurational change in 
apoE, conferring upon the protein the ability to be recognised by that hepatic 
receptor. In this way, the chylomicron is responsible for the delivery of dietary 
triglycerides to the tissues and cholesterol to the liver (Calvert and Abbey 
1985). 
In the dog, a protein with a relative molecular weight of 56 kDa has 
been isolated from hepatic membranes and is believed to be the functional 
receptor protein (Hui, Brecht, Hall, Friedman, Innerarity and Mahley 1986). In 
addition to the uptake of chylomicron remnants the receptor is also responsible 
for the uptake of $-VLDL and apoE-enriched HDL called HDLI (also known 
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as HDLc), two uruque lipoproteins which may be characteristic of 
hypercholesterolaemia in the dog (Mahley, Weisgraber and Innerarity 1974). 
Clearance of exogenous lipid from the circulation depends on a number 
of mechanisms, including the activity of lipoprotein lipase, the presence of 
apoC-II, the structural integrity of apoE and the activity of the hepatic apoE 
receptor. 
2.2. Hepatic Lipid Synthesis: Very Low Density Lipoproteins 
The liver is the central organ in the maintenance of plasma lipid levels and 
lipoprotein metabolism. Very low density lipoproteins, the major plasma 
vehicle of endogenous triglyceride are structurally similar to chylomicrons and 
are synthesised continuously by the liver. The major apolipoprotein of VLDL 
is apoB 100, which has a molecular weight approximately twice that of the 
protein synthesised in the intestine (apoB48). A single molecule of apoBlOO 
encircles the VLDL particle and remains with the lipoprotein throughout its 
lifetime in the circulation (Calvert and Abbey 1985). Following its synthesis in 
the endoplasmic reticulum, apoB is complexed with cholesteryl esters and 
transferred to the junction of the smooth endoplasmic reticulum, where 
triglycerides are added. Endogenous triglycerides incorporated into VLDL 
particles arise from the de novo synthesis of fatty acids, from extracellular 
NEF A, stored hepatic triglyceride or from lipoproteins processed by hepatic 
mechanisms (Gibbons 1990). After secretion by the Golgi apparatus, the 
VLDL enter the space of Disse where they acquire apoC and apoE from HDL. 
Upon entering the circulation, the core lipid of VLDL is subjected to the 
lipolytic action of lipoprotein lipase. This process results in partial delipidation 
of the lipoprotein; however, the final fate of the particle depends to a degree 
upon the size of the particle. Large, triglyceride-rich VLDL participate in 
further lipolytic reactions, followed by direct removal from the circulation via 
hepatic membrane receptors. Small cholesteryl ester enriched VLDL are 
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processed to intermediate density lipoproteins (IDL) , which may be removed 
directly from the circulation by the hepatic apoB,E receptor, or further 
modified to LDL by the action of a second endothelial lipase, hepatic lipase 
(Brown and Goldstein 1986). 
VLDL synthesis and secretion is influenced by nutritional and metabolic 
changes. The addition of insulin to hepatic cell cultures promotes the synthesis 
but prevents the secretion of triglyceride, resulting in accumulation of 
triglyceride within the cellular cytoplasm (Patsch, Prasad, Gotto and Bengtsson-
Olivecrona 1984). Secretion occurs following removal of the insulin (Gibbons 
1990). This may demonstrate a physiologic means of storing hepatic 
triglyceride in the postprandial period and allowing its release in the fasting 
period to provide an energy source for muscle. 
2.3. Intermediate Density Lipoproteins 
This class of lipoproteins is formed from VLDL particles through the lipolytic 
action of hepatic lipase. The species is therefore rich in cholesteryl esters and 
has been incriminated as one of the major atherogenic lipoprotein populations. 
The concentration of IDL in plasma is generally very low, reflecting its rapid 
conversion to LDL or direct removal from the circulation by the hepatic 
apoB,E receptor (Brown and Goldstein 1986). 
2.4. Low Density Lipoproteins 
LDL, the major cholesterol-carrying species in human plasma, is rich in 
cholesteryl esters and contains a single molecule of apoB 100 (Calvert and 
Abbey 1985). It is formed by the action of hepatic lipase on IDL and is 
considered to be the major participating lipoprotein in the process of 
atherosclerosis (Tyroler 1984). LDL is composed of a number of 
subpopulations which differ in their kinetic, chemical, physical and atherogenic 
properties (Babiak and Rudel 1987). 
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Clearance of LDL from the circulation is achieved by the apoB,E 
receptor which is expressed on hepatic and peripheral cell membranes (Mahley 
and Innerarity 1983). Once bound to the receptor glycoproteins, the LDL is 
rapidly internalised to form an endocytic vesicle which migrates through the 
cytoplasm and combines with a primary lysosome, forming a secondary 
lysosome. Release of cholesterol from the lysosome into the cell suppresses the 
HMGCoA reductase-catalysed synthesis of cholesterol and increases the 
activity of acylCoA:cholesterol acyl transferase activity (ACAT) which re-
esterifies the cholesterol. In addition, the apoB,E receptor is down-regulated, 
preventing excessive accumulation of cholesterol in the cell (Brown and 
Goldstein 1986). Mter delivery of the lipoprotein constituents to the lysosome 
the LDL receptor proteins are recycled to the cell membrane surface (Brown 
and Goldstein 1986). This receptor round-trip takes approximately 10 minutes 
and occurs irrespective of whether the receptor has collected LDL, ensuring a 
rapid response to alterations in cellular cholesterol requirements (Angel in, 
Raviola, Innerarity and Mahley 1983). The greatest number of LDL receptors 
are located on the liver which accounts for approximately 70% of whole body 
receptor activity (Brown and Goldstein 1986). In the dog, the expression of 
hepatic B,E receptors decreases as an animal matures, resulting in a higher 
fractional catabolic rate of LDL in young dogs, perhaps reflecting the metabolic 
requirements for growth (Mahley, Hui, Innerarity and Weisgraber 1981). The 
LDL receptor is also expressed on peripheral cells, in particular those with a 
high cholesterol demand, i.e., the adrenal glands and gonads, which require 
cholesterol for steroidogenesis (Mahley and Innerarity 1983). The circulating 
LDL which is not removed by the apoB,E receptor is cleared by non-regulated 
mechanisms including macrophage binding sites which display high affinity for 
chemically modified LDL (Mahley and Innerarity 1983). This is followed by 
the activation of macrophages which scavenge the lipid material. This non-
23 
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regulated uptake and accumulation of cholesteryl esters results in the formation 
of the typical lipid-laden "foam cells" which are thought to be the precursors of 
atherosclerotic lesions (Yamauchi and Hoff 1984). 
2.5. High Density Lipoproteins 
The HDL class shows marked heterogeneity, compnsmg of several 
subpopulations. In man two subclasses are found and are identified as HDL3 
and HDL2. The former is the mature particle formed by transfer of cholesterol 
from tissues and triglyceride-rich lipoproteins, while the latter is the 
triglyceride-rich species formed by transfer of triglycerides from other 
lipoproteins in exchange for cholesteryl ester. 
Nascent HDL is produced by the liver and intestine as a disc-like bilayer 
of phospholipid and protein, mainly apoA-I. Free cholesterol is drawn down a 
concentration gradient from the peripheral tissues into the disc (Nikkila 1978; 
Dory, Boquet, Hamilton, Sloop and Roheim 1985). Following entry to the 
lipoprotein, the cholesterol is esterified by the action of LCAT on the surface of 
the bilayer. The acquisition of additional cholesterol leads to progressive 
expansion of the lipoprotein core and to the development of the mature HDL 
particle. 
Many species, including man, possess a transfer protein which exchanges 
cholesteryl ester in the HDL core with triglyceride from the core of lower 
density lipoproteins. This exchange facilitates the formation of a triglyceride-
rich HDL particle (HDL2)' HDL2 is the preferred substrate of hepatic lipase, 
the action of which results in depletion of the core lipids with reformation of 
particles characteristic of the HDL3 population (Nestel 1987). Thus cycles of 
cholesterol uptake, triglyceride transfer and delipidation progress with 
distribution of HDL-derived cholesterol esters through lower density 
lipoprotein remnants to the liver. The exact nature of the uptake of HDL by 
the liver has not been determined, although the small proportion of particles 
24 
CHAPTER I 
which contain apoE may be directed to the apoB,E receptors. This completes 
the cycle of reverse cholesterol transport, i.e., the delivery of cholesterol from 
the peripheral tissues to the liver. 
In the dog, the metabolism of HDL displays import<mt differences from 
that of man. In this species, HDL is the major carrier of plasma cholesterol and 
the individual HDL subfractions, which are classified on the basis of their 
density, cholesterol and apoE content, and electrophoretic mobility, show few 
similarities to those of man (Terpstra, Sanchez-Muniz, West and Woodward 
1982). The characteristic lipoproteins in the normolipidaemic dog are HDL:o 
which have physical properties that lie between those reported for human 
HDL2 and HDL3 (Edelstein, Lewis, Shainoff, Naito and Scanu 1976). This 
subclass possesses apoA-I and no apoE, while apoE-containing HDL are also 
recognised. The latter are found in the plasma of normal dogs but are 
recognised predominantly in hypercholesterolaemic or cholesterol fed dogs and 
are known as HDLl or HDLc (Mahley, Weisgraber and Innerarity 1974; 
Mahley 1981). HDLl displays c¥2 mobility on agarose gel electrophoresis and is 
isolated from the LDL density range during preparative ultracentrifugation 
(Mahley, Weisgraber and Innerarity 1974). 
The initial stage of HDL production in the dog is similar to that of man, 
z.e., discoidal HDL, produced by the liver and intestines interacts with 
peripheral tissue resulting in accumulation of cholesterol in the lipoprotein 
core (Dory, Boquet, Hamilton, Sloop and Roheim 1985). Progressive 
accumulation of cholesterol and the action of LCAT results in expansion of the 
particle so that it decreases in density. Further extension of the lipoprotein 
requires the addition of apoE, which appears to be uniquely capable of 
permitting expansion of the HDL core to accommodate more cholesterol (Koo, 
Innerarity and Mahley 1985). The cholesteryl ester (50% by mass) and apoE 
enriched lipoprotein produced by this mechanism is HDL1, which may be 
isolated from the dl.006-1.063g/ml fraction of the plasma of 
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hypercholesterolaemic dogs (Sloop, Dory, Hamilton, Krause and Roheim 1983; 
Mahley and Innerarity 1983). The apoE of HDLI is responsible for the 
recognition and clearance of the lipoprotein by the hepatic apoB,E and E 
receptors (Koo, Innerarity and Mahley 1985), and acetylation of the lysine 
residues of this apolipoprotein retards the uptake of the particle (Sherrill, 
Innerarity and Mahley 1980). HDLI shows a higher binding affinity for the 
hepatic apoB,E receptor than LDL and competes with the LDL for receptor 
binding, internalisation and degradation (Mahley and Innerarity 1977; Koo, 
Innerarity and Mahley 1985). 
The dog has a low plasma cholesteryl ester transfer protein activity, 
ensuring that cholesteryl esters in the core of HDL are not transferred to other 
lipoprotein species, but are directed to the liver for excretion. The containment 
of cholesterol esters within the HDL class and their efficient uptake by hepatic 
receptors may play a major role in the protection of the dog from 
atherosclerosis. 
2.6. Miscellaneous lipoproteins 
,8-VLDL 
Beta-VLDL are cholesteryl ester enriched lipoproteins which accumulate in the 
serum of hypothyroid, cholesterol fed dogs (Mahley, Weisgraber and Innerarity 
1974) and human patients with type III hyperlipidaemia (DeWater, Hessels, 
Bakkeren and Van Berkel 1990). They are isolated from the d < 1.006g/ml 
range, contain both apoE and apoB and are thought to represent chylomicron 
and VLDL remnants (Fainaru, Funke, Boyles, Ludwig, Innerarity and Mahley 
1988). Patients with type III hyperlipidaemia may display apoE2 homozygosity 
which results in impaired clearance of lower density lipoprotein remnants from 
the circulation (Davignon, Gregg and Sing 1988). The accumulated remnants 
have the flotation characteristics of VLDL combined with the ,8 electrophoretic 
mobility of LDL and are therefore called ,8-VLDL. The appearance of this 
26 
CHAPTER I 
unusual lipoprotein species in cholesterol fed animals may have a different 
aetiology to man, since the apoE complement in these individuals has a normal 
structure (Mahley and Innerarity 1983). Beta-VLDL in the dog are cleared 
from the circulation via the hepatic aDoB,E receptor and by lipolytic conversion 
to IDL and LDL (Fainaru, Funke, Boyles Ludwig, Innerarity and Mahley 1988). 
In the rat, {3-VLDL is rapidly cleared by the apoB,E receptor of non-
macrophage cells (Goldstein, Ro, Brown, Innerarity and Mahley 1980) and the 
cholesteryl ester hydrolysed within lysosomes (DeWater, Ressels, Bakkeren 
and Van Berkel 1990). This feature, and the observation that incubation of 
canine {3-VLDL with human peritoneal macrophages results in massive 
cholesterol accumulation within the cellular cytoplasm, has prompted the belief 
that {3-VLDL is associated with a marked atherogenic potential (Goldstein, Ro, 
Brown, Innerarity and Mahley 1980). 
Lipoprotein X (Lp-X) 
This lipoprotein is characteristically identified in association with cholestatic 
disease in dogs (Danielsson, Ekman, Johansson and Petersson 1976) and has 
been isolated from the plasma of patients with familial LCAT deficiency 
(Miller 1990). The particle floats in the LDL density range but is rich in 
phospholipids and free cholesterol. The protein content of the lipoprotein is 
mainly albumin, which is held in the inner core (Riesen and KIoer 1989), and 
apoC (Danielsson, Ekman, Johansson and Petersson 1976). The physical 
properties of the lipoprotein result in a characteristic cathodic migration on 
agarose gel electrophoresis, allowing identification of the species in plasma 
(Durrington 1989). The mechanism of Lp-X production has not been 
determined, but the species may result from an interaction between plasma 
albumin and regurgitated biliary lipids. Neither lipoprotein lipase nor hepatic 
lipase appear to act upon the lipoprotein which is removed from the circulation 
by the cells of the reticulo-endothelial system (Riesen and KIoer 1989). 
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Despite this, Lp-X may interfere with the catabolism of chlyomicrons, leading 
to marked lipid abnormalities (Durrington 1989). The use of alterations of 
plasma Lp-X concentrations for the differentiation of intra and extrahepatic 
jaundice in man has been suggested, but has not been validated (Meredith 
1986). 
3. APOLIPOPROTEINS 
The apolipoproteins serve a number of functions which are vital in the 
synthesis, modification and metabolism of lipoproteins. The most important is 
their ability to form lipoprotein complexes from phospholipid bilayers and 
insoluble lipids. In addition, the proteins are instrumental in directing the 
metabolic fate of the lipoproteins in their role as enzyme cofactors and receptor 
ligands. The apolipoproteins of the dog are similar to those of man (Mahley 
and Weisgraber 1974). 
3.1. Apolipoprotein A 
ApoA-I is the major protein constituent of canine HDL (Edelstein, Lewis, 
Shainoff, Naito and Scanu 1976). The mature protein (molecular weight 
28kDa) is a crucial structural protein in the formation of HDL and is a cofactor 
in the enzymatic reaction catalysed by LCAT. It is possible that the 
apolipoprotein physically stabilises the enzyme with respect to its phospholipid 
substrate, ensuring maximal activity. The apolipoprotein is synthesised as pre-
pro-apoA-I in the intestines and liver. Translational cleavage forms pro-apoA-I 
which is secreted from the cell and undergoes proteolytic cleavage (by a pro-
apoA-I peptidase), resulting in formation of mature, plasma apoA-I (Calvert 
and Abbey 1985). 
ApoA-II is a minor protein component of HDL while apolipoprotein A-
IV is associated with the lower density lipoproteins (Weisgraber, Bersot and 
Mahley 1978). The exact function of apoA-IV is not certain (Nestel 1987; 
DeLamatre, Hoffmeier, Lacko and Roheim 1983). 
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3.2. Apolipoprotein B 
In contrast to the other apolipoproteins, apoB is insoluble and does not transfer 
between lipoproteins (Calvert and Abbey 1985). Two distinct forms of the 
protein have been recognised in canire plasma. ApoB 100, the major protein 
component of VLDL, IDL and LDL, is largely of hepatic origin, although a 
small amount may be synthesised in the intestines. This protein is one of the 
largest isolated monomeric proteins, with a molecular weight of 549kDa. The 
second form of apoB, designated apoB48 because its molecular weight is 48% 
of that of apoBlOO' is synthesised in the intestines and is secreted with exogenous 
lipid in the form of chylomicrons. Differentiation of the two forms, on the basis 
of molecular weight, can be achieved using sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis. 
3.3. Apolipoprotein C 
A number of species of apolipoprotein C have been identified using SDS 
polyacrylamide gel electrophoresis. Quantitatively the most important are C-II 
and C-III, although apoC-I, C-IV and C-V have also been identified. Each 
protein performs a different function in the pathways of lipoprotein 
metabolism. ApoC-I is identified in association with VLDL and HDL where its 
main role is in the stabilisation and binding of lipid for the enzymatic reaction 
catalysed by LCAT (Calvert and Abbey 1985). ApoC-II, also found in 
association with chylomicrons, VLDL and HDL is the essential activator of 
lipoprotein lipase. It appears to act by orientating the enzyme and substrate for 
maximal activity. The details of the role of apoC-III are not clear, although it 
does appear that the activation of lipoprotein lipase by apoC-II can be inhibited 
by apoC-III (Quinn, Shirai and Jackson 1982). 
3.4. Apolipoprotein E 
ApoE is associated with chylomicrons, VLDL, IDL and HDL. It is synthesised 
as a proprotein and undergoes intracellular proteolysis and glycosylation, and 
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extracellular desialation to form the apolipoprotein observed in plasma 
(Zannis, McPherson, Goldberger, Karathanasis and Breslow 1984). The 
protein is synthesised in peripheral tissues, including the adrenal glands and the 
kidneys (Blue, Williams, Zuckeer, Khan and Blum 1992), and by cholesterol-
loaded mouse peritoneal macrophages and human monocytes (Basu, Ho, 
Brown, Bilheimer, Anderson and Goldstein 1982). ApoE is secreted with 
phospholipids in lamellar discs and can be recognised by apoB,E receptors for 
which they show greater affinity then LDL (Basu, Ro, Brown, Bilheimer, 
Anderson and Goldstein 1982). The rate of apoE synthesis is increased two-
fold in cholesterol fed dogs when compared to control animals (Dory, Boquet, 
Tate and Sloop 1986). This evidence suggests that the production of apoE by 
peripheral tissues and its uptake by the LDL receptor may playa major role in 
reverse cholesterol transport, thought to be the mechanism of protection 
against atherosclerosis. However, the evidence for in vivo production of apoE 
by the peripheral tissues of the dog is controversial (Julien, Fong and Angel 
1988). 
In man, the gene specifying apoE is polymorphic. The protein products 
of the three common alleles are designated E2, E3 and E4. The most common 
allele is E3. Substitution of cysteine for the arginine at position 158 gives rise 
to the E4 allele, while replacement of the cysteine by arginine at position 112 
results in the formation of E2 (Zannis and Breslow 1981). The variation in size 
and/ or charge of the isoforms is due partly to genetic variation and partly to 
post-translational modification of the original polypeptide. These changes 
include sialation of the original polypeptide (Zannis and Breslow 1981), 
formation of apoE-apoE bonds and formation of an apoE-apoA-II complex 
(Weisgraber and Mahley 1978). Abnormalities of apoE binding affinity due to 
E2 homozygosity, rare apoE mutants or a deficiency of apoE results in type III 
hyperlipidaemia in man, a condition characterised by premature coronary 
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artery disease and peripheral vascular disease (Schaefer, Gregg, Ghiselli, Forte, 
Ordovas, Zech and Brewer 1986). 
Unlike the human apolipoprotein, apoE in the dog has four major 
isoforms (Dory, Boquet, Tate and Sl00p 1986) resulting from sialation of one 
parent polypeptide (Weisgraber, Troxler, RaIl and Mahley 1980). 
4. ENZYMES 
4.1. Lipoprotein lipase 
Lipoprotein lipase (EC 3.1.1.34) is responsible for the hydrolysis of triglyceride 
carried in chylomicrons and VLDL, and as such, is the rate-limiting step in the 
removal of these lipoproteins from the circulation. The enzyme is found on the 
capillary endothelium, particularly of adipose tissue, muscle and lactating 
mammary gland (Eckel 1989). Lipoprotein lipase allows delivery of free fatty 
acids to tissues, either for utilisation or for re-asssimilation to triglycerides and 
storage in adipose tissue. Reciprocal regulation of tissue enzyme activities 
ensures delivery of fatty acids to the adipose tissue during the postprandial 
period and channelling of fatty acids for utilisation by muscle tissue during 
periods of fasting (Cryer 1981). The activity of adipose tissue lipoprotein lipase 
correlates positively with plasma insulin concentrations (Semencovich, Chen, 
Wims, Luo, Li and Chan 1989) while catecholamines, ACTH, glucagon, TSH 
and oestrogen result in enzyme inhibition (Cryer 1981). 
Lipoprotein lipase is located on the endothelium and its activity can only 
be detected in the plasma after the administration of heparin (LaRosa, Levy, 
Windmueller and Fredrickson 1972). The enzyme is attached to the 
endothelium via glycosaminoglycan (heparan-sulfate) chains which present a 
number of enzyme molecules to each lipoprotein (Eckel 1989). Intravenously 
administered heparin binds to the endothelium, displacing lipoprotein lipase 
into the plasma, in which it may be measured (Hallberg 1968). The 
administration of heparin is not thought to induce lipoprotein lipase activity 
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although heparin does stabilise the purified protein by preventing surface 
denaturation (Quinn, Shirai and Jackson 1982). 
4.2. Hepatic lipase 
An enzyme with triglyceride lipase activity, similar to human hepatic lipase has 
been isolated from perfused canine livers (Greten, Sniderman, Chandler, 
Steinberg and Brown 1974; Frost, Shore and Havel 1982). This enzyme has 
action against triglycerides, mono glycerides and phospholipids (Ehnholm, 
Shaw, Greten and Brown 1975) and is responsible for the conversion of IDL to 
LDL, HDL2 to HDL3 and the clearance of chylomicrons from the circulation. 
The mechanism of this latter action is unclear (Sultan, Lagrange, Jansen and 
Griglio 1990). The role of hepatic lipase in the lipoprotein metabolism of the 
dog has not been elucidated. 
4.3. Lecithin:cholesterol acyl transferase 
Lecithin: cholesterol acyl transferase (EC 2.3.1.43) catalyses production of 
plasma cholesteryl esters and is the key enzyme in the transport of cholesterol 
from the peripheral tissues to the liver (Grove and Pownell 1991). The enzyme 
is produced by the liver (Riesen and KIoer 1989) and has both acyl transferase 
and phospholipase A activity which are stimulated by apoA-I (Grove and 
Pownell 1991; Chen and Albers 1983). The substrates for action include 
lecithin and cholesterol on the lipoprotein surface and the reaction involves the 
cleavage of the fatty acid on position 2 of lecithin and its transfer to free 
cholesterol, forming two products: cholesteryl ester and lysolecithin. The latter 
is then bound to albumin, while cholesteryl ester moves into the lipoprotein 
core (DeLamatre, Hoffmeier, Lacko and Roheim 1983). 
4.4. Cholesteryl ester transfer protein 
A variety of lipid transfer proteins have been identified in human plasma 
(Zilversmit 1984). Cholesteryl ester transfer protein (CETP) catalyses the 
transfer of cholesteryl esters from HDL to the other lipoprotein species in 
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exchange for triglyceride (Tall 1986; Brown, Inazu, Hesler, Agellon, Mann, 
Whitlock, Marcel, Milne, Koizumi, Mabuchi, Takeda and Tall 1989). 
There is a marked interspecies variation in CETP activity. Man is 
considered to have a high enzyme activity, while that in the dog is low (Ha and 
Barter 1982). Species lacking CETP activity are resistant to dietary 
atherosclerosis, while those with intermediate or high activities are susceptible 
(Tall 1986). In the former, HDL cholesteryl esters are removed directly from 
the circulation by the hepatic apoE receptor (Tall 1986). 
5. HYPERLIPIDAEMIA 
In clinical terms, hyperlipidaemia is defined as an elevation of plasma 
cholesterol and/or triglyceride concentrations. The condition may arise as the 
result of a primary, often inherited defect in lipoprotein metabolism or 
secondary to systemic disease processes. In man, the plasma lipid and 
lipoprotein concentrations may therefore be influenced by medical status, 
hormonal factors, dietary composition and genetic determinants (Tyroler 1984). 
The current understanding of the interactions of these factors with canme 
lipoprotein metabolism is based mainly on observations made during 
experimental procedures and a small number of clinical reports. The following 
is a review of these observations. 
5.1. Dietary influences 
A high dietary cholesterol intake over a number of months results in 
hypercholesterolaemia in dogs. This reflects an increase in the HDL 
concentration, in particular, HDLl (Julien, Fong and Angel 1988). Dietary 
cholesterol loading is also accompanied by increased plasma apoB and apoE 
concentrations (Melchior and Harwell 1985), which may be the result of 
overproduction rather than impaired catabolism, since the response to 
reduction in dietary cholesterol is rapid (Melchior, Dory and Roheim 1984). 
Expansion of the hepatic cholesterol pool may also be noted and although a 
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decrease in biliary excretion has been proposed as the major contributing 
factor, this has not been proven (Melchior and Harwell 1985). Beta-VLDL 
have been identified in the plasma of hypothyroid dogs fed on high cholesterol 
diets (Mahley, Weisgraber and Innerarity 1974; Mahley 1981). 
The lipid abnormalities produced when dogs are fed a high fat diet 
appear to depend on the degree of saturation of the fat (Grande and Schultz 
1968; McCullagh, Ehrhart and Butkas 1976). Atherosclerotic lesions of the 
abdominal aorta, coronary and cerebral arteries have been induced in dogs 
maintained on a diet rich in cholesterol and hydrogenated coconut oil for one 
year (Mahley, Innerarity, Weisgraber and Fry 1977). Marked 
hypercholesterolaemia appears to be a prerequisite for the development of 
lesions in the dog and vascular damage alone does not induce atherosclerosis 
(Schaub, Keith, Bell and Hunt 1987). 
Although the dog is relatively resistant to dietary induced 
hyperlipidaemia and atherosclerosis, it has been proposed that dietary and 
environmental factors may playa role in determining the fasting plasma lipid 
and lipoprotein cholesterol concentrations in normal dogs (Bass, Hoffman and 
Dorner 1976). It has been demonstrated that the total plasma cholesterol, 
VLDL-cholesterol and LDL-cholesterol concentrations in pet border collies 
were higher than those of working dogs (Crispin, Bolton and Downs 1992), but 
it was not possible to determine the relative effects of dietary fat intake and 
. . 
exerCIse regImes. 
5.2. Diabetes mellitus 
The studies of experimental diabetes mellitus in the dog have produced 
conflicting information, possibly as the result of differences in the methods for 
inducing the disease in laboratory animals. Streptozocin-alloxan induced 
diabetes mellitus was accompanied by increased plasma LDL, HDLl and apoE 
concentrations, but decreased concentrations of HDL2 (Wilson, Chan, Elstad, 
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Peric-Golia, Hejazi, Albu and Cutfield 1986; Gleeson, Hejazi, Kwong, Chan, 
Le, Alberts and Wilson 1990). However, the relevance of these findings to the 
clinical situation is limited since the toxic methods of inducing insulin 
deficiency may have resulted in ~ltered hepatic function, leading to an 
additional compromise of the lipoprotein metabolic pathways. Cholesterol 
feeding in addition to the induction of diabetes mellitus appears to be 
associated with increased concentrations of the triglyceride-rich lipoproteins 
which may arise either from increased hepatic triglyceride synthesis or 
decreased clearance from the circulation (Wilson, Chan, Elstad, Peric-Golia, 
Hejazi, Albu and Cutfield 1986). Although the activities of lipoprotein lipase 
and hepatic lipase have been measured in the postheparin plasma of dogs with 
experimental diabetes mellitus, the results are contrary. Wilson et al. (1986) 
found that the enzyme activities were the same in control and affected dogs, but 
pancreatectomised dogs showed a rise in the activity of hepatic lipase which 
was partially corrected by short term insulin therapy (Muller, Saudek and 
Applebaum-Bowden 1985). 
The rather complex nature of lipid abnormalities associated with 
experimental diabetes mellitus parallels the heterogeneity of disturbances 
noted in dogs with naturally-occurring disease. Rogers, Donovan, and Kociba, 
(1975b) noted that six of nine dogs with insulin dependent diabetes mellitus had 
increased plasma cholesterol and triglyceride concentrations. In most of these 
animals the lipid elevations were accounted for by increased LDL and HDL as 
assessed by agarose gel electrophoresis. In five of these dogs, chylomicrons 
were recognised on the basis of lipoprotein electrophoresis. After the 
introduction of insulin therapy there was a decrease in triglyceride 
concentration, but the cholesterol response was erratic. Ford (1977) suggested 
that the development of hyperlipidaemia in diabetes mellitus was restricted to 
dogs with metabolic complications, i.e., diabetic ketoacidosis, and that the 
abnormalities included hypertriglyceridaemia and hyperbetalipoproteinaemia. 
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These suggestions are contrary to the findings of Medaille, de La Farge, Braun, 
Valdiguie and Rico (1988) who identified no differences in the lipid 
concentrations of non-ketotic and ketotic diabetic dogs. 
The information regarding tl1e nature of hyperlipidaemia associated 
with canine diabetes mellitus is therefore rather confused. The comparison of 
results is hindered by a lack of standardisation of the methods of lipoprotein 
analysis, which have, to date, been limited to the use of semi-quantitative 
agarose gel electrophoresis. 
5.3. Obesity 
Obesity in both man and the rat has been associated with hypertriglyceridaemia 
and an increased VLDL production (Gibbons 1990). In the obese patient poor 
regulation of the flux of NEF A from the adipose tissue is a consequence of 
irregular control of the activity of hormone-sensitive lipase, the enzyme 
responsible for the hydrolysis of adipose triglyceride (Coppack, Evans, Fisher, 
Frayn, Gibbons, Humphreys, Kirk, Potts and Hockaday 1992). The increased 
flux of NEF A may have a number of effects including an increased hepatic 
triglyceride synthesis and impairment of the hepatic degradation of insulin 
(Anderson, Sobocinski, Freedman, Barboriak, Rimm and Gruchow 1988). The 
metabolic factors affecting the development of hyperlipidaemia in human 
obesity have not been fully defined (Durrington 1989). It has been proposed 
that obesity in the dog is associated with abnormalities of lipid metabolism 
(Zerbe 1986), but this hypothesis has not been tested. 
5.4. Hypothyroidism 
The induction of experimental hypothyroidism in combination with a high 
cholesterol diet has been used extensively to produce hypercholesterolaemia, 
hypertriglyceridaemia and atherosclerotic lesions in laboratory dogs (Moses 
1954; Grande and Schultz 1968). 
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Familial hypothyroidism and hyperlipidaemia has been recognised in 
beagles (Manning, Corwin and Middleton 1973; Manning 1979). Affected dogs 
showed increased plasma cholesterol, triglyceride, VLDL and LDL 
concentrations and on postmortem examination had moderate to severe 
atherosclerotic lesions of the coronary and renal arteries. In addition to this 
family of beagles, there are a number of reports of lipid abnormalities 
secondary to spontaneous hypothyroidism in the dog, including a survey by 
Larsson (1988) in which two thirds of animals with thyroid dysfunction were 
hypercholesterolaemic. The lipid disturbances may vary in severity and nature, 
ranging from mild hypercholesterolaemia with a small increase in the HDL 
concentration, to marked hypercholesterolaemia and hypertriglyceridaemia 
with intense staining of the aD (3 and pre-(3 regions on agarose gel 
electrophoresis (Mahley, Weisgraber and Innerarity 1974; Rogers, Donovan 
and Kociba 1975b; Medaille, de La Farge, Braun, Valdiguie and Rico 1988). 
The introduction of thyroid hormone replacement therapy produces resolution 
of the lipid abnormalities in affected dogs (Manning 1979). 
5.5. Hyperadrenocorticism 
In man, the effect of Cushing's syndrome or the administration of exogenous 
corticosteroids is predominantly to increase the plasma cholesterol, LDL-
cholesterol and occasionally VLDL-cholesterol concentrations (Durrington 
1989). 
Rogers (1977) stated that Cushing's syndrome in the dog was not 
associated with hyperlipidaemia. However, in a study of 115 cases of canine 
hyperadrenocorticism (Ling, Stabenfeldt, Comer, Gribble and Schechter 1979), 
90% of dogs presented with hypercholesterolaemia. Medaille et al. (1988) 
confirmed the latter finding and suggested that increased plasma HDL and 
LDL concentrations were responsible for the high plasma cholesterol 
concentrations observed. 
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5.6. Cholestasis 
Experimental cholestasis III the dog results in an increase in the LDL 
concentration, which is reflected in the total plasma cholesterol concentration 
(Bauer, Meyer, Goring, Beauchamp and Jones 1989). The increased LDL-
cholesterol concentration is thought to be due to the presence of LpX, the 
lipoprotein which is characteristically identifed in cholestatic disease in man. A 
lipoprotein which is similar to human LpX has been quantified in the plasma of 
dogs with experimental cholestasis (Ritland and Bergan 1975), but other 
investigators have failed to identify a lipoprotein which has the high free 
cholesterol content of the human species (Danielsson, Ekman, Johansson and 
Petersson 1976 and 1977). In the study by Ritland and Bergan (1975) the LpX 
concentration correlated inversely with the activity of LCAT, suggesting a role 
for the failure of cholesterol esterification in the formation of this characteristic 
lipoprotein species. The information regarding the lipid and lipoprotein 
abnormalities associated with cholestatic disease in the dog is restricted to 
experimental induction of the condition. 
5.7. Hepatocellular disease 
Experimental hepatic necrosis in the dog is accompanied by a decrease in the 
plasma triglyceride and LDL concentrations (Bass, Hoffmann and Dorner 
1976; Ford 1977). The triglyceride concentration may reflect a failure of 
hepatic synthesis and in acute hepatic disease it returned to normal before 
some of the parameters commonly used to assess hepatocellular insult and 
hepatic function, i.e., the plasma alanine aminotransferase activity and the 
sulphobromophthalein (BSP) retention test (Bass, Hoffmann and Dorner 
1976). This observation has led to the suggestion that lipid profiles may be an 
early prognostic indicator in acute hepatic disease in the dog (Ford 1977). The 
value of this approach has not been tested. 
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5.S. Glomerulonephritis 
~ephrotic syndrome in man is characterised by an increased synthesis of 
triglyceride-rich lipoproteins, accompanied by a marginal reduction III 
lipoprotein clearance (Kaysen, Mye:s, Couser, Rabkin and Felts 1986). In 
cases of gross proteinuria, there may be urinary loss of HDL, resulting in a 
reduction in the source of apoC, which may in turn prevent activation of 
lipoprotein lipase (Chan, Persaud, Ramdial, Varghese, Sweny and Moorhead 
1981). It has also been proposed that the reduction of the plasma heparan 
sulfate concentration detected in nephrotic humans may result in impaired 
lipoprotein lipase activity (Kaysen, Myers, Couser, Rabkin and Felts 1986). 
The plasma cholesterol and LDL cholesterol concentrations in nephrotic 
patients are increased and correlate inversely with the plasma albumin and 
plasma oncotic pressure (Appel, Blum, Chien, Kunis and Appel 1985; loven, 
Villabona, Vilella, Masana, Alberti and Valles 1990) 
Glomerulonephritis in the dog has been associated with a variety of lipid 
abnormalities. Medaille et al. (1988) reported moderate hypercholesterolaemia 
accompanied by increased plasma VLDL and decreased HDL concentrations, 
findings contrary to those of Ford (1977) who identified an increased HDL 
concentration. 
5.9. Acute pancreatitis 
It has been suggested that lipaemia is commonly associated with naturally-
occurring acute pancreatitis in the dog (Anderson, N.V., 1972). The 
identification of lipaemia, accompanied by variable increases in plasma HDL, 
LDL and VLDL concentrations in four dogs with pancreatitis supported this 
observation (Whitney, Boon, Rebar and Ford 1987). Similar increases in total 
plasma cholesterol and triglyceride concentrations with variable lipoprotein 
electrophoretic profiles have been noted by a number of investigators (Rogers, 
Donovan and Kociba 1975b; Ford 1977; Schaer 1979). 
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Experimental pancreatitis has been associated with an increase in the {3 
peak on lipoprotein electrophoresis, but the total plasma cholesterol and 
triglyceride concentrations were within the reference ranges (Whitney, Boon, 
Rebar and Ford 1987). Other investigators have had similar difficulty in 
reproducing the lipaemia associated with naturally-occurring pancreatitis by 
experimental means (Zieve 1968; Bass, Hoffman and Dorner 1976). The 
association of marked lipid and lipoprotein abnormalities with spontaneous, 
but not experimentally-induced canine pancreatitis may suggest that 
hyperlipidaemia is not a consequence of pancreatic disease, but plays a role in 
its aetiology. This is consistent with opinion in human medicine, where patients 
with fasting plasma triglyceride concentrations greater than 11mmoljl are 
considered at risk of developing acute pancreatitis (European Atherosclerosis 
Society 1988). 
5.10. Primary hyperlipidaemia 
In man, inherited defects of lipoprotein metabolism are well characterised and 
occur frequently in comparison to the dog, in which familial hyperlipidaemia is 
considered rare. The miniature schnauzer is one of the few breeds in which 
hyperlipidaemia is thought to be the result of an inherited defect. The lipid 
abnormalities associated with this condition, including hypertriglyceridaemia, 
hyperchylomicronaemia and hyperbetalipoproteinaemia were first described by 
Rogers et al. (1975a). Since the first description of the entity, investigators have 
been unable to elucidate the underlying defect in lipoprotein metabolism, 
although it appears that an absolute deficiency of the enzyme lipoprotein lipase 
is not involved (Rogers, Donovan, Kociba 1975a; Whitney 1987). The clinical 
signs in affected dogs include abdominal pain, vomiting, unexplained polydipsia 
and generalised seizures (Rogers, Donovan and Kociba 1975a; Bodkin 1992). 
The introduction of a low fat diet may improve the clinical signs (Bodkin 1992) 
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but has little effect on the electrophoretic lipoprotein profile of individual dogs 
(Rogers, Donovan and Kociba 1975a). 
Hypertriglyceridaemia and hyperchylomicronaemia was also described 
in two related Brittany spaniels (Hubert, de La Farge, BplJT', Magnol 1987). 
Serum electrophoresis confimed the presence of chylomicrons and increased 
VLDL concentrations. The effect of intravenous heparin administration was 
abnormal, suggesting impairment of lipoprotein lipase activity. One of these 
dogs presented with corneal lipid deposition and alopecia while the other was 
clinically healthy. 
Hyperlipidaemia, characterised by increased concentrations of aT 
migrating lipoproteins has been recognised in related beagle dogs (Wada, 
Minamisono, Ehrhart, Naito and Mise 1977). The presence of underlying 
endocrine disease was not excluded in these dogs and it is therefore possible 
that they were suffering from hyperlipidaemia secondary to familial 
hypothyroidism as described by Manning (1979). Increased density of the a2 
band has also been recognised in Briards in the United Kingdom (Watson, 
Simpson, Odedra and Bedford 1993). 
The aetiology, pathogenesis and inheritance of these proposed primary 
hyperlipidaemias of the dog have not been elucidated. 
6. AIMS OF THE STUDY 
The aim of this study was to characterise the lipid abnormalities recognised in 
the canine population, to evaluate the effect of such aberrations on the health 
of individuals and to investigate therapeutic regimes for their treatment. 
In order to standardise the investigation of lipid metabolism it was first 
necessary to identify procedures suitable for the quantitative and qualitative 
analysis of canine plasma lipoproteins. To this end, a combined 
ultracentrifugation/precipitation method was validated for the measurement of 
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lipoprotein cholesterol concentrations (Chapter II). Additional methods of 
quantitative and semi-quantitative analysis were evaluated to identify suitable 
alternatives for lipoprotein analysis in veterinary commercial laboratories 
(Chapter III) and thus expand thE' study of canine lipid metabolism. 
The validated method of quantitative analysis was used to identify the 
trends in plasma lipid and lipoprotein cholesterol concentrations in dogs with 
secondary hyperlipidaemia (Chapter IV). The increasing incidence of obesity 
in pet dogs and concern about the metabolic consequences of adiposity 
prompted a specific investigation of triglyceride metabolism in obese dogs 
(Chapter V). The effects of hyperlipidaemia on the health of the canine 
population are addressed in Chapter VI, where the prevalence of lipoprotein 
abnormalities and their clinical and pathological consequences are presented. 
A rational approach to the investigation of hyperlipidaemia and the 
management of idiopathic hyperlipidaemia is outlined in Chapter VII, followed 
by a discussion highlighting the significant findings of this thesis. 
CHAPTER II 
A METHOD FOR THE QUANTITATIVE ANALYSIS OF CANINE 
PLASMA LIPOPROTEINS 
CHAPTER II 
1. INTRODUCTION 
The importance of hyperlipidaemia as a risk factor for coronary heart disease 
in humans has necessitated the development of methods for the quantification 
of plasma lipids and lipoproteins. -.L~he three methods of analysis which are 
commonly used are: preparative ultracentrifugation, for the isolation of 
individual lipoprotein classes; precipitation techniques for the selective 
measurement of HDL cholesterol; and electrophoresis, for the identification of 
specific lipoproteins and apolipoproteins. Preparative ultracentrifugation, 
including density gradient ultracentrifugation (Chapman, Goldstein, Lagrange, 
Laplaud 1981) may be time-consuming and technically difficult, often resulting 
in protein contamination of the HDL fraction. More commonly, 
ultracentrifugation is combined with a precipitation step, allowing separation of 
VLDL, HDL and LDL, which are then quantified on the basis of their 
cholesterol content (Lipids Research Clinics Program, 1982; Bachorik and 
Albers 1986). This method is considered an ideal compromise between 
expense and precision. 
The four major lipoproteins of canine plasma have previously been 
quantified using density gradient ultracentrifugation (Terpestra, Sanchez-
Muniz, West and Woodward 1982; Hollanders, Mongin, N'Diaye, Hentz, Aude 
and Girard 1986) and analysed in a semi-quantitative fashion using agarose gel 
(Rogers, Donovan and Kociba 1975b) and Geon-Pevickon block 
electrophoresis (Mahley and Weisgraber 1974). Although electrophoresis gives 
good separation of the lipoprotein classes (Noble 1968) and may be necessary 
for the recognition of specific lipoproteins, e.g., (3-VLDL, it provides only semi-
quantitative data. Recently, attention has turned to the use of other methods 
for the analysis of canine plasma lipoproteins, including precipitation (Rhodes, 
Meyer, Fish and Kerns 1992) and combined ultracentrifugation/precipitation 
techniques (Weingand and Daggy 1992; Bolton, Downs and Crispin 1990). 
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While the application of these human procedures may facilitate the 
investigation of disorders of lipid metabolism in dogs, their continued use 
cannot be justified without proper validation with respect to the physical and 
chemical differences that exist between human and canine plasma lipoproteins. 
To this end, this study was designed to develop a method for the quantitative 
analysis of plasma lipoproteins in the dog and to fully validate the technique in 
healthy and hyperlipidaemic subjects. 
2. MATERIALS AND METHODS 
2.1. Sample collection 
Blood samples were collected by jugular venepuncture from dogs which had 
been fasted for a minimum of 16 hours. The samples were taken into disodium 
ethylene-diaminotetra-acetic acid (EDTA; final concentration 1mg/ml) and the 
plasma separated by low speed centrifugation at 4°C for 20 minutes (Beckman 
TJ-6 centrifuge; Beckman Instruments Inc). Plasma was stored at 4°C for not 
longer than 24 hours prior to analysis and plasma for interassay (between 
batch) precision studies was stored for a maximum period of six days. 
2.2. Quantification of lipoproteins 
The concentration of cholesterol in each lipoprotein fraction was measured 
following separation by a combined ultracentrifugation/precipitation 
technique. In this, 4ml of plasma was placed in a thermoplastic ultracentrifuge 
tube (Ultraclear, 13x64mm; Beckman Instruments Inc.) and overlayered with 
2.5ml normal saline (density 1.006g/ml). The tubes were capped and 
centrifuged at 164,000g, 4°C for 18 hours in a fixed angle rotor (type 50.4 Ti, 
Optima L-70 preparative ultracentrifuge; Beckman Instruments Inc.). The 
lipoproteins with density less than 1.006g/ml (VLDL) were removed in the top 
fraction by tube slicing and made up to a total volume of 3 ml with normal 
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saline. The cholesterol concentrations of the plasma and infranatant were 
measured on a Cob as MIRA clinical chemistry analyser (Roche) using an 
enzymatic colorimetric method (Ma-kit 100 Cholesterol PAP; Roche). The 
VLDL cholesterol (VLDL-C) was calculated as the difference between the 
cholesterol concentration of the plasma and that of the infranatant. 
The apoB-containing lipoproteins (i.e., LDL) were than precipitated 
from 1ml of the infranatant by the addition of 50lll of 92mM heparin-
manganese chloride, followed by incubation at 4°C for 30 minutes and 
centrifugation at 10,800g, 4°C for 30 minutes. The cholesterol concentration in 
the supernatant (HDL-C) was measured and the LDL cholesterol (LDL-C) 
calculated as the difference between the cholesterol concentration of the 
infranatant and the HDL-C. 
2.3. Assessment of lipoprotein separation 
As lipoprotein classes exhibit different electrophoretic mobilities, the efficiency 
of the separation of lipoprotein fractions was assessed in normolipidaemic and 
hyperlipidaemic dogs using agarose gel electrophoresis. The LDL precipitate 
was resolubilised with 0.25ml O.5M sodium citrate and 1ml 0.15M sodium 
chloride. The solution was dialysed overnight at 4°C against sodium 
chloride/azide (8.77g NaCl, O.13g NaN3, 0.372g Na3EDTA in 1 litre, pH7.3). 
The lipoprotein fractions (VLDL, LDL and HDL) were then made up to 3ml 
with 0.15M sodium chloride and applied to 0.5% agarose gels (Paragon 
Lipoprotein Electrophoresis Kit, Beckman Instruments Inc) and 
electrophoresis was performed according to the manufacturer's instructions. 
As it is possible that manipulation and storage of lipoproteins may alter 
their electrophoretic mobility, further confirmation of the efficiency of 
lipoprotein separation was sought by analysis of the apolipoprotein distribution 
within the fractions using SDS polyacrylamide gel electrophoresis. The density 
of the LDL and HDL fractions was altered to 1.225g/ml by the addition of 
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0.3Sg/ml KEr and the lipoproteins re-isolated by ultracentrifugation. The 
apolipoprotein content of each fraction was resolved by SDS polyacrylamide gel 
electrophoresis according to the method of Laemmli (1970) using a vertical slab 
apparatus (SE2S0; Hoefer Scientific Instruments). Samples were mixed in a 1:1 
ratio with treatment buffer (0.12SM Tris-CI pH6.8, 4% SDS, 20% glycerol, 10% 
2-mercaptoethanol). ApoA-I was identified on l.Smm thick 10% 
polyacrylamide gels (3.33ml 30% acrylamide/2.7% bisacrylamide solution, 
25ml 15M Tris-Cl pH 8.8, O.lml 10% SDS, 4.0ml distilled H 20, SOftl 10% 
ammonium persulfate and Sftl TEMED). ApoB was identified on 4% gels 
(1.33ml30% acrylamide/2.7% bisacrylamide solution, 6ml distilled H 20). Two 
multiple molecular weight standards (MW-SDS-70, Sigma Chemical Company 
and High molecular weight-SDS calibration kit, Pharmacia) were used to 
determine the Rf value for each protein band. Electrophoresis was performed 
at a constant 20rnA, for 60 minutes. The gels were stained with 1% Coomassie 
Blue R-2S0 for 20 minutes then destained with 7.5% acetic acid, 5% methanol 
overnight. Densitometric scanning was performed at 530nm (Chromoscan 3 
Densitometer; Joyce Loebl) 
2.4. Comparison of measured and calculated VLDL-C 
The VLDL cholesterol concentration, taken as the cholesterol concentration in 
the top fraction was measured and the results compared with the calculated 
VLDL-C concentration (VLDL-C = plasma cholesterol - infranatant). This 
was done for multiple aliquots from the plasma pool with total cholesterol 
concentration 2.67mmol/l (n = 12) and for samples from normo- and 
hyperlipidaemic dogs (n=28) with calculated VLDL-C concentrations ranging 
from 0.40 to 20.26 mmol/l. 
2.5. Imprecision of the method 
The intra-assay (within batch) imprecision was established for aliquots from 
two pools of plasma with cholesterol concentrations of 2.67 mmol/l (n= 12) and 
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8.14 mmol/l (n=6), analysed in a single assay run. The inter-assay (between 
batch) variation was determined by repeated analyses performed over six 
consecutive days of aliquots from the lower cholesterol pool that had been 
stored at -20 oe immediately after collection. 
2.6. Effects of storage 
A pool of normolipidaemic plasma was divided into 5ml aliquots and stored at 
-20 oe for eight weeks. Samples were removed from the freezer and analysed, 
as above, at two and eight weeks after collection. 
3. RESULTS 
3.1. Separation of lipoprotein fractions 
Individual lipoprotein classes were identified according to their characteristic 
electrophoretic mobility with the HDL in the a position, LDL in the {3 region 
and VLDL seen in the pre-{3 position. The VLDL band was only seen when the 
lipoprotein was concentrated. In normolipidaemic dogs there was no apparent 
contamination of the fractions by lipoproteins of other classes (Fig. 2.). 
Separation of the lipoprotein fractions of a dog with a plasma cholesterol 
concentration of 15mmol/l resulted in isolation of pure a-migrating HDL, but 
the LDL fractions contained lipoproteins with a and {3 mobility. 
Four major protein bands were detected when the LDL fractions of 
normo- and hyperlipidaemic dogs were applied to SDS polyacrylamide gels. 
The molecular weights were 500-570 kDa, assumed to be apoB, and smaller 
bands at 340-370 kDa, 132-140 kDa and 125-128 kDa that were assumed to 
represent fragments of apoB. The HDL fractions of normo- and 
hyperlipidaemic dogs applied to the same gels showed no evidence of 
contamination by these proteins, indicating complete precipitation of LDL 
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Figure 2. Agarose gel electrophoresis of native plasma and separated 
lipoproteins fractions. Track 1, plasma. Track 2, concentrated VLDL showing 
pre-iJ mobility. Track 3, infranatant (HDL) before precipitation of LDL. 
Tracks 4 and 5, infranatant after precipitation of LDL. Tracks 6 and 7, 
resolubilsed precipitate. 
pre-iJ iJ 
. ; 
1 2 3 4 5 6 7 
... 
from the infranatant. However, in samples from dogs with plasma cholesterol 
concentrations ranging from 4 to 15mmoljl there was some contamination of 
the LDL fraction by a protein of molecular weight 26.5-28.5 kDa, which was 
assumed to be apoA-I, the major protein of HDL (Fig. 3.). Densitometric 
scanning of the HDL and LDL tracks showed that in normolipidaemic dogs the 
mean ±sd percentage of total apoA-I that was present in the LDL fraction was 
3.68 ±2.42 % while in hyperlipidaemic dogs this value was 8.5 ±O.96 %. 
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Figure 3. Sodium dodecyl sulphate polyacrylamide gel (10%) electrophoresis 
of lipoproteins in HDL and LDL fractions. Tracks 1 and 2, infranatant (HDL) 
after precipitation of LDL. Track 3, resolubilsed LDL precipitate showing 
trace contamination with apolipoprotein A-I. S, molecular weight markers 
(daltons). 
'-
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3.2. Comparison of measured VLDL-C and calculated VLDL-C 
In samples with a total cholesterol concentration of 2.67 mmol/l, the mean ±sd 
measured VLDL-C (0.02 ±O.Olmmol/l) was lower (p<O.Ol) than the mean 
calculated VLDL-C (0.13 ±0.071nmol/l). For 28 normo- and hyperlipidaernic 
samples, the mean ±sd measured VLDL-C concentration (2.46 ±5.70mmol/l) 
was also lower (p < 0.001) than the calculated value (2.74 ±4.87mmol/l). The 
difference (mrnol/l) between the two methods correlated negatively with the 
VLDL-C concentration (r = -0.43, p < 0.05) (Appendix 5). 
3.3. Imprecision of the method 
The intra-assay (within batch) and interassay (between batch) coefficients of 
variation (CV) of HDL-C and LDL-C varied between 3.3% and 9.0% for 
plasma with cholesterol concentrations of 2.67mmo/l (n= 12) and 8.14mmol/l 
(n=6) (Table 1.) (Appendix 3). The intra-assay CV and interassay CV for 
VLDL-C were higher than those of the other lipoprotein classes. 
3.4. Effects of storage 
Aliquots of plasma stored at -20°C for 2-8 weeks showed approximately 9 % 
reduction in HDL-C concentration. The LDL-C increased after storage for 8 
weeks (Table 2.) (Appendix 4). During this period, there was no significant 
change in cholesterol concentration of the infranatant (HDL-C + LDL-C). 
However, the total plasma cholesterol concentration had increased at 2 weeks, 
which led to an increased calculated VLDL-C value. The increase in plasma 
cholesterol on storage was accompanied by the development of turbidity of the 
sample, which was cleared by low speed centrifugation and the measurements 
repeated. The total cholesterol concentrations after clearing the plasma were 
significantly lower (2.73 ±0.07mmol/l; p < 0.01) than those in the turbid 
samples (2.89 ±0.05mmol/l) and were not significantly different from the 
concentrations in the fresh samples. 
51 
CHAPTER II 
Table 1. Imprecision of the measurement of plasma lipoprotein fractions. 
Aliquots (5rnl) of pooled plasma with cholesterol concentrations of 2.67mmol/1 
(n= 12) and 8.00mmol/1 (n=6) were analysed. The coefficients of variation 
(CV) are expressed. 
Plasma 
Within batch: 
2.67 
(n= 12) 
8.14 
(n=6) 
between batch: 
2.67 
(n=6) 
4. DISCUSSION 
Cholesterol concentration (mmol/l) 
VLDL LDL HDL 
mean 
±sd 
0.13 
±0.07 
0.98 
±0.18 
0.40 
±0.09 
CV 
53.8 
18.4 
22.5 
mean 
±sd 
0.72 
±0.05 
3.63 
±0.21 
0.78 
±0.07 
CV 
6.9 
5.8 
9.0 
mean 
±sd 
1.82 
±0.06 
3.53 
±0.16 
1.66 
±0.12 
CV 
3.3 
4.5 
7.2 
The investigation of the metabolic abnormalities associated with 
hyperlipidaemia requires the recognition of both qualitative and quantitative 
changes in plasma lipoproteins. Qualitative changes are -commonly assessed on 
the basis of alterations in electrophoretic mobility (Rogers, Donovan and 
Kociba 1975a and b; Ford 1977), but the introduction of ultracentrifugation and 
precipitation techniques has facilitated the quantitative analysis of the human 
lipoprotein classes. The application of such techniques for the quantification of 
canine lipoproteins may be inappropriate since it has been reported that an 
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Table 2. The effect of storage at -20°C on mean ±sd plasma lipoprotein 
cholesterol concentrations in fresh (n= 12), 2 week old (n=6) and 8 week old 
(n=6) samples. 
Cholesterol concentration (mmol/l) 
Treatment Total Infranatant VLDL LDL BDL 
Fresh 2.67 2.54 0.13 0.72 1.82 
±0.06 ±0.06 ±0.07 ±0.05 ±0.06 
Storage, 2.87* 2.38 0.48* 0.74 1.64* 
2 weeks ±0.09 ±0.22 ±0.15 ±0.30 ±0.13 
Storage, 2.85* 2.45 0.40* 0.79* 1.66* 
8 weeks ±0.03 ±0.11 ±0.09 ±0.07 ±0.12 
* p<0.05 
apolipoprotein Erich subfraction of BDL, identified in the plasma of 
hypercholesterolaemic dogs (Mahley, Weisgraber and Innerarity 1974), may 
behave like LDL under certain precipitation conditions (Rhodes, Meyer, Fish 
and Kerns 1992). 
The combination of ultracentrifugation and precipitation described here 
produced an BDL fraction which was free from LDL. The purity of this 
fraction when applied to agarose and SDS-polyacrylamide gels suggested that 
92mM heparin-manganese chloride precipitated the total LDL content of 
camne plasma. These findings are similar to those in man where 92mM 
heparin-manganese chloride results in precipitation of the total apoB content of 
both fresh and stored plasma (Warnick, Cheung and Albers 1979; Gibson, 
Rubinstein and Brown 1984). 
Contamination of the LDL fraction with an a-migrating lipoprotein was 
evident when the lipoprotein fractions from hypercholesterolaemic dogs were 
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studied using agarose gel electrophoresis. It was possible that this was an 
artefact from the effects of manipulation and storage on the electrophoretic 
mobility of the lipoprotein. In addition, the precipitation of an apoE enriched, 
a-migrating lipoprotein by heparin-manganese chloride has previously been 
recognised (Mahley and Innerarity 1977). However, regardless of the 
electrophoretic phenomenon, resolution of the constituent apolipoproteins 
showed that only a small amount of the total apoA-I was present in the LDL 
fraction. Since apoA-I is not associated with LDL in the plasma, it followed 
that HDL was present as a contaminant of the precipitated LDL. This error 
was considered to be of low significance, representing only a 0.06mmoljl 
increase of the LDL-C in the normolipidaemic dog. 
It is recommended by the Lipid Research Clinics Program (1982) that 
the VLDL-cholesterol concentration in man is calculated rather than 
measured. The differences found between the calculated and measured values 
in this study suggest that this guideline should also be applied to the dog. These 
differences may result from poor recovery of the top fraction after 
centrifugation, or from problems in measuring the cholesterol content of 
VLDL, particularly in the dog, where its concentration is low (Chapman 1980) 
and is close to the lower limit of detection of the cholesterol assay. The latter 
may explain the high CV reported for low VLDL-cholesterol concentrations in 
this study, which are similar to those achieved in established human lipid 
laboratories (Cathcart and Dominiczak 1990). It is unlikely that the variations 
will affect clinical decisions since therapeutic approaches are rarely made 
where the triglyceride concentration is less than 5mmol/1. 
The storage of plasma samples may have deleterious effects upon the 
composition of lipoproteins (Bachorik, Albers, Ellefson, Kane and Wood 1982). 
These alterations may result from auto-oxidation, bacterial contamination and 
the effect of lipase and LCAT on the physical and chemical properties of the 
lipoproteins (Bachorik and Albers 1986). Changes in composition may alter 
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the precipitability of the lipoproteins. The reduction in HDL-C may therefore 
be a reflection of an increased precipitability of this lipoprotein class. In 
addition, it has been reported that prolonged storage of plasma reduces the 
precipitability of apoB-containing lipoproteins (Bachorik, Walker, Brownell, 
Stunkard and Kwiterovich 1980). This effect may become dominant in the 
plasma of dogs with high LDL-C concentrations. The present study showed 
that plasma for quantitative analysis should not be stored for periods of more 
than 2 weeks, and ideally, precipitation steps should be performed as soon as 
possible after sample collection. 
The combined ultracentrifugation and precipitation method described 
gave effective separation of the lipoproteins of canine plasma and is presented 
in the remainder of this thesis as the reference method for the quantitative 
analysis of canine plasma lipoproteins. 
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METHODS FOR THE ANALYSIS OF CANINE PLASMA 
LIPOPROTEINS 
CHAPTER III 
1. INTRODUCTION 
Three major procedures have been developed for the measurement of 
lipoproteins in clinical chemistry laboratories. These are ultracentrifugation, 
for the isolation of lipoprotein fractions (Terpestra, Sanchez-Muniz, West and 
Woodward 1982), precipitation techniques, for the measurement of HDL-C 
concentrations, and electrophoresis for lipoprotein and apolipoprotein 
characterisation. Ultracentrifugation or combined ultracentrifugation/ 
precipitation techniques (Lipid Research Clinics Program, 1982) are considered 
the reference methods for lipoprotein quantification but the techniques are 
more time-consuming and expensive than simple precipitation methods, 
limiting their availability to dedicated lipid laboratories and research 
establishments. As a result of these constraints, the precipitation methods, in 
conjunction with the estimation of LDL-C concentration by the Friedewald 
formula have gained popularity and are used in many routine chemical 
pathology laboratories. 
A number of classes of precipitation reagent have been employed, the 
most successful of which are high molecular weight polysaccharides (dextran 
sulphate), lower molecular weight polysaccharides with divalent metals 
(heparin-manganese; phosphotungstate-magnesium) and neutral polymers 
(polyethylene glycol; polyvinylsulphate (PVS» (Warnick, Cheung and Albers 
1979; Rifai, Warnick, McNamara, Belcher, Grinstead and Frantz 1992). The 
measurement of HDL-C concentrations by these precipitation techniques is 
often combined with the calculation of LDL-C using the formula derived by 
Friedewald et al. (1972). The use of this formula is restricted to fasted samples 
with no evidence of chylomicronaemia and a plasma triglyceride concentration 
less than 4.5mmol/L The formula is as follows: 
LDL-C = (total cholesterol) - (HDL-C) - (total triglyceride x 0.45) 
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The application of this formula only requires the measurement of plasma 
triglyceride, total cholesterol and HDL-C concentrations, and therefore 
provides an inexpensive alternative to ultracentrifugation methods for the 
analysis of many human samples 
In veterinary medicine, investigators have concentrated on the use of 
electrophoresis for the semi-quantitative analysis of canine plama lipoproteins 
(Rogers, Donovan and Kociba 1975a and b; Ford 1977). More recently, 
attention has focused on the use of precipitation techniques for the 
quantification of canine plasma lipoproteins. The selective measurement of 
HDL-C is achieved by the use of precipitation reagents which induce 
precipitation of all the lipoprotein classes except HDL, leaving this class in the 
supernatant. However, Rhodes, Meyer, Fish and Kerns (1992) determined that 
phosphotungstate in the presence of magnesium ions, a reagent commonly used 
for the selective measurement of human HDL-C, causes precipitation of canine 
HDL in addition to the apoB-containing lipoproteins which results in an 
appreciable underestimate of plasma HDL-C concentrations. Weingand and 
Daggy (1992) combined this precipitation reaction with a preceding 
ultracentrifugation step, a method which resulted in minimal contamination of 
the precipitate with HDL and is thus considered an appropriate method for the 
quantification of canine plasma lipoproteins. Downs, Bolton, Crispin and Wills 
(1993) also utilised a combined ultracentrifugation/precipitation technique to 
quantify the plasma lipoproteins of normal dogs but did not explain their 
validation techniques or quantify the analytical error incurred by their selected 
method. 
The aim of this study was to evaluate the use of commercially available 
precipitation reagents with canine plasma in order to identify techniques which 
might allow for the convenient and economical quantification of canine plasma 
lipoproteins. In addition, the application of the Friedewald formula for the 
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estimation of LDL-C and the use of electrophoresis for semi-quantitative 
analysis of canine lipoproteins was assessed. 
2. MATERIALS AND METHOD~ 
2.1. Blood collection 
Blood samples were collected from fasted dogs by jugular venepuncture. Serum 
was harvested for the evaluation of LDL precipitation reagents as 
recommended by the manufacturers, and disodium ethylene-diaminetetra-
acetic acid (EDTA; final concentration 1mg/ml) plasma collected for the 
assessment of HDL precipitation reagents and electrophoresis of plasma 
lipoproteins. All analytical procedures were performed on fresh plasma or 
serum. 
2.2. Evaluation of precipitation methods 
Five commercial reagents were selected for evaluation. Those for the 
measurement of HDL-C were phosphotungstic acid (0.55mmol/I)/magnesium 
chloride (25mmol/l) solution (HDL-cholesterol precipitant; Randox 
Laboratories) and polyethylene glycol in O.lM phosphate buffer (Quantolip 
HDL-cholesterol precipitation reagent; Immuno Ltd). The reagents for the 
quantification of LDL were heparin (50, OOOlU /l)/sodium citrate (0.064moljl, 
pH 5.04) solution (LDL-cholesterol; Randox Laboratories Ltd), PVS solution 
(LDL-cholesterol; Boehringer Mannheim GmbH Diagnostics) and dextran 
sulphate in a tris HCI buffer (pH 7.4) (Quantolip LDL-cholesterol precipitation 
reagent; Immuno Ltd). 
Each sample was aliquoted and analysed by the reference 
ultracentrifugation/precipitation method (Chapter II 2.2.) and by one or more 
of the selected precipitation methods. The agreement between each technique 
and the reference method was assessed as described (Chapter III 2.6.). 
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The efficiency of separation of the lipoprotein classes was determined by 
electrophoresis. The precipitates formed in both the HDL and LDL 
precipitation reactions were re-solubilised by the drop-wise addition of O.5M 
sodium citrate. The supernatants and dissolved precipitates were applied to 
0.5% agarose gels (Paragon Lipoprotein Electrophoresis Kit, Beckman, U.K.) 
and electrophoresis performed according to the manufacturer's instructions. 
2.3. Imprecision of the precipitation reagents 
The intra-assay coefficients of variation (CV) of HDL-C and LDL-C obtained 
by the precipitation reagents were measured on a pool of plasma with HDL-C 
concentration 5.22mmol/l and LDL-C concentration 1.09mmol/l (derived using 
the validated ultracentrifugation/precipitation method). 
2.4. The Friedewald formula and its modification 
The LDL-C concentration was measured III normo- (n=37) and 
hyperlipidaemic (n=44) dogs by the ultracentrifugation/precipitation 
technique. The estimated LDL-C was calculated according to the standard 
Friedewald formula described above, using the plasma cholesterol and 
triglyceride concentrations and the HDL-C concentration measured using the 
reference method (Chapter II 2.2.). 
Since the VLDL-C:plasma triglyceride ratio on which the Friedewald 
formula is based may differ slightly between selected populations and between 
species, the relationship between these two variables in 101 dogs (46 
normolipidaemic and 55 hyperlipidaemic) was determined by linear regression. 
The estimated LDL was then calculated using two modifications of the 
Friedewald formula and the results compared to the reference method. 
2.5. Electrophoresis 
Native plasma from 14 normo- and hyperlipidaemic cases was aliquoted and 
analysed by the reference method and by agarose gel electrophoresis. The 
native plasma was applied to 0.5% agarose gels (Paragon Lipoprotein 
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Electrophoresis Kit; Beckman Inc) and electrophoresis performed according to 
the manufacturer's instructions. Following electrophoresis, the gels were 
stained for lipid with Sudan Black B (7.0% w /w) and the lipid content of each 
band quantified by densitometric scanning (Appraise Junior Densitometer; 
Beckman Instruments Inc). The relative distribution of the lipoprotein 
fractions were compared to the percentage of the total plasma cholesterol 
measured in each lipoprotein class. 
2.6. Statistical methods 
The product moment correlation coefficient was used to describe the 
relationship between the lipoprotein concentrations measured by the reference 
method and those derived from the precipitation reactions and the Friedewald 
formula. Spearman's rank correlation coefficient was used in the assessment of 
measured lipoprotein cholesterol concentrations (HDL-C and LDL-C) and 
those determined by electrophoretic means. In addition, the agreements 
between lipoprotein cholesterol concentrations measured by 
ultracentrifugation/precipitation and those obtained using the techniques 
under evaluation were assessed using the method of Altman and Bland (1983). 
In this, a plot of the difference between the two methods against their mean 
illustrates the measurement error and reveals any relationship between the 
magnitude of the error and that of the mean. The difference in measurements 
can therefore be summarized by standard statistical descriptions, i.e., by the 
mean difference (d) and the standard deviation of the differences (s). 
Assuming the differences are normally distributed, 95% of the differences lie 
within d-2s and d + 2s. If the differences within these limits are not clinically 
significant then the test method may be used to replace the reference method. 
Since there is little information on the clinical significance of lipoprotein 
concentrations in the dog, the proposal of acceptable agreement limits between 
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methods was not undertaken and the data are presented III their original 
graphic form. 
The agreement between the Friedewald formula and the estimated 
LDL-C concentration has been asses'":ed in man by classifying the percentage of 
"acceptable" results in each study. An "acceptable" result was defined as one 
which fell within 10% of the LDL-C concentration measured by an 
ultracentrifugation/precipitation technique (Warnick, Knopp, Fitzpatrick and 
Branson 1990). The agreement between measured and estimated LDL-C in 
canine plasma was assessed by this method in addition to the manipulations of 
Altman and Bland (1983). 
3. RESULTS 
3.1. HDL-C concentrations: reference method vs precipitation reagents 
The mean ±sd HDL-C concentrations derived from the reference method for 
the sample pools (Table 3.) were greater than, although significantly correlated 
with, those obtained using the Randox (r=0.81, p<O.Ol) and the Immuno 
reagents (r = 0.83, P < 0.001) (Appendix 5). The mean ±sd differences between 
the HDL-C concentration derived from the reference method and from the test 
precipitation methods were 0.59 ±0.94mmol/l and 0.19 ± 1.64mmol/l, for the 
Randox and Immuno reagents respectively (Fig. 4.). In the case of the Randox 
reagent the HDL-C derived from the kit may be between 1.29mmol/lless than 
and 2.4 7mmol/l greater than the concentration measured by the standard 
technique, while for the Immuno reagent the value may fall between 
1.49mmol/l less than, and 1.87mmol/l greater than the reference HDL-C 
concentration. 
The intra-assay CVs for the Randox and Immuno reactions were 1.5% 
and 2.7% respectively (Table 4., Appendix 8). 
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The resolubilised precipitates from both the Randox and Immuno 
reactions contained lipoproteins of 0:' 2 mobility suggesting contamination of the 
precipitate with HDL 1. 
3.2. LDL-C concentrations: referenc~ method vs precipitation reagents 
The mean +sd LDL-C concentrations measured by the Randox (r=0.91, 
p<O.OOl), Immuno (r=0.67, p<O.Ol» and the Boehringer (r=-0.02, p=n.s.) 
reagents were less than the mean of the same samples analysed by the standard 
technique (Table 3., Appendix 7). The mean differences between these 
methods and the reference values were -0.18 ±5.70mmol/1 for the Randox 
reagent, 2.34±4.92mmol/1 for the Immuno reagent and 1.99 ±2.08 mmol/l for 
the Boehringer reagent (Fig. 5.). The LDL-C concentration obtained using the 
Randox kit may be between 11.58mmol/lless than, and 11.22mmol/1 greater 
than the LDL-C of the same sample using the reference method. These limits 
were similar for the Immuno and Boehringer reagents (Table 3.) 
Assessment of the precision of the precipitation techniques revealed 
intra-assy CV of 14.7%, 11.9% and 66.6% for the Randox, Immuno and 
Boehringer reagents, respectively (Table 4., Appendix 8). 
3.3. Comparison of the measured LDL-C concentration and the estimated 
LDL-C derived from the Friedewald formula 
The mean ±sd measured LDL-C in 81 samples was 4.16 ±4.24mmol/1 while 
that calculated by the Friedewald formula was 4.39 +4.39mmol/l (r = 0.994, 
P < 0.001) (Table 5., Appendix 9). The mean ±sd difference between the two 
methods was 0.23 ±0.50mmol/1. When samples with plasma triglyceride 
concentrations greater then 4.5mmol/1 were excluded (n=76) the mean ±sd 
measured LDL-C concentration was 3.56 ±2.66mmol/1 compared to an 
estimation of 3.75 ±2.71mmol/l (r=0.991, p < 0.001). The mean ±sd 
difference between the two methods was 0.20 ±0.35mmol/1. 
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Table 3. Lipoprotein cholesterol concentrations obtained using the reference 
method (method A) and 5 precipitation reagents. 
mean (±sd) cholesterol (mmol/l) mean 
------------------------ ---------------------------------- difference 
method A reagent difference ±2sd 
HDL-cholesterol reagents 
Randox 3.78 3.18 0.59 -1.29 - 2.47 
(n=13) ±1.46 ±1.55 ±0.94 
Immuno 3.90 3.70 0.19 -1.49 - 1.87 
(n= 12) ±1.44 ±1.41 ±1.68 
LDL-cholesterol reagents 
Randox 6.37 6.55 -0.18 -11.58 - 11.22 
n=13) ±2.82 ±2.21 ±5.70 
Immuno 5.34 2.99 2.34 -7.50 - 12.18 
(n= 13) ±6.11 ±2.19 ±4.92 
Boehringer 2.87 0.88 1.99 -2.17 - 6.15 
(n= 12) ±2.02 ±0.49 ±2.08 
Table 4. The intrassay precision of precipitation reagents (n = 8). 
mean (±sd) lipoprotein 
cholesterol concentration CV 
HDL reagents 
Randox 
Immuno 
LDL reagents 
Randox 
Boehringer 
Immuno 
(mmol/l) 91a 
5.16 ± 0.08 1.5 
5.26 ± 0.14 2.7 
1.83 ± 0.27 14.7 
0.15 ± 0.10 66.6 
1.85 ± 0.22 11.9 
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Figure 4. The difference between the HDL-C concentration derived from the 
reference method and a precipitation reagent plotted against the mean HDL-C 
derived from the two methods. A, Randox HDL-C precipitation reagent 
(n= 13). B, Immuno HDL-C precipitation reagent (n= 12). 
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Figure S. The difference between the LDL-C concentration derived from the 
reference method and a precipitation reagent plotted against the mean LDL-C 
derived from the two methods. A, Randox LDL-C precipitation reagent 
(n= 13). B, Boehringer LDL-C precipitation reagent (n= 12). C, Immuno 
HDL-C precipitation reagent (n-= 13). 
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When the raw data in this study are subjected to the criteria of Warnick, 
Knopp, Fitzpatrick, and Brarson (1990), the results may be classified as 
follows: for dogs with plasma triglyceride concentrations less than 1.75mmol/l, 
49/71 (69%) of results were accl,ptable, when the plasma triglyceride was 1.75-
4.5mmol/l only 2/5 (40%) of results were acceptable and in cases with plasma 
triglyceride concentrations greater than 4.5mmol/l, 2/5 (40%) values were 
within acceptable limits. When classified according to the LDL-cholesterol 
concentration, 4/8 (50%) samples with LDL-C less than 1.0mmol/l were 
acceptable while the values for samples with plasma LDL-C concentrations in 
the ranges 1-2mmol/l, 2-3mmol/l, 3-4mmol/l and greater than 4mmo/l were 
9/19(47%),7/15 (47%),5/11 (45%) and 23/28 (82%), respectively (Fig. 6.). 
3.4. Comparison of the measured LDL-C concentration and the estimated 
LDL-C derived from a modified Friedewald formula 
The equation of the linear regression between plasma VLDL-C concentration 
and plasma triglyceride concentration in 101 dogs was as follows: 
VLDL-C = 0.23 + 0.461 x triglyceride 
Two modifications of the Friedewald formula were therefore tested. The first 
(modified formula A) was as follows: 
LDL-C= plasma cholesterol - HDL-C - (plasma triglyceride x 0.46) 
For all 81 cases where the Friedewald formula was calculated, the mean ±sd 
estimated LDL-C concentration was 4.39 ±4.40mmol/l (r = 0.993, P < 0.001) 
and the mean ±sd difference between this and the measured LDL-C 
concentration was 0.20 ±0.35mmol/l (Table 5.). After exclusion of the five 
cases with plasma triglyceride concentrations greater than 4.5mmol/l, the mean 
±sd estimated LDL-C and mean ±sd difference were 3.56 ±2.66mmol/l 
(r = 0.991, P < 0.001) and 0.20 ±0.35mmol/l, respectively. The second 
modification of the Friedewald formula (modified formula B) was: 
LDL-C =plasma cholesterol- HDL-C - {(plasma triglyceride x 0.46) +0.23} 
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For the total population the mean estimated LDL-C concentration using this 
formula was 4.14 ±4.39mmol/l (r=0.993, p<O.OOl), with a mean difference 
between the estimated and measured values of -0.02 ±0.52mmol/1. Removal 
of samples with high triglyceride concentrations altered these to 3.51 ± 
2.72rnrnol/l (r=0.990, p<O.OOl) and -0.05 ±0.38mmol/l for the mean ±sd 
estimated LDL-C and difference, respectively (Table 5.). 
Table 5. Mean (±sd) estimated LDL-C concentration (mmoljl) for the 
Friedewald formula, modified formula A and modified formula B. The mean 
measured LDL-C in 81 cases was 4.16±4.24mmol/l and for 76 cases with 
plasma triglyceride concentrations less than 4.5mmol/l, the mean 
concentration was 3.56±2.66mmoljl. 
n=81 n=76 
LDL-C difference LDL-C difference 
Friedewald 4.39 0.23 3.75 0.20 
Formula ±4.39 ±0.50 ±2.71 ±0.35 
Formula 4.39 0.23 3.75 0.20 
A ±4.40 ±0.53 ±2.70 ±0.35 
Formula 4.14 -0.02 3.51 -0.05 
B ±4.39 ±0.52 ±2.72 ±0.38 
3.5. Comparison of semiquantitative electrophoresis and a quantitative 
method of lipoprotein analysis 
The mean ±sd measured HDL-C and LDL-C were 3.78 ± 1.40mmol/l and 1.31 
±0.94rnrnoljl, respectively. When converted to percentages of the total plasma 
cholesterol these represented 66.5 ± 12.9% and 19.6 ±7.9%, respectively. The 
electrophoretic estimations of relative distributions of HDL and LDL were 74.9 
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±16.0% (r=0.77, p<O.Ol) and 17.84 ±7.46% (r=0.56, p<0.05), respectively. 
In only 2/14 cases was VLDL clearly identified as a separate band in the pre-;3 
region (Appendix 10). 
Figure 6. The measured LDL-C concentration versus the number of samples 
classified as acceptable and unacceptable. 
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4. DISCUSSION 
D Acceptable 
• Unacceptable 
The precipitation of apoB-containing lipoproteins by polyanions (dextran, 
heparin) and divalent cations (Mn2+, Mg2+) is frequently used as a means of 
measurement of human HDL-C, since the HDL class remains in the 
supernatant of the incubation and may be measured directly. It is recognised 
that each precipitation technique may give rise to considerable differences in 
HDL-C quantification (Warnick, Cheung and Albers 1979), e.g., 
phosphotungstic acid precipitation yields a lower HDL-C concentration than 
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heparin manganese methods (Warnick, Mayfield and Albers 1981). This is 
confirmed in the present study of canine plasma, where the HDL-C 
concentration obtained with the Randox method was lower than that of the 
combined ultracentrifugation/precipitation method. This was caused by a 
greater precipitation of HDL by phosphotungstic acid than by heparin 
manganese solutions. The co-precipitation of HDLI with the former 
precipitation reagent was also noted by Rhodes, Meyer, Fish and Kerns (1992). 
In the human medicine, this is not considered of quantitative importance 
(Gibson, Rubinstein and Brown 1984), but in the hyperlipidaemic dog, in which 
HDLI is one of the major cholesterol carriers, this source of error may be of 
considerable importance. 
Despite a significant correlation between the Randox precipitation 
reagent and the reference method, the study of the mean difference and the 
standard deviation of the differences between the two methods indicates that 
95% of the HDL-C concentrations derived by the phosphotungstic acid method 
would lie between 1.29mmoljlless than and 2.47mmol/1 greater than the HDL-
C value achieved using the heparin manganese method. This lack of agreement 
may suggest that the reagent is not suitable for use with canine plasma, but 
considering the ease of performance of this method and the random nature of 
the differences between it and the reference procedure it is worth considering 
means of improvement. These may include alteration of the concentration of 
the reagent or the analysis of multiple aliquots from each sample and recording 
the mean HDL-C concentration. 
The use of polyethylene glycol reagents for the quantification of human 
HDL has been associated with concentrations lower than those achieved with 
heparin manganese (Warnick, Mayfield and Albers 1981), a feature also 
confirmed in the analysis of canine plasma HDL-C. This reagent showed 
favourable correlation with the reference method, but the correlation 
coefficient failed to reveal the lack of agreement between the two methods 
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demonstrated by the distribution of the mean differences. This presentation of 
polyethylene glycol is therefore not ~,uitable for the quantification of HDL-C in 
canine plasma; however modification of the concentration of the reagent may 
alter the precipitation properties fav'1urably (Chira, Akizawa, Fujisawa, Osaka-
Nakamori, Iwasaki, Suzuki, Intoh, Matsuno, Mitamura and Kobayashi 1992). 
The phosphotungstate and the polyethylene glycol reagents displayed 
favourable CV but both methods produced mean HDL-C concentrations lower 
than that of the reference method. The lack of agreement between these 
methods appeared to be a result of excessive precipitation of HDL. This has 
also been recognised in human lipid chemistry, where precipitates from such 
reactions have a higher apoA-I content (an index of HDL) in samples from 
female patients than samples from males (Warnick, Cheung and Albers 1979). 
The implications of this source of error are obviously of importance in the dog, 
in which HDL is the major cholesterol carrier (Solyom, Bradford and Furman 
1971; Mahley and Weisgraber 1974). 
The quantification of plasma LDL by precipitation methods produces 
lower concentrations than obtained by ultracentrifugation/precipitation 
techniques (Rifai, Warnick, McNamara, Belcher, Grinstead and Frantz 1992) 
and show poor precision at clinically significant LDL concentrations (Cathcart 
and Dominiczak 1990). The same trends were identified in this study, where 
the mean LDL-C concentrations using precipitation reagents were less than 
those achieved using the reference method. Precipitation of human LDL by 
PVS has been reported to give good agreement with ultracentrifugation 
techniques when the total plasma triglyceride concentration is low (Rifai, 
Warnick, McNamara, Belcher, Grinstead and Frantz 1992). However, in this 
study there was a marked negative bias in LDL-C concentration derived from 
the PVS reaction and examination of the distribution of the differences 
between the two methods indicates that the method is not acceptable for use 
with canine plasma. 
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Study of the three reagents revealed large, unacceptable discrepancies in 
the measurement of LDL-C in canine plasma. Despite data sheet indications 
that LDL precipitation reagents may be used with samples with high 
triglyceride concentrations, two samples with markedly elevated triglyceride 
concentrations (18.3mmoljl and 39mmoljl) displayed large differences 
between precipitation methods and the reference method. Using the heparin 
reagent, the differences were 17.44mmol/l and 6.29mmol/l, respectively, while 
the dextran sulphate reagent produced differences of 17.43mmol/l and 
1.23mmol/l, respectively. 
The CVs of the LDL precipitation reagents were much poorer than 
those of the HDL methods suggesting that in addition to poor agreement with 
the reference method the kits do not display adequate repeatability 
characteristics when used with canine plasma. 
Agarose gel electrophoresis gives good separation of the plasma 
lipoproteins (Noble 1968) and is the most commonly used means of lipoprotein 
analysis in the dog (Rogers, Donovan and Kociba 1975a and b; Ford 1977). 
The lipoprotein classes are separated on the basis of their size and charge, 
resulting in migration to a characteristic position, i.e., LDL in the (3 position, 
VLDL in a pre-(3 position and HDL displaying a mobility. The lipid content of 
the lipoprotein is then stained with a fat soluble dye, e.g., Sudan Black. The 
differential affinity of Sudan Black for triglyceride versus cholesterol has not 
been determined and therefore the relative distribution assessed by 
densitometric scanning may not reflect the absolute cholesterol content of the 
lipoprotein classes. If the staining characteristics are not equal it may explain 
the poor visualisation of VLDL (a triglyceride-rich and cholesterol poor 
lipoprotein) using this electrophoretic protocol. Despite this unknown variable 
there was a significant correlation between electrophoretic HDL 
concentrations and the measured HDL-C value and a moderate correlation 
between the LDL concentrations derived by the two methods. 
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Electrophoresis remains essential for the evaluation of lipoprotein 
mobility and the recognition of individual lipoproteins, e.g., {3-VLDL and LpX 
(Danielsson, Ekman, Johansson and Petersson 1976). In addition, it may be 
used to give an estimate of relative plasma concentrations of HDL and LDL 
but the poor visualisation of VLDL limits its use in the investigation of lipid 
abnormalities. Nevertheless, electrophoresis, in combination with the 
measurement of plasma cholesterol and triglyceride concentrations, is integral 
to the investigation of hyperlipidaemia and the relative inexpense of the 
procedure is obviously attractive to clinical pathology laboratories. The clinical 
applications of electrophoresis may improve on the introduction of agarose gel 
electrophoresis combined with enzymatic cholesterol assays, allowing the 
derivation of the absolute HDL-C and LDL-C concentrations from the total 
plasma cholesterol concentration and the relative distribution of cholesterol 
(Warwick, Packard and Shepherd 1990). 
A common approach to lipoprotein analysis in human medicine is the 
direct measurement of plasma triglyceride, cholesterol and HDL-C 
concentrations. The LDL-C concentration is then calculated by the Friedewald 
formula. In the analysis of human plasma this allows the estimation of LDL-C 
without the use of preparative ultracentrifugation. The formula is used on the 
premiss that VLDL is the major carrier of plasma triglyceride. However, in the 
case of type III hyperlipidaemia the VLDL cholesterol content is very high and 
is underestimated by the use of the Friedewald formula. The converse is true 
of samples with low VLDL cholesterol concentrations, resulting in an 
underestimation of the plasma LDL-cholesterol concentration. The formula is 
not recommended for use in cases of hypertriglyceridaemia where the plasma 
triglyceride concentration is greater than 4.5mmoljl, since the ratio of VLDL 
cholesterol to triglyceride is lower than 0.45 in these samples. 
In the canine population studied here there was a good correlation 
between the LDL-C measured by the reference technique and that estimated 
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by the Friedewald formula. However the agreement, either by the statistical 
method of Altman and Bland (1983) or by the 10% limits used by Warnick, 
Knopp, Fitzpatrick and Branson (1990), is not sufficient to allow replacement 
of measurement of LDL by estination using this formula. ~'nmination of the 
number of acceptable samples versus the LDL-C concentration indicated that 
the agreement between the measured and calculated values are improved at 
higher LDL-C concentrations. This may simply be a result of the number of 
cases in each group but may also reflect poorer precision in the quantitative 
method at lower LDL concentrations. The Friedewald formula may therefore 
be an acceptable alternative to ultracentrifugation/precipitation methods in the 
evaluation of hypercholesterolaemic cases which display only marginal 
elevations of plasma triglyceride concentrations. 
It may be predicted that alteration of the factors used in the Friedewald 
formula to account for the VLDL-C/triglyceride ratio in the dog may allow 
derivation of a more appropriate formula for the estimation of canine plasma 
LDL-C concentrations. However, modification of the formula did not correct 
for the heterogeneity of VLDL in the population and therefore gave no 
improvement on the original factor of 0.45. 
In this evaluation of the Friedewald formula, the HDL-C concentration 
was measured using the combined ultracentrifugation/precipitation technique, 
but the estimation of LDL-C will not provide an additional benefit in labour 
and equipment costs until a suitable reagent is identified for the direct 
measurement of HDL in plasma. 
In conclusion, it has been demonstrated that the precipitation methods 
currently available for the quantification of human plasma lipoprotein 
concentrations are not suitable replacements for the quantification of canine 
plasma lipoproteins by validated ultracentrifugation/precipitation techniques. 
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The use of electrophoresis for the detection of {3-VLDL and HDLl remains an 
essential part of the investigation of hyperlipidaemia in the dog. 
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PLASMA LIPID AND LIPOPROTEIN CHOLESTEROL 
CONCENTRATIONS IN THE DOG: THE EFFECTS OF AGE, 
BREED, SEX AND SYSTEMIC DISEASE 
CHAPTER IV 
1. INTRODUCTION 
The lipoprotein abnormalities associated with spontaneous disease in the dog 
have been characterised by measuring plasma lipid concentrations and 
electrophoretic profiles (Rogers, Donovan and Kociba 1975b; Ford 1977). In 
addition to the effects of disease, a small number of investigators have 
attempted to define the influence of breed (Downs, Bolton, Crispin and Wills 
1993) and environment (Schiller, Berglund, Terry, Reichlin, Trueheart and Cox 
1964; Crispin, Bolton and Downs 1992) upon plasma lipoprotein concentrations 
in the dog. To date, the lack of standardised methods for the quantification of 
canine plasma lipoproteins has limited our understanding of lipoprotein 
metabolism in the healthy and hyperlipidaernic dogs. In addition, the paucity of 
information regarding the plasma activities of lipoprotein lipase and hepatic 
lipase in dogs has contributed to the lack of progress in this area of research. In 
this study the influences of breed, age and gender on the plasma lipid and 
lipoprotein concentrations of the dog have been evaluated, and the lipoprotein 
abnormalities associated with spontaneous systemic disease and obesity 
quantified. Lastly, the activities of lipoprotein lipase and hepatic lipase were 
measured in dogs with endocrine dysfunction. 
2. MATERIALS AND METHODS 
2.1. Case selection 
Dogs suffering from diabetes mellitus, hyperadrenocorticism, hypothyroidism, 
protein-losing nephropathy, hepatic disease and obesity were selected from 
cases referred to Glasgow University Veterinary School (G.U.V.S.). The health 
status of each individual was established by routine screening, which included 
urinalysis and haematology /biochernistry profiles. The diagnoses were 
confirmed as follows: diabetes mellitus by glucosuria and fasting blood glucose 
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> 12mmol/l; hyperadrenocorticism by Synacthen (Ciba Laboratories) 
stimulation test (60 minute cortisol > 660nmol/l) and followed, where 
necessary by a low dose dexamethasone suppression test (O.Olmg/kg; 8 hour 
cortisol >40nmol/I); hypothyroidism by TSH (thyroid stimulating hormone; 
Sigma T-3538) stimulation test (5 LU.; 6 hour thyroxine increased to a 
concentration less than 1.5 times the basal concentration). The assay of serum 
cortisol and thyroxine were performed by Serono Clinical Laboratory Services, 
Cambridge. The diagnosis of protein-losing nephropathy was made on the 
basis of persistent proteinuria and hypoalbuminaemia. Hepatic disease was 
defined biochemically as a condition which resulted in impaired hepatic 
function with or without hepatocellular enzyme leakage. Obese animals were 
selected on the basis that their body weight was greater than 115% of their 
breed and sex ideal weights (Lewis, Morris and Hand 1987; Glover 1977). The 
control group of dogs was comprised of clinically healthy animals screened as 
part of a routine health or pre-anaesthetic examination at G.U.V.S. 
The total postheparin lipolytic, lipoprotein lipase and hepatic lipase 
activities were measured in six clinically normal, adult beagles, 10 dogs with 
diabetes mellitus and five dogs with hypothyroidism. All the diabetic dogs were 
receiving insulin at the time of sampling, but had been referred to G.U.V.S. 
because of apparent poor glycaemic control. The postheparin lipolytic activity 
was also measured in two of the hypothyroid dogs after six weeks of thyroid 
replacement therapy. 
2.2. Routine blood biochemistry 
Measurement of biochemical parameters was performed using commercial 
reagent kits on a Cobas MIRA clinical chemistry analyser (Roche). Alkaline 
phosphatase (ALP), aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured by standard methods (Unimate 3 ALP 
DGKC, Uni-kit II ASAT, Ma-kit 10 ALAT; Roche). Glucose concentrations 
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were determined by enzymatic, colorimetric means (Unimate 7 Gluc-P AP). 
Total protein was measured by a modified biuret reaction with blank correction 
and albumin by a bromocresol green automated method on a Technicon Auto 
Analyser AAII (Technicon InstrumeTlts Corporation). Quality assurance was 
guaranteed using control sera (Precipath U and Precilip EL; Boehringer 
Mannheim GmbH). Quality control was monitored by the Scottish Quality 
Assessment Scheme and UKEQAS for general clinical chemistry (Appendix 1). 
2.3. Patient preparation, blood collection and lipoprotein analysis 
Blood samples were collected for lipoprotein quantification as previously 
described (Chapter III 2.1.) and all analyses were performed within 24 hours. 
Blood was collected into fluoride oxalate for glucose estimation and lithium 
heparin for the remaining biochemical analyses. Quantification of the plasma 
lipoproteins was performed using the ultracentrifugation/precipitation 
technique previously validated for use with canine plasma (Chapter III 2.2.). 
Qualitative analysis of the plasma lipoproteins was performed by agarose gel 
electrophoresis (Paragon Lipoprotein Electrophoresis Kit; Beckman Inc.) 
according to the manufacturer's instructions. Since the VLDL band of canine 
plasma is rarely recognised in native plasma, the concentrated VLDL fraction 
isolated by ultracentrifugation was also applied to the gels. 
2.4. Postheparin lipolytic and lipoprotein lipase activity 
Postheparin plasma lipase activities were measured in heparinised plasma from 
fasted dogs. Blood was collected before, and 10 minutes after the intravenous 
administration (70 IU /kg) of sodium heparin (Heparin (Mucous) Injection BP; 
Leo Laboratories Ltd.). Samples were collected into lithium heparin and 
placed on ice before separation by low speed centrifugation at 4°C for 15 
minutes. The plasma was divided into 1ml aliquots and stored at -20°C for no 
longer than 12 weeks before analysis. 
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Radioactive triolein was formed by the addition of 50jLCi glycerol tri (1-
14C) oleate (CFA 258; Amersham International plc) to 24.5ml toluene, then 
divided into 3.5ml aliquots and placed in round bottom glass flasks. To each 
flask was added 3.5ml cold triolein (500mg triolein (17140; Sigma) in 25ml 
toluene). The substrate was then dried down under nitrogen in a water bath at 
55°C, washed three times with 3ml heptane and stored under nitrogen at -20°e. 
The substrate emulsion was prepared 30 minutes prior to use by the addition of 
5.5ml 5% gum arabic in O.2M Tris-HCI pH 8.4, followed by sonication at 18 
microns for 4 minutes. Then 5.5ml 10% bovine serum albumin (Fraction V; 
Sigma A-4503) in O.2M Tris-HCI, pH8.4 was added. 
For the measurement of total postheparin plasma (PHP) lipase activity, 
10jLI of post heparin plasma was diluted in 30jLI 0.15M NaCI and incubated in 
duplicate with 200jLI substrate, 250jLI low salt buffer (0.2M Tris, 0.2M NaCl, 
pH8.4) and 50jLI pooled, heat-inactivated serum at 28°C for 60 minutes. 
Hepatic lipase (HL) activity was assayed by the dilution of 10jLI postheparin 
plasma in 30jLI 0.15M NaCI and incubated in duplicate with 200jLI substrate, 250 
JLI high salt buffer (0.2M Tris, 2.0M NaCI, pH8.4) under the same conditions. 
Fatty acids were extracted by adding 3.25ml methanol:chloroform:heptane 
(1.41:1.25:1 parts) and 0.75ml 0.14M K2C03, 0.14M H3B03, pH10.5. The tubes 
were vortexed and centrifuged at 3,000 rpm, 4°C for 30 minutes. One ml of the 
upper fraction was removed and counted in 10ml liquid scintillant (Ultima 
Gold; Packard Instrument Co.) and 200jLI acetic acid. The radioactivity in 1ml 
of the upper fraction of blank incubations (containing 10jLI 0.15M sodium 
chloride instead of postheparin plasma) was subtracted from the sample counts 
and the total radioactivity taken as the counts in 1ml of the lower fraction of the 
blank incubations. The lipolytic activity was calculated according to the 
following equation (see Appendix 2 for derivation): 
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Activity (JLmoIFA/ml/hr) = (Sample cpm - Blank cpm) x 755.1 
Total cpm -background count 
Lipoprotein lipase (LPL) activity was calculated as the difference between the 
total postheparin lipolytic activity and hepatic lipase activity. 
2.5. Statistical Analyses 
The independent effects of breed, age, gender and health status (control, 
diabetes mellitus, hyperadrenocorticism, hypothyroidism, protein-losing 
nephropathy, hepatic disease or obesity) on plasma lipid and lipoprotein 
concentrations of the dogs were determined by analysis of covariance; breed, 
age, gender and health status were fitted as fixed effects while age was fitted as 
a covariate. The mean values for each group, i.e., control, diseased, obese were 
then estimated after correcting for the effects of breed, age and gender by the 
least squares method. When the main effect was statistically significant, means 
were then compared by multiple t-tests. Analyses were performed on the SAS 
software package (SAS Institute Inc., U.S.A.). The lipid and lipoprotein 
concentrations of two dogs with obstructive jaundice were noted, but no 
statistical analysis was performed. The analysis of paired plasma enzyme 
activites from the same individual was performed using the Sign test. The level 
of significance, unless stated otherwise, was taken as p < 0.05. 
3. RESULTS 
3.1. Age, breed and gender distribution in the control and disease populations 
The disease populations in this study showed a gender bias with a 
preponderance of neutered females in both the obese (10/20) and 
hyperadrenocorticism (6/14) groups and a preponderance of entire males in 
the other populations (Table 6.). The mean ±sd age was significantly greater 
III dogs suffering from diabetes mellitus (9.46 ±3.1 years), 
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hyperadrenocorticism (11.36 ±1.5 years) and hepatic disease (11.00 ±2.45 
years) than in the controls (6.36 ±3.7 years). 
Tahle 6. Breed, gender and ag~ distribution of control, obese and systemic 
disease groups. 
Number of cases 
Breed Sex Age 
S M L G M F MN FN (mean +sd) 
Control 
(n=33) 5 12 16 0 18 11 0 4 6.4(±3.7) 
Obesity 
(n=20) 5 2 12 1 4 4 2 10 7.1(± 1.9) 
Diabetes mellitus 
(n= 11) 6 1 4 0 4 5 0 2 9.5(±3.1) * 
Hyperadrenocorticism 
(n=14) 4 9 1 0 3 5 0 6 11.5( ± 1.5) * 
Hypothyroidism 
(n= 10) 1 2 7 0 6 2 1 1 7.6(±2.9) 
Protein-losing nephropathy 
(n=4) 1 0 3 0 4 0 0 0 6.3(±3.2) 
Hepatic disease 
(n=6) 2 1 3 0 5 0 0 1 11.0( ±2.5) * 
* p<0.05 
S = small, M = medium, L = large, G = giant, M = male, F = female, MN = 
neutered male, FN = neutered female. 
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3.2. The effect of age, breed and sex on plasma lipid and lipoprotein 
concentrations 
The plasma concentrations of cholesterol, VLDL-C, LDL-C and HDL-C were 
unaffected by breed or age. The same was largely true of gender, with the 
notable exception that mean ±sem HDL-C concentration was significantly 
lower in entire males (least squares mean +sem; 3.19 ±0.26mmol/l) than 
intact females (3.99 ±0.31mmol/l; p<O.Ol) and neutered females (3.75 ± 
0.29mmol/l; p < 0.05). The effect of gender on the plasma triglyceride 
concentration approached statistical significance (p = 0.07), with highest mean 
concentration in neutered females and the lowest in entire males. 
3.3. The effect of disease on plasma lipid and lipoprotein concentrations 
Plasma cholesterol concentrations were significantly greater than those of the 
control group in animals with diabetes mellitus (p < 0.01), hyperadrenocorticism 
(p<O.Ol) hypothyroidism (p<O.OOl), protein-losing nephropathy (p<O.Ol) and 
obstructive jaundice (Table 7.; Appendix 11). In dogs with diabetes mellitus 
this was due to significantly increased concentrations of VLDL-C (p < 0.01) and 
HDL-C. The concentration of LDL-C was significantly increased in the dogs 
with hyperadrenocorticism and obstructive jaundice, while in the hypothyroid 
dogs, plasma triglyceride, VLDL-C, LDL-C (p < 0.001) and HDL-C were 
significantly higher than the control group. Protein-losing nephropathy was 
characterised by significant increases in LDL-C and HDL-C. The plasma lipid 
and lipoprotein concentrations in obese dogs and dogs with hepatic disease 
were not significantly different from the control dogs. The plasma cholesterol 
(p < 0.001) and LDL-C (p < 0.001) were greater in dogs with hypothyroidism 
than those with either diabetes mellitus or hyperadrenocorticism. The plasma 
lipid and lipoprotein concentrations in dog with hyperadrenocorticism and 
those with diabetes mellitus were not significantly different. 
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Table 7. The mean ±sd plasma lipid and lipoprotein cholesterol 
concentrations in dogs with systemic diseases and in clinically healthy dogs. 
Plasma concentration (mmol/l) 
Triglyceride Cholesterol VLDL-C LDL-C HDL-C 
Control 0.61 4.51 0047 1.72 2.34 
(n=33) ±0.20 ±1.49 +0.70 ±1.88 ±0.70 
Diabetes mellitus 1.78 9.31** 1.79** 3.58 3.92* 
(n= 11) ±1.33 ±3.76 ±2.23 ±2.60 ±1.04 
Hyperadrenocorticism 1.59 8.86** 0.87 4.14** 3.82 
(n=14) ±1.41 ±2.32 ±0.70 ±2.05 ±1.25 
Hypothyroidism 3049*** 16.17*** 2.05* 10.65*** 3048* 
(n=lO) ±3.96 ±9.93 ±2.34 ±8.23 ±1.02 
Obesity 1.04 6.03 0.70 1.88 3.47 
(n=20) ±0.53 ±1.79 ±0.31 +1.19 ±1.22 
Nephropathy 0.73 10.69* * 0.55 5.86* 4.28* 
(n=4) ±0.39 ±1.21 ±OAO ±1.85 ±0.84 
Hepatic disease 1.06 6046 0049 3.11 2.89 
(n=6) ±0.84 ±2.26 +0.34 ±1.09 ±1.57 
EHBDO 1.96 18.22 0.84 5.06 2.32 
(n=2) ±1.62 ±4.53 ±0.07 ±5.04 ±0.59 
* p<0.05, ** p<O.Ol, *** p<O.OOl 
EHBDO = Extrahepatic bile duct obstruction 
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3.4. Agarose gel electrophoresis 
The individual lipoproteins were identified according to their characteristic 
electrophoretic mobility, i.e., bands of a-migrating lipoproteins (HDL), (3-
migrating lipoproteins (LDL) and prr;-(3 migrating species (VLDL), isolated 
from the fraction containing lipoproteins of density less than 1.006gjml. 
Electrophoresis of the plasma of one diabetic dog showed evidence of 
hyperchylomicronaemia, indicated by the presence of chylomicrons at the 
origin of the geL Beta-VLDL were identified in the plasma of one dog with 
spontaneous hypothyroidism. 
3.5. Plasma lipolytic activity associated with secondary and idiopathic 
hyperlipidaemia in the dog 
The total plasma lipolytic activity and the lipoprotein lipase activity in dogs with 
diabetes mellitus were similar to those of control beagles, but the hepatic lipase 
activity was significantly higher (Table 8., Appendix 18). On initial 
presentation, the total lipolytic, lipoprotein lipase and hepatic lipase activities 
were lower in dogs with hypothyroidism (p < 0.01), but the activities increased 
after appropriate drug therapy (n.s.). 
4. DISCUSSION 
The effect of disease upon the lipoprotein phenotype of the dog has been 
studied previously using semi-quantitative electrophoretic and densitometric 
scanning methods (Rogers, Donovan and Kociba 1975a and b; Rogers 1977). 
These studies did not allow for the effects of breed, age and gender on plasma 
lipid and lipoprotein concentrations. Here, a quantitative method of 
lipoprotein analysis has been used to estimate and correct for the effect of 
these individual factors. 
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Table 8. The mean ±sd total plasma lipolytic, LPL and HL activities in dogs 
with diabetes mellitus and hypothyroidism (before and after replacement 
therapy) and a control group of six beagles. 
Li;>olytic activity (jlmoIFA/ml/hr) 
Group Total LPL HL 
Control 17.65 10.73 6.92 
(n=6) ±1.45 ±2.66 ±1.44 
Diabetes mellitus 22.39# 10.31 10.78* 
(n=5) ±10.31 ±5.37 ±2.04 
Hypothryoidism (before) 5.16** 3.20**" 1.96* * 
(n=5) ±1.18 ±1.50 ±1.27 
Hypothyroidism (after) 13.40 5.16 10.24 
(n=2) ±3.11 ±1.05 ±4.89 
* p<0.05, ** p<O.OI, # n = 10 
In man, total plasma cholesterol concentrations are dependent upon age 
and gender. The plasma cholesterol concentrations of both men and women 
rise from childhood to mid-life. This trend is more marked in males than in 
females although in the latter, plasma cholesterol concentrations increase again 
in the post-menopausal period (Kissebah and Schectman 1987). The present 
study failed to reveal any change in canine plasma cholesterol and lipoprotein 
concentrations with age. It may be that no such trends exist but it is also 
possible that the number of animals included in this study was insufficient to 
identify any relationships. The mean HDL-C concentration in women is higher 
than that of men (Crook and Seed 1990), a feature which may be explained by 
the lower hepatic lipase activity in females. This study showed a similar pattern 
in the canine population, where the mean HDL-C concentration in entire 
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bitches was greater than that of entire males. The effect of gender upon the 
activity of hepatic lipase in the dog has not been determined. 
Genetic mutations or variations, resulting in abnormalities of 
lipoprotein metabolism, may give rise to hyperlipidaemia in man, e.g., familial 
hypercholesterolaemia. In this way, the prevalence of hyperlipidaemia in a 
population depends to a degree upon the gene pool. In the dog, such genetic 
predisposition to lipoprotein disorders is rare, but recently, investigators have 
suggested that clinically normal dogs of different breeds may display variation 
in plasma cholesterol concentrations (Armstrong and Ford 1989). No such 
breed variation in lipid concentrations was noted in this study, although the 
limited number of cases in each population dictated that only breed type (small, 
medium, large and giant) was tested in the analysis of covariance. A more 
comprehensive study may therefore be necessary before final conclusions are 
drawn regarding breed variation in plasma lipid and lipoprotein concentrations. 
The plasma lipid and lipoprotein concentrations associated with 
experimentally-induced camne hypothyroidism, m combination with 
cholesterol-loading have been studied previously (Mahley, Weisgraber and 
Innerarity 1974). Under these circumstances there was a heterogeneous 
response with some dogs classed as hypo-responders, in which a moderate 
increase in plasma cholesterol was accompanied by an increase in HDL and 
LDL concentrations. The present study has corroborated these results; dogs 
with spontaneous hypothyroidism displayed an increase in plasma cholesterol, 
LDL-C and HDL-C concentrations. In the original experimental study 
(Mahley, Weisgraber and Innerarity 1974), a second group of animals, classed 
as hyper-responders, developed very high cholesterol levels with an increase in 
HDL concentrations and the appearance of a novel lipoprotein with a density 
less than 1.006g/ml, but displaying /3-migration on electrophoresis, called /3-
VLDL. In the present study, /3-VLDL was evident on electrophoresis of the 
plasma of one dog with spontaneous hypothyroidism (Chapter VII 3.2.). The 
87 
CHAPTER IV 
hypercholesterolaemia in this case was particularly marked (47.80mmol/l), but 
the clinical and pathological factors which dictate the accumulation of the 
lipoprotein remnants in this case and not in others have not been determined. 
The lipoprotein abnormalities noted in the dogs with hypothyroidism 
may be explained as follows. First, it has been demonstrated that 
hypothyroidism results in a down-regulation of the hepatic LDL receptor 
(Scarabottolo, Trezzi, Roma and Catapano 1986) secondary to deficiency of tri-
iodoythyronine (T3) (Chait, Bierman and Albers 1979). Since T3 plays a role 
in the regulation of biliary excretion, a deficiency of this hormone results in an 
increased hepatic cholesterol pool, followed by down-regulation of LDL 
receptor activity which prevents excess sterol accumulation in the liver. 
Consistent with this, impaired clearance of LDL from the circulation appeared 
to be the predominant abnormality of lipoprotein metabolism associated with 
hypothyroidism in the dog. 
However, hypothyroidism III humans is accompanied by reduced 
activities of lipoprotein lipase and hepatic lipase (Valdemarsson, Hansson, 
Hedner and Nilsson-Ehle 1983). Lipoprotein lipase is responsible for the 
hydrolysis of the core lipid of triglyceride-rich lipoproteins and their 
modification to remnant particles, thus facilitating their removal from the 
circulation. The impaired lipoprotein lipase activity recorded in this study may 
account for the raised plasma triglyceride and VLDL-C concentrations found in 
the dogs with hypothyroidism. Hepatic lipase is responsible for the conversion 
of VLDL to IDL, IDL to LDL, and the interconversion of HDL subfractions. It 
is possible that the decreased hepatic lipase activity contributed to the changes 
in HDL-C concentration noted with hypothyroidism. Although the number of 
cases included in this study is small and the changes are not significant, it does 
appear that thyroid relacement therapy results in an increase in the plasma 
activities of these enzymes. It has been proposed that the increased lipoprotein 
lipase activity is mediated via increased protein synthesis, while hepatic lipase is 
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under direct control by thyroid hormones (Valdermarsson, Hedner and 
Nilsson-Ehle 1982). 
Insulin-dependent diabetes mellitus in man is associated with a number 
of lipoprotein abnormalities. Diabetic ketoacidosis is commonly accompanied 
by raised plasma triglyceride and VLDL concentrations secondary to an 
increased flux of NEF A from the adipose tissue. In the dog, however, 
experimental evidence suggests that the hypertriglyceridaemia associated with 
diabetes mellitus is the result of impaired clearance of triglyceride from the 
circulation (Basso and Havel 1970), possibly as a consequence of decreased 
lipoprotein lipase activity. The reduced catabolism of VLDL, with or without 
an increase in its synthesis would explain the raised VLDL-C concentrations 
associated with canine diabetes mellitus in this study. 
It has been reported previously that dogs with diabetes mellitus have an 
intensely staining {3-band on lipoprotein electrophoresis consistent with 
increased LDL (Rogers 1977). Individual animals examined in this study had 
raised LDL-C, but the group was heterogeneous in this respect and the mean 
value was not significantly different from the control population. The increase 
in plasma LDL-C concentrations in individual dogs may be the result of over-
production of the lipoprotein class, secondary to raised VLDL concentrations. 
The raised HDL-C concentration found in dogs with spontaneous disease has 
previously been recognised in the hyperlipidaemia of experimental canine 
diabetes mellitus combined with dietary cholesterol loading (Wilson, Chan, 
Elstad, Peric-Golia, Hejazi, Albu and Cutfield 1986). The increase in this 
lipoprotein class may reflect an increase in cholesterol synthesis, or be the 
consequence of impaired removal of the lipoprotein from the circulation 
secondary to alterations in hepatic receptor activity (Gleeson, Hejazi, Kwong, 
Chan, Le, Alberts and Wilson 1990). 
In humans, diabetes mellitus IS accompanied by a reduction in 
lipoprotein lipase activity (Abbate and Brunzell 1990), which corrects rapidly 
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on insulin therapy (Nikkila, Huttunen and Ehnholm 1977). It is not surprising 
therefore, that in diabetic dogs receiving insulin therapy the lipoprotein lipase 
activities are not significantly different from controls. The plasma lipolytic 
activities in two dogs (29.40 JLI"'olFA/ml/hr and 40.46 fLmolFA/ml/hr) were 
considerably greater than in control dogs (upper limit, 19.10JLmolFA/ml/hr). 
In one of these the lipoprotein lipase activity was also increased (18.50 fL 
molFA/ml/hr). This may reflect the effect of hyperinsulinaemia secondary to 
the systemic administration of insulin. The activity of hepatic lipase is 
increased both in diabetic humans (Nikkila, Huttunen and Ehnholm 1977) and 
dogs with experimental diabetes mellitus which are under poor glycaemic 
control (Muller, Saudek and Applebaum-Bowden 1985). The present study 
confirmed these findings in naturally-occurring diabetes mellitus in the dog 
although the exact mechanism of the increase in plasma hepatic lipase activity 
is not clear. 
Hyperadrenocorticism in man is not commonly associated with plasma 
lipoprotein abnormalities, although the administration of prednisolone resulLs 
in increased plasma cholesterol and HDL-C concentrations in both sexes, and 
plasma triglyceride concentrations in females (Zimmerman, Fainaru, Eisenberg 
1984). In one study of canine Cushing's syndrome, 90% of all cases showed 
increased plasma cholesterol concentrations (Ling, Stabenfeldt, Comer, 
Gribble and Schechter 1979). In the present study, dogs with 
hyperadrenocorticism had raised plasma cholesterol and LDL-C 
concentrations. If the underlying defects in lipoprotein metabolism were the 
consequence of glucocorticoid antagonism of insulin alone, then elevations of 
plasma triglyceride and triglyceride-rich lipoproteins would be expected. These 
features were, in fact, present in only three of the 14 cases of canine Cushing's 
syndrome. The most consistent abnormality was raised LDL-C, resulting in 
increased plasma cholesterol concentrations. One effect of the administration 
of synthetic steroids is an alteration in the bile acid composition, resulting in a 
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reduction of the rate of biliary excretion (Berk and Javitt 1978). Such an effect 
may increase the hepatic sterol pool with a consequent down-regulation of the 
hepatic LDL receptor and an increase in circulating LDL concentrations. 
Lipoprotein abnormalities similar t~ those described in this study have also 
been recognised in dogs with experimentally-induced obstructive jaundice 
(Bauer, Meyer, Goring, Beauchamp and Jones 1989). The changes seen in 
these dogs and in dogs with hyperadrenocorticism may therefore be the result 
of down-regulation of the hepatic LDL receptor secondary to reduced biliary 
excretion, or as a consequence of hepatocellular pathology. 
Dogs which presented with hepatic disease per se showed a 
heterogeneity of abnormalities including hypercholesterolaemia, 
hypo cholesterolaemia and hypertriglyceridaemia. Under these circumstances 
the underlying hepatic pathology and, in particular, the degree of biliary stasis 
versus hepatocellular damage may play an important role in determining the 
character and severity of lipoprotein abnormalities. Extra-hepatic bile duct 
obstruction secondary to chronic pancreatic disease was found to induce 
increases in plasma cholesterol and LDL-C concentrations similar to previous 
reports of experimentally-produced lesions (Danielsson, Ekman, Johansson and 
Petersson 1977). Hepatic parenchymal disease, however, was associated with a 
wide variety of lipoprotein disturbances which may have been the result of a 
combination of factors including down-regulation of the LDL receptors, 
decreased activities of LCAT and hepatic lipase and increased hepatic 
cholesterol synthesis. Lipoprotein-X, an unusual lipoprotein identified 
specifically in cholestasis and LCAT deficiency in man (Miller 1990) was not 
identified from the plasma of dogs with naturally-occurring hepatic disease in 
this study. 
Obesity in man may be associated with lipoprotein abnormalities which 
do not necessarily result in overt hyperlipidaemia (Kissebah and Schectman 
1978). Increased adipose tissue mass, particularly abdominal adiposity 
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(Despres 1991) results in increased flux of NEFA via the portal circulation to 
the liver, stimulating over-product:on of VLDL. Hormone sensitive lipase 
regulates the release of NEF A from the adipose tissue. In healthy individuals 
the activity of this enzyme decreases in the postprandial period but in the obese 
patient this response is less marked (Coppack, Evans, Fisher, Frayn, Gibbons, 
Humphreys, Kirk, Potts and Hockaday 1992), resulting in poor regulation of the 
flux of NEF A from adipose tissue. In our population, the mean plasma VLDL-
C concentration was higher than that of control dogs, but this difference was 
not significant. It is possible, therefore, that kinetic disorders, similar to those 
recognised in man may exist in the canine population and that studies including 
a greater number of cases may identify such abnormalities. 
In conclusion, this study has identified and quantified a range of 
abnormalities of lipid metabolism associated with systemic disease in the dog. 
Such lipoprotein phenotyping may help in the differential diagnosis of 
hyperlipidaernia in the dog. 
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ABNORMALITIES IN LIPID AND LIPOPROTEIN 
METABOLISM ASSOCIATED WITH CANINE OBESITY 
CHAPTER V 
1. INTRODUCTION 
Obesity is defined as the exceSSlVe accumulation of fat (triglyceride) in the 
adipose tissue of the body, leading to physiological dysfunction and a 
deterioration of health (Anderson, J., 1972). In man, the condition IS 
associated with a high incidence of metabolic abnormalities, including insulin 
resistance, hypertriglyceridaemia, hyper cholesterolaemia and cardiovascular 
disease (Grundy 1987). The development of such metabolic disorders is related 
not only to the presence of excessive adipose tissue but also to the distribution 
of the adipose tissue in the body. In particular, several indicators of poor 
health, including hypertension, hypercholesterolaemia, hypertriglyceridaemia 
and illness in terms of sick leave, were accompanied by an accumulation of fat 
in the deep and subcutaneous abdominal tissues, rather than the gluteal-
femoral region (Despres 1991). 
The disturbances of lipoprotein metabolism include an overproduction 
of VLDL, which may be compensated for by an increase in the removal rate of 
triglyceride from the circulation. Plasma triglyceride concentrations in many 
obese individuals are therefore maintained within normal limits, and exception 
to this suggests that there is concurrent impairment of the mechanisms of 
triglyceride clearance (Kissebah and Schectman 1987). Since adipose tissue is 
an important cholesterol storage organ and is capable of making a major 
contribution to lipid production, its excessive accumulation may also be 
associated with hypercholesterolaemia (Krause and Hartman 1984). Adiposity 
is considered an independent risk factor for coronary heart disease, an 
observation which suggests that even without overt hyperlipidaemia there may 
be impairments of lipid metabolism which contribute to the development of 
atherosclerosis (Kissebah and Schectman 1987). All of the disturbances of lipid 
metabolism associated with obesity are reversible by calorie restriction and 
weight reduction (Grundy 1987). 
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In the dog, the excessive accumulation of adipose tissue has been 
associated with glucose intolerance and hyperinsulinaemia (Mattheeuws, 
Rottiers, Baeyens and Vermeulen 1984) and is related to the development of 
other abnormalities, including respintory, neoplastic and locomotor disorders 
(elutton 1988). It has been proposed that obesity in the dog may contribute to 
the development of hyperlipidaemia (Hand 1988; Whitney 1992), but this 
relationship has not been investigated. The aim of this study was to identify if 
there are abnormalities of lipoprotein metabolism associated with obesity in 
the dog and to evaluate the role of calorie restriction and weight loss in the 
correction of any such disturbances. 
2. MATERIALS AND METHODS 
2.1. Inclusion criteria and experimental design 
Thirteen obese dogs were recruited from veterinary practices in the Glasgow 
area for inclusion in this study. All the dogs were greater than 115% of the 
ideal weight for their breed, age and sex (Lewis, Morris and Hand 1987; Glover 
1977). The animals were considered clinically healthy as judged by 
examination, routine haematology and biochemistry profiles, and urinalysis. 
Where necessary, endocrine disorders were excluded by the methods previously 
described (Chapter IV 2.1.). The dogs included in this study formed a subgroup 
of the obese dogs described in Chapter IV 2.1. 
After confirmation of the satisfactory health status of each individual, 
samples for plasma lipoprotein analysis and postheparin plasma lipase activity 
were collected. Three days elapsed between these manipulations and the 
performance of an intravenous fat tolerance test. Plasma lipid and lipoprotein 
cholesterol concentrations were quantified at two weekly intervals and 
intravenous fat tolerance tests and postheparin plasma lipase assays repeated at 
the end of the study (6-8 weeks). 
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After diagnostic testing and collection of baseline samples, each dog was 
gradually introduced to a reduced calorie, high fibre diet with a nutritional 
analysis (% dry matter) of 22% protein and 8% fat, metabolizable energy 
3.30kcal/g (Perform Lite; The Cr;nter for Animal Nutrition, Glendale, 
California). The daily ration was calculated for 70% maintenance requirement 
(Hand 1988). The weight, and dimensions of the neck, girth and the thigh 
above the stifle were recorded at weekly intervals for each dog. In individuals 
displaying no weight loss for two consecutive visits, the dietary intake was 
reduced by a further 20%. In addition to dietary manipulation, owners were 
encouraged to exercise their animals for increasing periods of time, tailored to 
the individual client and animal. 
The control group consisted of six, non-obese, healthy, normolipidaemic 
adult beagles (4 entire males, 2 entire females) maintained on a commercial 
dry diet, on which plasma lipid and lipoprotein analysis, postheparin plasma 
lipase activities and intravenous fat tolerance tests were performed. 
2.2. Plasma lipids and lipoproteins 
Plasma lipid and lipoprotein concentrations were quantified by the 
ultracentrifugation/precipitation method validated for use in the dog (Chapter 
II 2.2.). Agarose gel electrophoresis was performed on plasma and VLDL 
fractions in order to confirm the presence of normal lipoprotein electrophoretic 
mobility and exclude the presence of tS-VLDL particles (Chapter II 2.3.). Non-
esterified fatty acids were measured using an enzymatic colorimetric method 
(NEFA- C; Wako) modified for use on the Cobas MIRA (Roche Diagnostics). 
2.3. Postheparin plasma lipase activities 
Total plasma postheparin lipase activity, lipoprotein lipase and hepatic lipase 
activities were assayed according to the methods described in Chapter IV 2.4. 
Samples were collected before introduction to the reducing diet and at the end 
of a six week period, irrespective of the degree of weight loss. 
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2.4. Intravenous fat tolerance tests 
Dogs were fasted for a minimum of 16 hours and a baseline blood sample taken 
into EDTA (final concentration 1mg/ml). A soya bean triglyceride/egg yolk 
phosphatidyl choline emulsion (Intralipid* 10%; Kabi Pharmacia Ltd.) was 
administered by intravenous injection (O.lg/ml) at a rate of one to three 
millilitres per second. Serial blood samples were collected at 5, 10, 20, 30, 40, 
90, and 120 minutes after Intralipid * administration and immediately placed 
onto ice. The triglyceride concentration of the samples was measured and 
corrected for free glycerol (GY105; Randox Laboratories). 
The triglyceride clearance characteristics for each intravenous fat 
tolerance test were calculated by analysing the changes in plasma triglyceride 
concentration versus time. All the kinetic analyses were performed using a 
nonlinear regression Fortran IV curve stripping computer program, CSTRIP. 
All samples were standardised by subtracting the fasting plasma triglyceride 
concentration from each time point. 
The initial plasma concentration (CpO) in mmol/l was the calulated 
triglyceride concentration at time 0 (extrapolated from the regression line) 
(Fig. 7.) and the Cmax was taken as the peak observed plasma triglyceride 
concentration. The area under the plasma concentration versus time curve for 
observed values (AUCots), in mmol.min/l, from time 0 to time infinity, was 
determined for observed concentrations using the trapezoidal rule (Matthews, 
Altman, Campbell and Royston 1990). The area under the regression line 
between time 0 and the first sample and the area between the last sample and 
baseline were calculated (Appendix 17). The area under the first moment 
curve for observed values (AUMCots) for time 0 to time infinity, i.e. the plasma 
concentration time versus time curve in mmol.min2/1, was calculated in a 
similar fashion. The ratio of AUMC to AUC for any substance is a measure of 
its mean residence time (MRT), which is a quantitative estimate of the 
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persistence of the substance in the body and the time taken for 63.2% of the 
dose to be eliminated. 
Figure 7. A diagramatic representation of the parameters used m the 
description of the plasma triglyceride clearance curves. 
Triglyceride (mmol/I) 
CpO regression line 
/ 
• 
• 
A B C 
- - - - - - - - -
-'-
baseline 
5 120 
Time (minutes) 
Baseline: baseline triglyceride concentration. 
regression line: regression line through observed points. 
- - - -
CpO: Initial triglyceride concentration m plasma following Intralipd* 
administration. 
A: area of the triangle between time 0 and the first sample. 
B: area under the plasma concentration versus time curve for observed 
values. 
C: area of the triangle between the last sample and 0 concentration. 
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2.S. Statistical methods 
Plasma lipid and lipoprotein cholesterol concentrations, enzyme activities and 
triglyceride clearance curve characteristics were compared using the Mann 
Whitney test for non-parametric data. In addition, the independent effect of 
obesity on the plasma lipid and lipoprotein concentrations were determined by 
analysis of covariance, correcting for the effects of breed, age and gender 
(Chapter IV 2.5.). Paired data derived from the same animals were analysed by 
the Sign test. 
The relationship between the plasma lipid and lipoprotein 
concentrations and the following parameters were described by the product-
moment correlation coefficient and tested by linear regression: body weight, 
neck, girth and thigh circumference, and the ratios of the neck circumference to 
weight, the girth circumference to weight and the stifle circumference to weight. 
3. RESULTS 
3.1. Population distribution 
The study group consisted of nine neutered females, two entire females, one 
entire male and one neutered male (Table 9.). The mean ±sd age was 7.10 ± 
2.36 years. One neutered female was withdrawn from the trial soon after the 
start and two were lost to follow up at 4 weeks. The mean ±sd weight loss over 
the trial period for the 10 remaining dogs was 9.2 ±5.7% of the initial body 
weight, which represented 41 ±27.3% of the target weight loss. In four dogs 
the weight reduction was minimal «25% target weight loss). A failure of 
owner compliance with the feeding regime was suspected as the underlying 
cause for poor weight reduction in 2 cases. 
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Table 9. Details of obese dogs. 
Number Breed Age (yrs) Sex 
1 Labrador retriever 6.0 MN 
2 Labrador retriever X 10.0 FN 
3 Springer spaniel 10.0 FN 
4 Rottweiller 7.5 M 
5 Labrador retriever X 7.0 FN 
6 Bernese mountain dog 10.0 FN 
7 Golden retriever 10.1 FN 
8 Rough collie 7.0 FN 
9 Jack Russell terrier 5.0 FN 
10 Shetland sheepdog 3.2 F 
11 Shetland sheepdog 6.1 F 
12 Beagle 4.0 FN 
13 Terrier X 6.0 FN 
3.2. Plasma lipid and lipoprotein concentrations before and after dietary 
intervention 
On initial presentation, four of the obese dogs were hypercholesterolaemic, one 
of which was also hypertriglyceridaemic. The mean plasma triglyceride, VLDL-
C and LDL-C concentrations in obese dogs were significantly (p < 0.05) greater 
than those of control dogs (Table 10., Appendix 12). The plasma cholesterol, 
HDL-C and concentrations of the obese dogs were not significantly different 
from control animals (Table 10.). The NEFA concentration in obese animals 
was similar to that of the controls (0.98 ±0.25mmol/1 and 0.92 ±0.47mmol/l, 
respectively). When determined by analysis of covariance, obesity had no 
significant effect on the plasma lipid or any of the lipoprotein concentrations. 
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The plasma cholesterol, triglyceride, VLDL-C and LDL-C 
concentrations in obese dogs after calorie restriction for 6 weeks, were lower 
than those on initial presentation (Table 10.) and the HDL-C concentration 
was higher after introduction of the reducing diet. None of the differences in 
lipid and lipoprotein concentrations before and after caloric restriction were 
statistically significant at p < O.OS. 
There were moderate correlations between the VLDL-C concentration 
and the stifle circumference (r=0.60; p<O.OS), VLDL-C and the stifle:weight 
ratio (r=-0.64; p<O.OS) and LDL-C and the percentage weight over the ideal 
weight (r=0.S8, p<O.OS) on initial presentation (Appendix 13). The 
relationships which were close to significance at the O.OS level were plasma 
triglyceride and stifle:weight ratio (r=-O.Sl; p=0.09), VLDL-C and neck 
circumference (r=0.49; p=0.09), VLDL-C and girth circumference (r=O.SO; 
p=0.08), and VLDL-C and neck:weight ratio (r=-0.S2; p=0.07). 
Table 10. Mean +sd plasma lipid and lipoprotein cholesterol concentrations 
(mmol/l) in obese dogs before and after maintainance on a restricted calorie 
intake. 
Before 
(n= 12) 
After 
(n= 12) 
Control 
(n=6) 
* p<O.OS 
Plasma 
Triglyceride 
0.97* 
±0.44 
0.82* 
±0.31 
0.47 
±0.19 
Plasma 
S.97 
±2.01 
S.3S 
±1.24 
4.43 
±1.76 
Cholesterol concentration (mmol/l) 
VLDL LDL HDL 
0.61 * 1.7S* 3.61 
±0.30 ±1.28 ±0.99 
0.51 1.21 3.78 
±0.21 ±0.53 ±0.70 
0.32 0.69 3.41 
±0.13 ±0.46 ±1.36 
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3.3. Postheparin plasma lipase activities 
For 13 obese dogs, on initial presentation, the total plasma lipase and 
lipoprotein lipase activities were significantly lower than those of the control 
population (Table 11., Appendix 14). The plasma hepatic lipase activities were 
not significantly different. In eight dogs, calorie restriction resulted in no 
significant alteration in these enzyme activities (Table 12., Appendix 15). 
Table 11. Mean (±sd) PHP, LPL and HL activities in obese and control dogs. 
Lipolytic activity (fLmolFA/ml/hr) 
PHP HL LPL 
Obese 10.00* * 4.89 5.11 * * 
(n=13) ±6.59 ±2.73 ±4.70 
Control 17.65 6.92 10.73 
(n=6) ±1.45 +1.44 ±2.66 
**p<O.Ol 
Table 12. Mean (±sd) PHP, LPL and HL activities in eight obese dogs before 
and after dietary intervention. 
Before 
After 
Lipolytic activity (fLmolF A/ml/hr) 
Pill HL ilL 
11.19 
±7.92 
10.84 
±5.21 
5.83 
±2.80 
6.71 
±3.33 
5.37 
±5.65 
4.12 
±2.50 
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3.4. Intravenous fat tolerance tests 
The plasma triglyceride concentrations (mmol/l) at 0, 5, 10, 20, 30, 40, 90 and 
120 minutes after the intravenous administration of Intralipid*, for the obese 
population before and after dietary intervention are shown in Table 13 
(Appendix 16). 
The triglyceride concentrations in samples taken at 0, 5, 10, 15, 30, 45, 
60,90 and 120 minutes from the control group are shown in Table 14. 
In the analysis of the intravenous fat tolerance tests the curves from the 
obese and control populations fitted a single exponential (r2> 0.80), but two 
curves fitted with poorer r2 values (r=0.68). These clearance curves also had 
the highest AVC values and were obtained from two obese dogs prior to weight 
loss. The triglyceride clearance curve after administration of an Intralipid * 
bolus to Case 4 on initial presentation did not fit a single exponential model 
(r2=0.02). When the test was repeated after dietary intervention, the clearance 
data fitted a monoexponential equation with a poor r2 value (r2=0.62). While 
the other triglyceride concentration versus time curves showed a maximum 
concentration at five minutes, the first clearance curve from Case 4 reached a 
peak at 20 minutes. The owner did not consider it possible that the dog had 
gained access to food in the 16 hours prior to the performance of the 
intravenous fat tolerance test and therefore the abnormalities displayed by this 
case were considered to be genuine rather than an effect of intestinal fat 
absorption. The data sets from two obese dogs could be fitted by both 
monoexponential and bi-exponential equations, but to facilitate 
standardisation, the characteristics quoted are calculated from the former. 
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Table 13. Mean + sd plasma triglyceride concentration at serial time points 
after the intravenous administration of O.lmg/kg Intralipid* to obese dogs 
(n = 8) before and after dietary manipulation. 
Time (minutes) 
o 5 10 20 30 40 90 120 
Before 0.56 1.74 1.55 1.52 1.22 1.05 0.51 0.62 
±0.60 ±0.52 ±0.48 ±0.48 ±0.65 +0.73 ±0.41 ±0.63 
After 0.42 1.39 1.23 1.09 0.96 0.87 0.52 0.47 
±0.24 ±0.39 ±0.49 ±0.45 ±0.48 ±0.48 ±0.36 ±0.34 
Table 14. Mean ±sd plasma triglyceride concentration at serial time points 
after the intravenous administration of O.lmg/kg Intralipid * to control dogs 
(n=6). 
Time (minutes) 
o 5 10 15 30 45 60 90 120 
Control 0.20 1.54 0.92 0.56 0.22 0.20 0.18 0.17 0.18 
±0.06 ±0.46 ±0.39 ±0.23 ±0.07 ±0.06 ±0.07 ±0.07 ±0.07 
The AUCobs, AUMCobs and MRT were significantly (p<0.05) greater in 
the obese population than in the control dogs (Table 15.). After calorie 
restriction for 6 weeks the AUCobs, AUMCobs and MRT were not significantly 
different from the values on initial presentation (Table 15.). When examined 
according to weight loss, the mean ±sd AUCobs values before and after dietary 
intervention for four cases with a mean weight loss of 3.2 ±3.2% of body weight 
(12.0 ± 10.6% target weight loss) were 76.3 ±25.1mmol.min/l and 68.0 ± 
27.8mmol.min/1 compared to 68.4 ±48.6mmol.min/l and 33.7 ± 
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15.3mmol.min/l for four cases with mean weight loss of 11.9 ± 1.13 % of 
bodyweight (62.3 ± 11.8% target weight loss). 
Since some clearance curves did not fit a single exponential, the AUC 
from time 5 minutes to time 120 minutes was calculated in C'rder to test the 
relationship between the AUC and the other curve characteristics and was 
found to correlate negatively with the lipoprotein lipase activity (r=-0.63, 
p < 0.05). The peak plasma triglyceride concentration (Cmax) correlated 
positively with the fasting triglyceride concentration (r=0.74, p<O.Ol) and there 
were weak correlations between the fasting triglyceride and LPL activity (r =-
0.41; n.s.), Cmax and LPL activity (r=-0.45; n.s.), and Cmax and the AUC 
(r=0.40; n.s.). 
Table 15. The mean ±sd AUCobs (mmol.min/l) and AUMCobs (mmol.min2jl) 
from time 0 to time infinity and MRT (mins) for the triglyceride clearance 
curves of eight obese dogs before and after calorie restriction and for six 
control dogs. 
Obese 
(before) 
Obese 
(after) 
Control 
Aue 
(mmol.min/l) 
76.8 
±36.5 
50.9 
±27.7 
21.9 
±8.4 
AUMC 
(mmol.min2jl) 
3288 
±2533 
2179 
±2151 
179 
±87 
MRT 
(mins) 
37.9 
±17.5 
35.1 
±17.7 
7.9 
±1.4 
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4. DISCUSSION 
In man, hypertriglyceridaemia is often recognised in association with obesity. 
This is the result of an increase in hepatic VLDL production which arises 
secondary to an increased flux of NEF A from the adipose tissue (Durrington 
1989). In the obese dogs, fasting plasma triglyceride, VLDL-C and LDL-C 
concentrations were significantly greater than those of the control group of 
adult, non-obese beagles. However, these findings are contrary to the findings 
of Chapter IV which suggest that the lipid and lipoprotein concentrations in 
obese dogs were not significantly different from a control group of healthy pet 
dogs. There are two main contributing factors to the differences in these 
findings. The first important consideration is the selection of the control dogs. 
In the study of Chapter IV, 20 obese dogs were compared with a control 
population of 33 healthy pet dogs. It is recognised that breed differences 
(Downs, Bolton, Crispin and Wills 1993) and environmental factors may 
influence plasma LDL-C and HDL-C concentrations (Crispin, Bolton and 
Downs 1992). When the control dogs of Chapter IV were compared with the 
beagles used as control animals in this study, it was evident that the 
experimental dogs have lower triglyceride, VLDL-C and LDL-C 
concentrations. No significant differences in plasma lipid and lipoprotein 
concentrations were observed when this group of thirteen obese dogs were 
compared to the control population of pet dogs. 
Different methods of statistical analysis were used to identify population 
variations in this data set and that described in Chapter IV. In the previous 
chapter, the effect of breed, age, gender, and health status on plasma lipid and 
lipoprotein concentrations were determined by analysis of covariance. This is 
particularly important since the gender effect on plasma triglyceride 
concentrations was close to statistical significance. Since the small subset of 
obese dogs presented in this chapter was composed predominantly of spayed 
106 
CHAPTER V 
bitches, it is possible that the gender effect resulted in a population bias which 
was not accounted for by the Mann Whitney test. This data highlights the 
necessity for the formation of lipid and lipoprotein reference ranges for the 
population to be studied, i.e., pet dogs versus laboratory animals. However, 
irrespective of the control population selected, the obese dogs do show similar 
lipoprotein trends to the obese human, i.e. hypertriglyceridaemia and raised 
VLDL-C concentrations. 
The abnormalities of lipoprotein metabolism associated with obesity in 
man are corrected by prolonged fasting (Yeshurun, Aviram, Barak, Baruch and 
Brook 1986), calorie restriction and weight reduction (Grundy 1987). In the 
obese dogs which presented with hyperlipidaemia, there was partial correction 
of these abnormalities after calorie restriction. However, since only a minority 
of the obese animals did, in fact, present with raised lipid concentrations, the 
effect of calorie restriction on the whole group was minimal. There was a 
decrease in the LDL-C concentration which was reflected in a small decrease in 
the plasma cholesterol concentration. The minimal elevation of the mean 
HDL-C after dietary intervention masked the marked increase in some 
individuals. Calorie restriction results in mobilisation of adipose tissue 
cholesterol stores (Krause and Hartman 1984), which, in turn, may cause an 
elevation of the plasma concentration of HDL, the lipoprotein which serves as 
an acceptor of lipid from peripheral tissues. 
Gender-specific patterns of obesity are recognised in people. The 
presence of abdominal adiposity (android obesity), commonly described in 
men, is associated with an increased risk of the development of coronary heart 
disease, non-insulin dependent diabetes mellitus and hyperlipidaemia, when 
compared to the relatively benign gluteal-femoral adiposity (gynoid obesity) 
recognised in women (Despres 1991). An estimation of these patterns of 
obesity may be achieved by applying a number of simple computations, 
induding the waist girth, hip girth, the waist:hip circumference ratio (WHR) 
107 
CHAPTER V 
and the Quetelet index (kg/height2). These anthropometric estimates correlate 
positively with plasma cholesterol and triglyceride concentrations, and 
negatively with HDL-C concentrations. The lipoprotein profile associated with 
human obesity is therefore also associated with an increase in atherogenic risk 
(Anderson, Sobocinski, Freedman, Barboriak, Rimm and Gruchow 1988). 
Gender-specific patterns of obesity have not been described in the dog, 
although reports indicate that bitches have, on average, 16% more body fat 
than males (Meyer and Stadtfeld 1980) and that the prevalence of obesity is 
greater in the female (Mason 1970). Excess adipose tissue tends to accumulate 
over the thorax and tailhead, cranial to the tuber coxae and intra-abdominally. 
A number of methods have been proposed for the assessment of obesity in the 
dog (Wilkinson and Mooney 1991) but for all practical purposes this remains a 
subjective evaluation (Hand 1988). The use of bioelectrical impedence (Hand, 
Armstrong and Allen 1989) and A mode ultrasound (Wilkinson and McEwan 
1991) may, in the future, allow improved estimation of the degree of obesity of 
individual dogs. In the meantime, the measurement of obesity is dependent 
upon manual and visual appraisal (Edney and Smith 1986), peripheral body 
measurements and the percentage over "ideal" body weight. This practical 
difficulty undoubtedly creates an obstacle when attempting to assess the effect 
of obesity on canine metabolism. The anthropometric indices evaluated in this 
study do show some correlation with the plasma triglyceride and triglyceride-
rich lipoprotein concentrations, suggesting that in the dog, obesity may be 
associated with abnormalities of chylomicron and VLDL lipoprotein 
metabolism. Since the dietary fat intake may playa role in the determination 
of obesity and the plasma lipid concentrations it would be of interest to 
determine the independent effects of both factors. However, this was not 
possible within the scope of this study due to the small number of cases 
included and the difficulty in assessing the fat content of the diet, considering 
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that most of the animals, including those on commercial reducing diets were 
fed varying quantities of home-cooked food each day. 
The hypertriglyceridaemia identified in obese humans has been 
attributed to an increased VLDL production (Despres 1991). In patients with 
normal triglyceride concentrations, the increased VLDL synthesis is balanced 
by an increased removal of the lipoprotein from the circulation (Kissebah and 
Schectman 1978). In support of this, increased lipoprotein lipase activities per 
single fat cell and per total body fat mass have been described in association 
with obesity in man (Taskinen and Nikkila 1981). However, in this study there 
was a decreased lipoprotein lipase activity in the postheparin plasma of obese 
dogs, compared with control animals. It is noted in man that caloric restriction 
is associated with a decrease in adipose tissue lipoprotein lipase activity 
(Taskinen and Nikkila 1981). Three of the dogs included in this study were 
already receiving a reduced calorie diet before evaluation. In the remaining 
nine dogs, the owners reported unsuccessful attempts at weight reduction. It 
may be that partial caloric restriction in the six weeks between owners agreeing 
to participate in this trial and the beginning of the trial was sufficient to 
suppress lipoprotein lipase activity when compared to a normal population. 
There was a further reduction in lipoprotein lipase activity throughout the 
period of calorie restriction, but this change was not significant. Since the 
lipoprotein lipase of postheparin plasma is derived from both skeletal muscle 
and adipose tissue it is possible that the alterations in activity reflect changes in 
the muscle rather than the adipose tissue enzyme. 
The Intralipid * intravenous fat tolerance test for the assessment of 
chylomicron clearance has been employed in both man (Cohen 1989) and the 
dog (Carlson and Hallberg 1963). In both species the clearance of 
intravenously-administered Intralipid * follows the same kinetics as chylomicron 
clearance. It has been proposed that the clearance curve in man may be fitted 
by a single exponential in all subjects (Carlson and Rossner 1972; Cohen 1989). 
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This confirmed the earlier findings of Carlson and Hallberg (1963), who found 
that the elimination of Intralipid* (O.lgjkg administered intravenously) in 
clinically healthy dogs could be fitted to a single exponential. The same was 
true for the control dogs and most of the obese dogs in this study. However, 
four data sets displayed a very poor fit to a monoexponential equation. When 
these plasma triglyceride curves were examined it was evident that the 
concentrations in these cases increased at some point during the 120 minutes 
sample time, i.e., the clearance curve had a second "peak" or "shoulder". A 
number of hypotheses may explain the complex nature of these curves. It is 
possible, that in the obese dog, the Intralipid* triglyceride was rapidly cleared 
to a body compartment from which it was later released, e.g., rapid hepatic 
uptake, followed by secretion in the form of VLDL triglyceride. In the normal 
scenario, insulin results in an increased synthesis of VLDL triglyceride 
accompanied by a reduction in secretion, resulting in an intracellular 
accumulation of triglyceride which is released on decline of the circulating 
insulin concentrations (Gibbons 1990). Prolonged exposure of hepatocytes to 
insulin results in down-regulation of the insulin receptors and an increase in 
hepatic VLDL secretion. It is possible that in obese dogs, in which insulin 
resistance is a metabolic complication, the inhibitory effect of insulin upon 
hepatic triglyceride secretion is lost and such animals may produce VLDL 
particles in a poorly regulated fashion. The increase in plasma triglyceride 
concentrations during the intravenous fat tolerance tests in the obese dogs of 
this study may, therefore, reflect abnormal regulation of hepatic triglyceride 
synthesis. 
The delayed clearance in obese patients was consistent with the 
identification of reduced lipoprotein lipase activity in obese dogs when 
compared to the non-obese control population. It is evident from this data that 
obese individuals display a prolonged plasma triglyceride clearance which may 
exacerbate the postprandial hyperlipidaemia noted in normal individuals 
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(Watson, MacKenzie, Packard and Shepherd 1993). In cases where the lipid 
metabolism of an individual is further compromised, e.g., in dogs with 
concurrent familial or secondary hyperlipidaernia, the compound effect may 
result in marked hypertriglyceridaemia. The delayed clearance of triglyceride 
from the circulation of the obese dog in the postprandial period may explain 
the higher incidence of acute pancreatitis in obese animals fed a high fat diet 
(Anderson, N.V., 1972). 
With the exception of two cases which lost minimal quantities of weight 
(Cases 4 and 9), and in one case (Case 12) which may have gained access to 
food on the morning of the second test, the values for the areas under the 
triglyceride clearance curves were reduced after caloric restriction. This was 
irrespective of the degree of weight reduction. The owner's compliance with 
the feeding regime was questioned in one case in which the AUC did not 
decrease, but in the other case, no such problem was suspected. It appears, 
therefore, that caloric restriction alone may improve plasma triglyceride 
clearance in obese dogs. This may be related to a decreased plasma 
triglyceride pool, i.e., a reduction in endogenous triglyceride synthesis 
(Taskinen and NikkiHi 1981). However, the reduction in AUC values in the 
group which lost weight does suggest that there is an effect of weight reduction 
per se on the triglyceride clearance curves, in addition to any effect secondary 
to caloric restriction. This may reflect changes in hepatic triglyceride synthesis, 
since there was no significant change in lipoprotein lipase activity. 
These findings confirm the benefits of weight reduction in the correction 
of the kinetic lipoprotein abnormalities associated with obesity and may reduce 
the risk of the development of pancreatitis. 
CHAPTER VI 
THE CLINICAL PRESENTATIONS AND METABOLIC 
CONSEQUENCES OF HYPERLIPIDAEMIA IN THE DOG 
CHAPTER VI 
1. INTRODUCTION 
The literature regarding idiopathic and secondary hyperlipidaemia in the dog is 
limited to the description of small numbers of cases (Rogers, Donovan and 
Kociba 1975a and b; Ford 1977) and review articles (DeBowes 1987; 
Armstrong and Ford 1989). The incidence and prevalence of hyperlipidaemia 
in the canine population have not been determined. 
The pathological consequences of hyperlipidaemia have been alluded to 
by some investigators (Zerbe 1986) and may be classified according to the role 
of hypertriglyceridaemia or hypercholesterolaemia in the induction of certain 
lesions. Hypertriglyceridaemia may be associated with the development of 
ocular lesions, pancreatitis, eruptive xanthomas and more uncommonly, 
disturbances of the central nervous system (Shepherd and Packard 1987). The 
ocular abnormalities include lipid-laden aqueous humor and lipaemia retinalis. 
In man, these clinical and pathological aberrations are generally detected in 
association with a marked increase in the plasma triglyceride concentration 
( > 11mmoljl) and are collectively referred to as the chylomicronaemia 
syndrome (Brunzell and Bierman 1982). Hypertriglyceridaemia has also been 
implicated in the pathogenesis of hepatic lipidosis in both the dog and the cat 
(Hardy 1989). Hypercholesterolaemia is associated with atherosclerosis and 
corneal arcus, an arc-like lipid deposit of the cornea (Crispin and Barnett 
1983). The effect of increased plasma cholesterol concentrations upon the 
cholesterol content of cell membranes, in particular red blood cells and 
platelets, may result in haematological abnormalities, which may predispose the 
individual to thrombosis (Gasser and Betteridge 1990) and the blood to in vitro 
haemolysis. 
The aim of this study was to determine the incidence of idiopathic and 
secondary hyperlipidaemia in a referral population and to catalogue the 
associated clinical signs and the pathological findings. 
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2. MATERIALS AND METHODS 
2.1. The incidence of hyperlipid aemia 
The incidence of hyperlipidaemia in a referral population at G.U.V.S. was 
assessed during the six month period from October 1990 to March 1991. For 
the purposes of the study, hyperlipidaernia was defined by raised fasting plasma 
concentrations of cholesterol (> 6.5mmol/l) and/ or triglyceride 
(> 1.75mmol/I). Plasma lipid concentrations were measured by the routine 
chemical methods described in Chapter II 2.2. 
Affected dogs were allocated to a group depending on their health 
status: secondary hyperlipidaemia associated with underlying disease process 
previously recognised as a cause of lipid disorders, i.e., hypothyroidism, 
hyperadrenocorticism, diabetes mellitus, nephrotic syndrome and obstructive 
jaundice. If no underlying disease process was detected, the hyperlipidaemia 
was defined as idiopathic (or primary). 
2.2. Classification of hyperlipidaemia 
Samples for lipid analysis were collected from 128 dogs referred to G.U.Y.S. 
with hyperlipidaemia or diseases commonly associated with the development of 
lipoprotein abnormalities. Fasting plasma cholesterol and triglyceride 
concentrations were measured and the animals classified on the basis of the 
presence of no lipid abnormalities, hypercholesterolaemia, 
hypertriglyceridaemia, or combined hyperlipidaemia (increased plasma 
cholesterol and triglyceride). 
2.3. The clinical signs and alterations in haematological and biochemical 
parameters associated with hyperlipidaemia 
Hyperlipidaemia was identified in 92 dogs referred to G.U.V.S. for the 
investigation of medical or surgical disorders. In 57 cases the hyperlipidaemia 
was associated with systemic disease: diabetes mellitus (10), 
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hyperadrenocorticism (13), hypothyroidism (15), hepatic disease (5), nephrotic 
syndrome (4), septicaemia (3) and obesity (7). No underlying pathological 
process was identified in 35 dogs with hyperlipidaemia (idiopathic 
hyperlipidaemia). In addition to the sases examined at G.U.V.S., case histories 
and plasma for lipoprotein quantification were submitted from nine dogs with 
corneal lipid deposition. The clinical signs and pathological abnormalities 
putatively associated with hyperlipidaemia were recorded. The biochemical 
indicators of hepatocellular insult and renal disease, in addition to 
haematological abnormalities were also noted. 
3. RESULTS AND DISCUSSION 
3.1. The incidence of hyperlipidaemia 
During the period of the study, 362 new, consecutive canine referrals were 
examined at G.U.V.S. Hyperlipidaemia was identified in 53 dogs (15%), of 
which 43 (81%) had secondary hyperlipidaemia. No underlying disease was 
found in 10 dogs (19%), in which the hyperlipidaemia was considered 
idiopathic (Table 16.). The secondary hyperlipidaemia group consisted of dogs 
with diabetes mellitus, hyperadrenocorticism, hypothyroidism, nephrotic 
syndrome, obstructive jaundice, hepatic disease other than obstructive jaundice, 
renal disease other than protein-losing nephropathy and septicaemia. 
Concurrent hypothyroidism or hyperadrenocorticism was identified in a 
number of dogs with diabetes mellitus. 
The pattern of disease distribution III this survey reflects both the 
incidence of diseases known to be associated with hyperlipidaemia in the dog 
and the type of medical cases referred to Glasgow University Veterinary 
School. Hyperlipidaemia has previously been reported in association with 
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Table 16. The classification of hyperlipidaemia in 53 dogs according to disease 
association. 
Classification Number 
Secondary hyperlipidaemia 43 
Diabetes mellitus * 17 
Hyperadrenocorticism 13 
Hypothyroidism 3 
Nephrotic syndrome 2 
Obstructive jaundice 1 
Hepatic disease 4 
Renal disease 1 
Septicaemia 2 
Idiopathic hyperlipidaemia 10 
* Five cases with concurrent hyperadrenocorticism and two with concurrent 
hypothyroidism. 
endocrine disease in the dog (Rogers 1977; Medaille, de La Farge, Braun, 
Valdiguie and Rico 1988). The identification in this study of increased plasma 
lipid concentrations in dogs with diabetes mellitus. hypothyroidism and 
hyperadrenocorticism therefore confirms previous reports. The incidence of 
secondary hyperlipidaemia in a referral clinic is dictated by a number of factors, 
not entirely related to the incidence of the disease in the general population. 
At the time of this study, a clinical trial designed to evaluate a new insulin 
product was also in progress and certainly resulted in a higher number of 
diabetic dogs referred to the hospital. Dogs with diabetes mellitus and 
hyperadrenocorticism are generally under poor glycaemic control, and are 
therefore referred for further investigative or therapeutic measures, explaining 
the high incidence of complicated diabetes mellitus in this hospital population. 
Hypothyroidism, although considered a relatively common endocrine disease in 
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the dog is not well represented in this study, possibly due to ease of diagnosis 
and therapy of the condition in general practice. Conversely, the toxicity of 
op'DDD therapy for hyperadrenocorticism results in a high referral rate for the 
diagnosis and management of the disease. 
Disorders of lipid metabolism have been noted in both experimental 
(Bass, Hoffman and Dorner 1976) and naturally-occurring liver disease 
(McCullagh 1978) in the dog. The appearance of hyperlipidaemia in 
association with both obstructive jaundice and hepatic dysfunction is therefore 
consistent with the limited information available for the dog, and with 
extrapolation from human lipid metabolism (Miller 1990). The relationship 
between hyperlipidaemia and renal disease (impaired glomerular filtration rate 
or protein-losing nephropathy) has been established in man (BrQlns, 
Christensen and HQlrder 1972; Short and Durrington 1990). The results of the 
present study and previous case reports (Ford 1977) suggest that similar 
associations may exist in the dog. 
Hypercholesterolaemia and hypertriglyceridaemia have been observed 
in dogs naturally infected with Leishmania infantum (Nieto, Barrera, Habela, 
Navarrete, Molina, Jimenez and Serrera 1992) and with experimental gram 
negative sepsis (Griffiths, Groves and Leung 1973). The increase in plasma 
lipids and lipoproteins in these processes may serve to modulate the immune or 
host reaction to the pathogen and may be related to an increase in the 
circulating concentrations of tumour-necrosis factor (Feingold and Grunfeld 
1987). In the light of these experimental findings and the association between 
septicaemic processes and hyperlipidaemia demonstrated in this study, it would 
seem that further lines of investigation in this direction may yield information 
regarding the role of lipids in the regulation of the immune system. 
Primary, inherited hyperlipidaemia is considered a rare condition in the 
dog, although a familial disturbance of lipoprotein metabolism is recognised in 
the miniature schnauzer in North America (Rogers, Donovan and Kociba 
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1975a; Whitney 1987) and is suspected in the Briard in the United Kingdom 
(Watson, Simpson, Odedra and Bedford 1993). On examination of the results 
of this study, however, it is apparent that the prevalence of idiopathic 
hyperlipidaemia is much higher than suggested by the prevalence of recorded 
inherited lipoprotein disorders. Since investigations into hyperlipidaemia in the 
dog are in their infancy, it is possible that additional inherited lipoprotein 
disorders may be recognised and characterised in the future, or that diet, age 
and other undetermined environmental factors may be important in the 
aetiology of such abnormalities. 
3.2. Classification of hyperlipidaemia 
Blood samples were collected from dogs with diabetes mellitus (n= 12), 
hyperadrenocorticism (n= 17), hypothyroidism (n= 15), renal disease (n=4), 
hepatic disease (n=6), obesity (n=20) and idiopathic hyperlipidaemia (n=35). 
Normolipidaemic dogs were present in the dogs with diabetes mellitus (2/12), 
hyperadrenocorticism (3/17), hepatic disease (2/6) and obesity (13/20) (Table 
17.). None of the cases presented with hypertriglyceridaemia alone. 
Hypercholesterolaemia was the predominant lipoprotein abnormality in all 
groups, with the exception of the hypothyroid dogs, where increases in both 
plasma cholesterol and triglyceride concentrations were more common. 
Increased plasma cholesterol, with or without concurrent 
hypertriglyceridaemia, has previously been recognised in association with 
diabetes mellitus and hypothyroidism in the dog (Zerbe 1986). Ford (1977) 
suggested that dogs with uncomplicated diabetes mellitus have no lipoprotein 
abnormalities, while those with ketoacidosis are hypertriglyceridaemic and 
possess increased plasma LDL concentrations (detected by lipoprotein 
electrophoresis). This observation agrees in part with the findings of our study, 
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Table 17. Characterisation of the lipid abnormalities associated with secondary 
and idiopathic hyperlipidaemia. The number of cases with 
hypercholesterolaemia (HC), combined hyperlipidaemia (CH) and normal lipid 
concentrations (N) are expressed. No dogs had hypertriglyceridaemia alone. 
Number of cases 
N HC CH 
Obesity 13 5 2 
Diabetes mellitus 2 6 4 
Hyperadrenocorticism 3 10 4 
Hypothyroidism 0 6 9 
Renal 0 4 0 
Hepatic disease 2 3 1 
Idiopathic hyperlipidaemia 0 25 10 
where the four dogs with combined hyperlipidaemia were also suffering from 
diabetic ketoacidosis (characterised by glucose and ketones in the urine, 
hyperglycaemia and dehydration). However, six dogs with uncomplicated 
diabetes mellitus were hypercholesterolaemic. The two normolipidaemic dogs 
had received insulin therapy, but were under poor glycaemic control. The 
plasma lipid concentrations prior to therapy were not available and therefore 
the effect of therapy in these two cases could not be determined. 
Rogers (1977) stated that hyperadrenocorticism is not associated with 
the development of hyperlipidaemia, and that the finding of lipid abnormalities 
in dogs with Cushing's syndrome should prompt further investigation to identify 
the aetiology. This suggestion is, however, contrary to the findings of other 
authors and to the data presented in this study. A study of 117 cases of canine 
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hyperadrenocorticism (Ling, Stabenfeldt, Comer, Gribble and Schechter 1979) 
confirmed hypercholesterolaemia in 90% of individuals, while the present study 
identified increased cholesterol concentrations in 82% of dogs. Feldman and 
Nelson (1987) suggested that lipaemia is at least as frequent as 
hypercholesterolaemia in canine Cushing's syndrome. This statement was not 
confirmed in the present study where hypertriglyceridaemia was present in only 
31 % of dogs. 
Hypercholesterolaemia is present in approximately two thirds of dogs 
with hypothyroidism (Rogers, Donovan and Kociba 1975b; Larsson 1988). Of 
these, approximately 50% have combined hyperlipidaemia (Rogers, Donovan 
and Kociba 1975b) which is similar to the present study. The cases of canine 
hypothyroidism sampled at G.U.V.S. were all hyperlipidaemic. Since 
hypothyroidism is commonly recognised, diagnosed and treated by veterinary 
surgeons in general practice, cases referred to Glasgow University may reflect 
the positive selection of cases with hyperlipidaemia, rather than suspected 
hypothyroidism. This would certainly explain the difference between the 
prevalence of hyperlipidaemia in dogs with hypothyroidism reported by Rogers 
et al. (1975b) and that described here. 
3.3. Gastrointestinal disease, abdominal pain and pancreatitis 
In this study, anterior abdominal pain, characterised by restlessness, a praying 
stance and pain on palpation, was detected in four dogs. Plasma amylase and 
lipase activities were raised, indicative of acute pancreatitis, in only two of these 
cases. The first of these, a 5.5 year-old, neutered, female Tibetan terrier (Case 
112714, Appendix 19) was suffering from concurrent diabetes mellitus and 
hypothyroidism with marked hyperlipidaemia (plasma cholesterol 17.51 mmol/l 
and triglyceride 14.15 mmol/l). The second, a 12 year-old golden retriever 
bitch (Case 122074, Appendix 19) presented with anorexia, vomiting and 
depression. Biochemical analyses revealed increases in alkaline phosphatase 
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activity (1155 IV/I), plasma cholesterol (14.88mmol/l) and triglyceride 
concentrations (4.37mmol/l). Plasma from both dogs was visibly lipaemic. The 
clinical signs of both animals were consistent with acute pancreatic disease and 
the pain was localised to the anterior abdomen by the eX'l.rrining veterinary 
surgeon. 
In two other dogs hyperlipidaemia was accompanied by intermittent 
episodes of anorexia, vomiting and abdominal pain. In neither case was the 
pain convincingly localised to the anterior abdomen, nor were plasma amylase 
and lipase activities increased. The first case was a seven year-old crossbred 
neutered dog (Case 119993, Appendix 19) which presented to the referring 
veterinary surgeon with recurrent vague signs of abdominal discomfort and 
vomiting. The plasma was lipaemic and a routine biochemical profile revealed 
a triglyceride concentration of 39.00mmol/1 and cholesterol of 16.48mmol/1. 
The second dog was an eight year-old neutered bitch (Case 120360, Appendix 
19) with a history of weekly episodes of vomiting and anorexia, which 
responded to dietary restriction and antibiotic therapy. The plasma cholesterol 
concentration in this bitch was within the reference range (6.23mmol/l) but the 
triglyceride concentration was markedly raised (11.30mmol/I). 
In three of the four animals which presented with abdominal pain and 
intestinal signs, no underlying disease process was detected to which the 
hyperlipidaemia may have been attributable. The question remains as to 
whether the lipid disturbances were responsible for the clinical signs or whether 
both the hyperlipidaemia and the clinical manifestations were the result of a 
common pathological process. The introduction of a low fat diet (Canine low 
fat diet; Waltham) resulted in partial resolution of the hyperlipidaemia and 
complete remission of the clinical signs in all three cases, with no recurrence to 
date. It is likely that hyperlipidaemia, and in particular hypertriglyceridaemia, 
plays a role in the development of the symptoms described. The clinical signs 
in the latter two cases were similar to those of classical recurrent pancreatitis 
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with the major exception of the generalised, rather than localised abdominal 
pain. This has also been noted in the chylomicronaemia syndrome of man 
(Brunzell and Bierman 1982) and may indicate pathological processes, as yet 
undetermined. It is possible, however, that these two dogs were indeed 
suffering from classical pancreatitis, but that interference in the analysis of 
amylase by the lipaemia of the plasma samples resulted in spuriously low 
results. 
Investigators have previously attempted to clarify the relationship 
between hyperlipidaemia and pancreatitis by studying the lipid changes in 
experimentally-induced canine pancreatitis. The infusion of bile into the 
pancreatic duct of dogs resulted in slight increases in the plasma triglyceride 
concentrations and decreases in the rate of triglyceride clearance from the 
circulation (Zieve 1968), while bile duct ligation (Whitney, Boon, Rebar and 
Ford 1977) induced hypercholesterolaemia secondary to an increase in LDL 
concentrations. Plasma from three of the four dogs presented in this study was 
submitted for lipoprotein quantification. All the samples contained increased 
concentrations of VLDL-cholesterol and LDL-cholesterol (Appendix 19). In 
the one dog with concurrent diabetes mellitus and hypothyroidism, these 
changes are likely to be secondary to the underlying disease processes, but the 
fact that the other three dogs presented with similar clinical and lipoprotein 
disturbances suggests an association between this lipoprotein profile and the 
clinical syndrome. These data confirm that hypertriglyceridaemia plays a role 
in the development of pancreatitis, rather than arising as a consequence of 
pancreatic disease. The aetiology may involve the formation of lipid emboli 
and ischaemia of pancreatic tissue. 
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3.4. Ocular abnormalities 
One case, a 3 year old, female cocker spaniel (Case 116313, Appendix 19), was 
referred for the investigation of bilateral corneal opacities (Figs 8. and 9.). 
Lipid accumulation was noted in both corneas, with denser areas laterally and 
fainter deposits medially. In the right eye the lesion was horse-shoe shaped and 
early vascularisation was identified on both sides. The plasma cholesterol 
concentration at this time was above the upper limit of the reference range 
(8.4mmoljl), but the triglyceride concentration was normal (0.59mmoljl). The 
dog was considered moderately obese and a low fat diet (Hills r j d diet, Hills 
Pet Products Ltd) was introduced to induce weight reduction and control the 
hyperlipidaemia. Within three weeks of the initial presentation the plasma 
cholesterol concentration had fallen to 5.7mmoljl and by six weeks to 
4.3mmoljl. The lipid concentrations remained within normal limits and the 
corneal lesions remained unchanged for the following six months. The dog 
then presented with bilateral epiphora and anterior segment inflammation 
which persisted for approximately one year, despite topical therapy, at which 
point she developed an episcleral mass on the lateral aspect of the left globe. 
Biopsy of the lesion revealed an inflammatory reaction consistent with 
sclerititisjepiscleritis. Systemic and topical corticosteroid therapy relieved the 
scleral inflammation and epiphora but an increase in the extent and density of 
the corneal lipid deposition was noted. The latter appeared to worsen after 
each inflammatory episode, suggesting that anterior segment inflammatory 
disease and corneal oedema may have played a role in the development of 
corneal lipid deposition in this dog. 
A small, dense lipid deposit was also noted in the ventrolateral quadrant 
of right eye of an adult male Dobermann (Case 112876, Appendix 19) suffering 
from hypothyroidism. On presentation the dog was both hypercholesterolaemic 
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Figure 8. Corneal lipid deposition in the right eye of Case 116313. 
Figure 9. Corneal lipid deposition in the left eye of Case 116313. 
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(17.67mmol/l) and hypertriglyceridaemic (2.61mmol/I). After the introduction 
of thyroid replacement therapy the lesion became fainter but was still present 
six months later. 
In addition to the cases examined at Glasgow Veterinary School, plasma 
samples from nine dogs (Cases 1-9, Appendix 19) with corneal lipidosis were 
submitted for plasma lipoprotein quantification. Of these, one dog with 
unilateral facial nerve paralysis and corneal lipid deposition was also 
hypothyroid. This animal was hypercholesterolaemic (14.41mmol/l) and 
hypertriglyceridaemic (2.04mmol/I). Of the remaining dogs, four (50%) were 
hypercholesterolaemic (range 6.93mmol/1 - 11.35mmol/l) and one dog was 
hypertriglyceridaemic (1.84mmol/I). The hyperlipidaemia in the latter case 
may have reflected insufficient fasting before sampling. 
Arcus lipoides corneae is an annular lipid infiltration of the peripheral 
cornea and perilimbal zone of the sclera by lipid. There is usually a clear ring 
at the limbus but the lesion may extend towards the central cornea. The 
condition has been recognised as an infiltration of cholesterol, fatty acids and 
phospholipids III German shepherd dogs with hypothyroidism and 
hyperlipidaemia (Crispin and Barnett 1978). In the present study three dogs 
with corneal lipid deposition were German shepherd dogs, but none of these 
animals was hyperlipidaemic or had clinical signs of hypothyroidism. In these 
three cases, and in that of the cocker spaniel with anterior segment disease, the 
corneal lipid deposition may have been secondary to local changes in blood 
vessel permeability or inflammatory reactions, resulting in an increased transfer 
of lipids into the corneal stroma (Crispin 1989), rather than systemic factors. 
Lipaemia retinalis is the alteration in colour of the retinal vessels due to 
hyperlipidaemia and has been recognised III cats with inherited 
chylomicronaemia (Jones, Wallace, Harding, Hancock and Campbell 1983), but 
appears to be rarely identified in dogs (Wyman and McKissick 1973). The 
condition is only of diagnostic significance since the excess of blood lipids has 
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been demonstrated to have no detrimental effect on the retina (Gelatt 1991). 
Crispin and Barnett (1978) described a single case of lipaemia retinalis in a dog 
with a plasma cholesterol concentration of 22.1mmol/1. The plasma 
triglyceride concentration was not recorded. Lipaemia retinalis was not among 
the ocular abnormalities detected in the present series of cases, which included 
one dog with a plasma triglyceride concentration of 39mmol/1 at the time of 
ophthalmic examination. The failure to recognise lipaemia retinal is in any of 
the cases studied at Glasgow Veterinary School may, however, reflect 
ophthalmic inexperience, rather than absence of the condition. This must be 
considered the most likely scenario, since the appearance of blood samples 
from a number of cases resembled "tomato-soup" or "strawberry milk shake" 
and such abnormalities might well be associated with visual distortion of the 
retinal vessels. 
3.5. Atherosclerosis 
Experimentally, canine atherosclerosis may be induced by oral vitamin D 
poisoning (McAllister and Waters 1950), the chemical or surgical induction of 
hypothroidism combined with high cholesterol diets (Moses 1954) and by 
feeding semisynthetic diets for prolonged periods (McCullagh, Ehrhart and 
Butkus 1976; Mahley, Innerarity, Weisgraber and Fry 1977). Naturally-
occurring atherosclerosis is rarely reported in the dog, but has been recognised 
in association with thyroid dysfunction (Robinson 1976; Patterson, Rusley and 
Zachary 1985; Liu, Tilley, Tappe and Fox 1986). The development of 
atherosclerosis in the dog usually begins in small vessels and later in the aorta 
and coronary arteries (McGill 1965). 
Atherosclerosis was recognised III a 9 year-old, male whippet (Case 
114522, Appendix 19). The dog presented with hind limb paresis. On clinical 
examination the hind limbs were cold and the nailbeds cyanosed. No femoral 
pulse was detected on the right side but a thickened cord, thought to be the 
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femoral artery was identified. A provisional diagnosis of aortic saddle 
thrombosis was made. Biochemical analyses revealed hyper cholesterolaemia 
(47.80mmol/l) and hypertriglyceridaemia (5.60mmol/l). A TSH stimulation 
test confirmed the presence of thyroid dysfunction. The dog was euthanased on 
humane grounds and post mortem examination revealed the presence of 
atherosclerotic plaques of the coronary vessels, descending aorta and 
peripheral vessels (Fig. 10.). A large thrombus was present in 
approximately one third of the right femoral artery and the right testicle was 
completely infarcted secondary to vessel occlusion. 
Histologically the lesions were characterised by an accumulation of lipid 
deposits in the media of the vessels (Fig. 11.). The peripheral vascular disease 
observed in this case was similar to that found in human type III 
hyperlipidaemia (European Atherosclerosis Society 1988). It is interesting to 
note that type III hyperlipidaemia is associated with the accumulation of (3-
VLDL, an unusual lipoprotein which represents the accumulation of remnants 
of triglyceride-rich lipoproteins. Beta-VLDL was also isolated from the plasma 
of this case of canine hypothyroidism (Chapter VII 3.2.), suggesting a possible 
role for this lipoprotein in the pathogenesis of peripheral vascular disease in 
the dog. 
3.6. Neurological disturbances 
In man, dementia, characterised by fluctuations in memory performance which 
correlated inversely with plasma lipid concentrations, has infrequently been 
recognised in association with hyperlipidaemia (Mathew, Meyer, Achari and 
Dodson 1976). Disorientation, coma, circling and visual impairment have been 
noted III dogs with cerebral atherosclerosis secondary to primary 
hypothyroidism (Liu, Tilley, Tappe and Fox 1986; Patterson, Rusley and 
Zachary 1985). Similar signs were noted in the hypothyroid whippet previously 
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Figure 10. Atherosclerosis of a branch of the left coronary artery. The 
epicardial arteries appear as prominent cord-like structures due to narrow 
irregular white plaques within their walls. 
Figure 11. Cross section of the carotid artery showing clear spaces where lipid 
filled macrophages have replaced the smooth muscle cells of the media. 
Cholesterol clefts are also present (c). (Sirius Red) 
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mentioned. This dog had sporadic episodes of aimless wandering and apparent 
confusion during the three months prior to referral to G.U.V.S. 
Generalised seizures have been reported in miniature schnauzers with 
variable plasma triglyceride concentrations (Rogers, Donovan and Kociba 
1975a; Bodkin 1992). The relationship between hyperlipidaemia and disorders 
of the central nervous system have not been determined. None of the dogs with 
hyperlipidaemia identified in the presented study suffered from seizures. 
3.7. Peripheral neuropathies 
Peripheral neuropathies in man have been associated with diabetes mellitus 
and hyperlipidaemia, but have also been identified in a small number of non-
diabetic hyperlipidaemic cases suggesting that hyperlipidaemia, per se has a role 
in the aetiology of such neurological deficits (Sandbank, Bechar and Bornstein 
1971; Mathew, Meyer, Achari and Dodson 1976). In the present study, 
peripheral neuropathies were detected in a number of dogs with endocrine 
disease. Two dogs with diabetes mellitus had hind limb polyneuropathies and 
one had paralysis of the parasympathetic component of the third cranial nerve. 
One dog with hypothyroidism had a polyneuropathy and one dog with 
hyperadrenocorticism showed signs of generalised weakness and paralysis of 
the seventh cranial nerve. 
Only one dog with idiopathic hyperlipidaemia (Case 119993, plasma 
cholesterol 16.48mmol/1 and triglyceride 39.00mmol/l) had evidence of 
peripheral nerve dysfunction. In this case, the dog presented to the referring 
veterinary surgeon with a unilateral facial nerve paralysis and hyperlipidaemia. 
The dog had previously suffered recurrent episodes of bilateral otitis externa 
which may have progressed to otitis media, resulting in neurological signs. At 
the time of this presentation, however, auriscopic examination revealed only 
minor erythematous changes in the ipsilateral ear. 
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In man, the pathogenesis of hyperlipidaemic neuropathy is associated 
with demyelination, myelin disorganisation and perineural connective tissue 
proliferation (Mathew, Meyer, Achari and Dodson 1976; Sandbank, Becher and 
Bornstein 1971), while ill cats with idiopathic hyperlipidaemia peripheral 
neuropathy is believed to be the result of compression by subcutaneous 
xanthomata (Jones, Johnstone, Hancock and Wallace 1986). Due to the 
impracticalities of nerve biopsy, it was not possible to study the pathology 
associated with the endocrine and hyperlipidaemia related neuropathies 
identified in this study. 
3.8. Cutaneous xanthomatosis 
Xanthoma are dermatological lesions which result from the accumulation of 
lipids in foam cells of the dermis. The lipids contained within them are thought 
to originate from circulating plasma lipids, a theory which is supported by the 
appearance and regression of xanthomas in concert with the changes in plasma 
lipoproteins. In their eruptive phase, the lesions are particularly triglyceride-
rich, while the resolving lesions are cholesterol enriched (Parker, Bagdade, 
Odland and Bierman 1970). Cutaneous xanthomas have been described rarely 
in animals but are recognised in association with feline idiopathic 
hyperchylomicronaemia (Jones, Johnstone, Hancock and Wallace 1986) and 
diabetes mellitus in both the dog (Chastain and Graham 1978) and the cat 
(Jones, Wallace, Hancock, Harding and Johnstone 1985). The paucity of case 
reports was reflected in the present study, where skin lesions were detected in 
only one case, i.e., the adult, male Dobermann with hypothyroidism and corneal 
lipid deposition (Case 112876; Appendix 19, see section 3.4.). Raised, 
thickened plaques with a grey surface and hyperkeratotic edges were present on 
the pinnae, hocks and elbows of this dog. The lesions regressed within one 
month of thyroid hormone replacement, but their exact nature was not 
classified by histological examination. If these lesions were classical xanthomas, 
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it IS surprising that this individual animal, with a plasma triglyceride 
concentration of 2.63mmol/l (plasma cholesterol 19. 13mmol/l) should be 
affected and others with more severe lipid abnormalities did not show 
dermatological lesions. However, the presence of xanthomas with a major 
fibrohistiocytic proliferation have been reported in normolipidaemic dogs, 
although the origin of the lipid component has not been determined (Gross and 
Ihrke 1992). 
3.9. Pseudopregnancy 
The female cocker spaniel previously described (case 116313) has been 
maintained on a low fat diet (Hills rid diet, Hills Pet Products Ltd.) from the 
time of her initial consultation at G.U.V.S. (January 1991) to the present date. 
During this period her plasma cholesterol concentrations, which were 
monitored at four to six weekly intervals, remained between 3.0mmol/l and 
4.0mmol/1. The plasma triglyceride concentration was stabilised at 0.50-
0.65mmol/1. On 21 August 1991, the bitch's plasma cholesterol concentration 
was 3.55mmol/L This rose to 5.59mmol/l on 1 October and 7.13mmol/l on 24 
October 1991. This increased plasma cholesterol concentration reflected an 
increase in both HDL-C and LDL-C concentrations (3.69mmol/l and 
2.71mmol/l, respectively). From 4-10 October the dog displayed behavioural 
changes and milk production consistent with pseudopregnancy. The clinical 
signs regressed within 8 days without the use of medical therapy. 
Pseudopregnancy in the bitch is believed to be a an exaggeration of the normal 
non-pregnant state. The onset is dependent on falling progesterone and rising 
oestrogen concentrations, in addition to an increased prolactin concentration 
(Feldman and Nelson 1987). Hyperlipidaemia is commonly recognised in 
pregnant women and in those prescribed certain oral contraceptives (Crook 
and Seed 1990). Under these circumstances, lipoprotein metabolism appears to 
be influenced by changes in progesterone, oestrogen and insulin. The effect of 
131 
CHAPTER VI 
lactation per se appears to be limited to an increase in the cholesterol content 
of HDL particles (Knopp, Bergelin, Wahl and Walden 1985). It is possible, 
therefore, that the hormone changes responsible for the development of 
pseudopregnancy in the cocker spaniel bitch presented here may also have 
resulted in alterations of lipid metabolism. 
3.10. Hepatic enzymes 
The alkaline phosphatase, ALT and AST activities in obese dogs and dogs with 
idiopathic and secondary hyperlipidaemia (Table 18., Appendix 20) were 
compared with the plasma lipid and lipoprotein concentrations. In each group, 
the correlations were very weak, with the exception of those dogs with 
idiopathic hyperlipidaemia, in which the following relationships were noted: 
plasma cholesterol and alkaline phosphatase activity (r = 0.46, P < O.OS), AST 
activity (r=0.64, p<O.Ol) and ALT activity (r=0.52, p<O.OS); LDL-C and AST 
activity (r=0.70, p < 0.01) and ALT activity (r=0.S4, p <O.OS); plasma 
triglyceride and alkaline phosphatase (r=0.S6, p < O.OS) and AST activity 
(r=0.79, p<O.OOl), and plasma VLDL-C and AST activity (r=0.71, p<O.Ol) 
and ALT activity (r=0.58, p<O.Ol). In addition, a negative relationship 
(r=-0.49, p<O.OS) was observed between plasma HDL-C and AST activity. 
The increases in hepatic enzyme activities in diabetes mellitus, 
hyperadrenocorticism and hepatic disease reflect the underlying pathology in 
these cases. There were only two cases of obstructive jaundice, a disease 
process in which one might expect the plasma cholesterol concentration to be 
related to the degree of cholestasis (judged by the alkaline phosphatase 
activity) and these were not included in this study. When considering 
hyperadrenocorticism it is important to note that the increase in liver enzyme 
activities is related to the induction of a specific isoenzyme of alkaline 
phosphatase and hepatocyte swelling secondary to glycogen accumulation. 
Under these circumstances a relationship between plasma lipid concentrations 
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and hepatic enzyme activities might not be expected. However, in diabetes 
mellitus, where the underlying pathology includes hepatic lipidosis, i.e., 
hepatocellular triglyceride accumulation, it would seem likely that a 
relationship between plasma lipids and hepatocellular insult might exist. Such 
a relationship has not been demonstrated by this study, perhaps because of 
insufficient data. It is, for example possible that the effect of hepatocyte 
triglyceride accumulation on the activities of hepatic enzymes is 
disproportionate to the effect of insulin deficiency on the circulating plasma 
lipoproteins. It is perhaps more likely that the activities of alkaline 
phosphatase, ALT and AST in the plasma do not reflect the degree of lipid 
accumulation in the hepatocytes, particularly in dogs with other metabolic 
disturbances, e.g., cardiovascular hypoxia. 
The relationships described between plasma lipid and lipoprotein 
concentrations and hepatic enzyme activities may be artefactual, resulting from 
the small number of cases, or as a consequence of leakage of red cell 
constituents secondary to in vitro haemolysis, which is often noted in lipaemic 
samples. This latter hypothesis may explain the positive correlation between 
the plasma triglyceride concentration and VLDL-C concentration and the AST 
and AL T activities. If, however, these relationships are a consequence of 
physiological rather than technical influences, it is possible that increases in 
plasma triglyceride and VLDL are accompanied by hepatic triglyceride 
accumulation, resulting in swelling of the hepatocytes and release of AST and 
ALT. 
3.11. Renal parameters and plasma lipoprotein concentrations in protein-
losing nephropathy 
Hyperlipidaemia is recognised as a component of the nephrotic syndrome in 
man (Keane and Kasiske 1990). A significant negative correlation has been 
identified between the total plasma cholesterol and both the plasma albumin 
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and the plasma oncotic pressure (Appel, Blum, Chien, Kunis and Appel 1985). 
In the present study, very weak negative correlations, which were not 
significant, were identified between the plasma triglyceride and cholesterol 
concentrations and and plasma albumin (r=-0.26 and r=-0.16, respectively) 
and between the plasma triglyceride and total protein concentrations (r = -0.55) 
in dogs with protein-losing nephropathy (n=4). The small number of cases in 
this study make it impossible to form any meaningful conclusions regarding the 
relationships between plasma lipoprotein and protein concentrations in the 
dog. 
3.12. Haematological abnormalities 
The haemoglobin, mean cell haemoglobin and mean cell haemoglobin 
concentrations were above the upper limit of the reference range in three cases 
with lipaemic plasma. Non-regenerative anaemia was noted in one obese dog, 
one dog with hypothyroidism and one case with hepatic dysfunction. Target 
cells were identified in blood smears from one dog with hyperadrenocorticism 
and one with hepatic disease. 
Lipaemia of a sample may interfere with the determination of 
haemoglobin by spectrophotometric means, in a similar fashion to the 
interference with biochemical parameters (DeBowes 1(87). The erroneously 
elevated haemoglobin concentration in lipaernic samples subsequently affects 
the mean corpuscular haemoglobin and the mean corpuscular haemoglobin 
concentration, as reported here. 
Non-regenerative anaemia IS a common haematological abnormality 
associated with hypothyroidism (Feldman and Nelson 1987) and hepatic 
disease in the dog (Center 1989) and the occurrence of this complication in 
dogs included in this study is therefore not surprising. Target cells (leptocytes) 
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Table 18. The mean ±sd alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) activities in 
obese dogs and dogs with idiopathic and secondary hyperlipidaemia. 
Disease 
Status 
Obesity 
(n= 17) 
Diabetes mellitus 
(n=7) 
Hyperadrenocorticism 
(n= 14) 
Hypothyroidism 
(n=9) 
Nephropathy 
(n=4) 
Hepatic disease 
(n=6) 
Idiopathic hyperlipidaemia 
(n=20) 
Reference range 
ALP 
lUll 
246 
±324 
1649 
±2399 
1840 
±1792 
142 
±154 
240 
±180 
4143 
±3015 
404 
±405 
<230 
ALT 
lUll 
42 
±57 
155 
±215 
165 
+162 
37 
±8 
40 
±10 
177 
±670 
52 
±31 
<35 
AST 
lUll 
23 
±10 
38 
±23 
34 
±17 
52 
±81 
65 
±35 
61 
±57 
32 
±26 
<35 
have been recognised in portosytemic shunts and obstructive jaundice in the 
dog. Their occurrence in association with a deficiency of plasma LCAT activity 
in man (Barter, Hopkins and Rajaram 1987) suggests a role for excess 
accumulation of cell membrane cholesterol and lecithin in their formation. It is 
possible that the hepatic pathology present in the two cases in which target cells 
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were identified may have resulted III impaired LCAT function and 
abnormalities of the red cell membrane. 
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THE INVESTIGATION AND MANAGEMENT OF 
HYPERLIPIDAEMIA IN THE DOG 
CHAPTER VII 
1. INTRODUCTION 
Secondary hyperlipidaemia is more common in dogs than idiopathic or primary 
hyperlipidaemia (Chapter VI 3.1.). Despite this, idiopathic hyperlipidaemia was 
identified in a significant number of animals in the survey described in Chapter 
VI. In an attempt to identify the underlying lipid disturbances in these cases, the 
quantification of plasma lipids and lipoproteins, the measurement of postheparin 
plasma lipase activities, the performance of intravenous fat tolerance tests and 
the assessment of lipoprotein mobility by electrophoresis has been undertaken. 
Following the identification of hyperlipidaemia, it is then necessary to 
consider whether, and what therapeutic strategies should be implemented. In 
the dog, where atherosclerosis is rare, the need for such lipid-lowering therapy is 
not immediately obvious. However, the clinical findings associated with 
hyperlipidaemia (Chapter VI 3.3-3.12), including classical pancreatitis, 
abdominal and gastrointestinal signs, neurological defects and ocular 
abnormalities, suggest that lipid-lowering could be important in the management 
of idiopathic hyperlipidaemia. The first line of approach in any hyperlipidaemic 
case is to exclude the possibility of underlying disease processes, particularly, 
endocrine disease. In cases of secondary hyperlipidaemia the lipoprotein 
abnormalities resolve partially or completely after therapy for the underlying 
condition (Ford 1977), but in the case of idiopathic hyperlipidaemia specific 
therapy may be required. In man, initial therapy involves the introduction of a 
low fat diet, that is followed, where necessary, by additional lipid-lowering drugs. 
The aim of this study was to characterise the lipoprotein abnormalities 
associated with idiopathic hyperlipidaemia in the dog and to evaluate the efficacy 
of therapeutic regimes. 
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2. MATERIALS AND METHODS 
Idiopathic hyperlipidaemia was diagnosed In dogs with increased plasma 
cholesterol and/or triglyceride concentrations with no identifiable systemic 
disease process. Endocrine disease and organ dysfunction were excluded by the 
investigations desribed in Chapter IV 2.l. 
The quantification of the plasma lipoproteins was performed by an 
ultacentrifugation/precipitation method (Chapter II 2.2.) and the effect of breed, 
age and gender on the lipoprotein concentrations were corrected for by the 
methods described in Chapter IV 2.5. Lipoprotein electrophoresis was 
performed to identify the presence of (3-VLDL as described in Chapter II 2.3. 
3. RESULTS AND DISCUSSION 
3.1. The characterisation of idiopathic hyperlipidaemia 
The mean ±sd age of this group was 7.34 ± 3.2 years. These were 16 entire 
males, seven entire females and 12 neutered females. Nine dogs had increased 
plasma cholesterol and triglyceride concentrations while 26 had 
hypercholesterolaemia alone. The distributions of the cholesterol and 
triglyceride concentrations are shown in Figures 12 and 13. The plasma 
cholesterol and LDL-C concentrations (Table 19., Appendix 10) in the group 
were significantly greater (p < 0.001 and p:::; 0.01, respectively) than those of the 
control population. 
Idiopathic hyperlipidaemia in the dog was accompanied by increased 
plasma concentrations of cholesterol, triglyceride, VLDL-C, LDL-C and HDL-C. 
Due to the marked heterogeneity of the group, only the increases in total 
cholesterol and LDL-cholesterol were significant. The plasma triglyceride 
concentration associated with hyperlipidaemia was biased by three dogs with 
hypertriglyceridaemia (cases 119993, 122074 and 120360). In these cases, the 
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plasma triglyceride, VLDL-C and plasma LDL-C concentrations were increased. 
These abnormalities may be the consequence of increased hepatic triglyceride 
synthesis or delayed clearance of both triglyceride-rich lipoproteins and LDL 
from the circulation. 
Table 19. The plasma lipid and lipoprotein concentrations (mmol/l) in dogs with 
idiopathic hyperlipidaemia (n=35) and control dogs (n=33). 
Plasma concentration (mmol/) 
Triglyceride Cholesterol VLDL-C LDL-C HDL-C 
Control 0.60 4.51 0.47 1.72 2.34 
(n=33) ±0.20 ±1.49 ±0.70 ±1.88 ±0.70 
Idiopathic 2.44 8.86** 0.98 3.95* 3.84 
(n=35) ±6:72 ±2.93 ±1.03 ±2.31 ±1.39 
* p = 0.01, * *p < 0.001. 
3.2. ,B-VLDL and apolipoprotein E 
Beta-VLDL was identified on the basis of its density and migration to the ,B 
position on agarose gel electrophoresis. This lipoprotein was detected in the 
plasma of one dog referred to G.U.V.S., a 10 year old male Whippet (Case 
114522, Appendix 16) suffering from bilateral hind limb paresis and iliac 
thrombosis (Chapter VI 3.5.). On examination, the blood collected for routine 
haematological and biochemical evaluation was lipaemic and the dog was 
diagnosed as suffering from thyroid dysfunction on the basis of a thyroid 
hormone stimulation test, although the animal showed no clinical signs of 
hypothyroidism. The plasma cholesterol, triglyceride and VLDL-C and LDL-C 
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Figure 12. The distribution of plasma cholesterol concentrations of dogs with 
idiopathic hyperlipidaernia (n =35). 
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14.----------------------------, 
12 ..... 
10 ..... 
8 ..... 
6 
4 
2 
O~ __ ~_L ___ LL ___ LL ______ ~ ______ ~ ______ ~ 
9-10 10-15 >15 6.5-7 7-8 8-9 
Cholesterol concentration (mmol/I) 
Figure 13. The distribution of the plasma triglyceride concentrations of dogs 
with idiopathic hyperlipidaernia (n=35). 
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concentrations were 47.80 rnmol/l, 5.60 mmol/l, 22.31 mmol/l and 23.74mmol/l, 
rec;pectively. The extremely high cholesterol content of the lipoproteins with 
density less than 1.006 g/ml is characteristic of {3-VLDL. On agarose gel 
electrophoresis the lipoproteins of this density also displayed {3-migration. The {3 
-VLDL previously recognised in plasma from dogs fed high cholesterol diets 
possessed a normal apoE complement. However, an abnormality of apoE 
function in addition to endocrine disease may have resulted in the formation of {3 
-VLDL in this pet dog which was not receiving a high fat diet and this is still 
under investigation. 
3.3. The management of hyperlipidaemia in the dog 
Ten cases of idiopathic hyperlipidaemia were selected for the evaluation of the 
efficacy of dietary management. Nine of the dogs presented with 
hypercholesterolaemia and six were hypertriglyceridaemic (Appendix 21). The 
mean ±sd plasma cholesterol and triglyceride concentrations after dietary 
intervention (8.74 ±4.18 mmol/l and 4.17 ± 7.15 mmol/l, respectively) were 
lower then those before introduction of the low fat diet (11.93 ±4.04 mmol/l and 
5.89 ±5.59 mmol/l) (Appendix 18). The alterations in plasma cholesterol were 
significant (p < 0.01), but those of triglyceride were not. Taken on an individual 
basis, the hyperlipidaemia resolved in three dogs. In sIX cases 
hypercholesterolaemia persisted and in four dogs the hypertriglyceridaemia did 
not resolve. On initial presentation three of these cases displayed 
gastrointestinal signs, while two additional dogs were considered at risk of 
developing pancreatitis secondary to hypertriglyceridaemia. Of these five cases, 
only two dogs retained the marked elevations of plasma triglyceride after dietary 
manipulation. 
One dog (Case 119993) with marked increases of plasma cholesterol 
(16.48 mmol/l) and triglyceride (39.00 mmol/l) concentrations did not respond 
to dietary fat restriction and therapy with gemfibrizol (Lopid*, Parke-Davis; 300 
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mg daily) was introduced. This fibric acid derivative was selected because its 
main actions include the reduction of triglyceride concentrations by decreasing 
hepatic VLDL synthesis and increasing the activity of lipoprotein lipase 
(Tikkanen 1990). After six weeks of therapy there was no reduction of the 
cholesterol and triglyceride concentrations. At this point repeat biochemical 
analyses and urinalysis revealed a moderate hypoalburninaernia secondary to 
proteinuria. Gemfibrizol therapy was discontinued. The toxicological studies on 
this drug indicate that it was well tolerated by dogs in the short term and in the 
long term it was tolerated at doses of 15 times the normal human dosage 
(15mg/kg) (Kurtz, Fitzgerald, Fisken, Schardein, Reutner and Lucas 1976). It is 
unlikely, therefore, that the protein-losing nephropathy was a consequence of 
drug therapy and more likely that the dog was suffering from a previously 
unrecognised renal disorder. At this point a home-formulated low fat, low 
protein diet was introduced and the plasma triglyceride and cholesterol 
concentration steadily declined over the following three weeks. Since then, the 
plasma cholesterol has remained moderately increased (7-9 mmoljl), but the 
triglyceride concentration has been consistently within normal limits « 1.75 
mmol/l). At no time did the dog show signs of weight loss and the 
hypoalbuminaernia and proteinuria are steadily resolving. Long term remission 
and spontaneous recovery of canine nephropathies have been noted and the 
findings in this case are believed to be consistent with this observation, although 
the possibility that renal disease was drug-induced cannot be completely 
excluded. 
In two other dogs it was necessary to consider means of reducing the 
plasma triglyceride concentration. One dog (Case 116313, Appendix 19) did not 
display fasting hypertriglyceridaernia, but suffered persistent corneal lipid 
deposition secondary to anterior segment disease. The owner was keen to 
maintain the fasting triglyceride concentrations at a minimum. The second dog, 
a 9 year-old male Cavalier King Charles spaniel (Case 120848, Appendix 19) was 
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suffering from idiopathic hyperlipidaemia with lethargy and intermittent 
anorexia. The hyperlipidaemia in this case not respond completely to dietary fat 
restriction. 
Therapy with fish oils (omega-3 polyunsaturated fatty acids) has been 
advocated in human hypertriglyceridaemia (Phillipson, Rothrock, Connor, Harris 
and Illingworth 1985) where it is particularly effective in moderating 
postprandial lipaemia (Williams, Moore, Morgan and Wright 1992). The 
supplementation of fish oils is also associated with few side effects and may be 
used for the treatment of hypertriglyceridaemia in patients who cannot tolerate 
other therapies (Schaefer 1988). For these reasons an omega-3 polyunsaturated 
fatty acid supplement was administered to the two cases described above in an 
attempt to limit the plasma triglyceride concentrations. The fasting and 
postprandial triglyceride concentrations of both dogs were measured before and 
after the inclusion of an omega-3 polyunsaturated fatty acid supplement 
(Maxepa liquid, 15mgjkgjday; Duncan, Flockhart) in the diet. The results 
(Table 20.) indicate that fish oil supplementation in the dog is effective in the 
reduction of hypertriglyceridaemia, particularly postprandial 
hypertriglyceridaemia. It is possible that this therapy may play a role in 
modulating the hypertriglyceridaemia associated with some cases of idiopathic 
hyperlipidaemia and with familial hyperlipidaemia in the miniature schnauzer, 
thus reducing the predisposition to clinical manifestations, including pancreatitis. 
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Table 20. The fasting and postprandial triglyceride concentrations (mmol/l) in 
two dogs before and 3 weeks after dietary supplementation with omega-3 fatty 
acids. 
120848 116313 
before after before after 
Fasting 2.13 1.47 0.62 0.38 
Postprandial 
0.5 hr 2.09 1.40 0.58 0.44 
1 hr 2.12 1.48 0.73 0.70 
2 hr 2.96 1.78 0.71 0.77 
3 hr 3.28 n.d. n.d. 0.10 
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CONCLUSIONS AND FUTURE STRATEGIES 
CHAPTER VIII 
The aim of this thesis was to characterise the abnormalities of lipid metabolism 
recognised in dogs, to establish the effect of such aberrations on the health of 
individuals and to evaluate the efficacy of therapeutic regimes. The purpose of 
this chapter is to collate the signific'mt findings of the study and to outline 
future avenues of investigation in the field of canine lipid metabolism. 
1. THE ANALYSIS OF CANINE PLASMA LIPOPROTEINS 
Methods of quantitative lipoprotein analysis have not previously been applied 
to the investigation of canine lipid abnormalities associated with naturally-
occurring disease. Differences in the physical and chemical properties of the 
lipoproteins between humans and dogs necessitated techniques specific for 
canine plasma. The validation of an ultracentrifugation/precipitation method 
for the quantification of lipoprotein cholesterol concentrations was therefore 
central to the execution of this study. Attempts to identify an accurate, 
reproducible and inexpensive technique for use in veterinary laboratories 
without ultracentrifugation facilities were unsuccessful. However, the 
combination of the measurement of HDL-C by a precipitation procedure, 
followed by the estimation of the LDL cholesterol using the Friedewald 
formula may have potential. The development of a simple method for the 
measurement of HDL-C will allow both researchers and clinicians access to 
information which will help in understanding hyperlipidaemia in the canine 
population. Electrophoresis remains a useful adjunct in the investigation of 
lipid disorders, facilitating the recognition of chylomicrons, HDL1 and j3-VLDL 
which are not isolated by the combined precipitation/ultracentrifugation 
technique. 
This thesis has demonstrated that camne plasma lipoprotein 
concentrations are influenced by gender and perhaps by dietary and/or other 
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environmental factors. This highlights the need for specific lipoprotein 
reference ranges that take these effects into account. 
2. THE LIPID ABNORMALITIES ASSOCIATED WITH SYSTEMIC 
DISEASE 
Quantitative lipoprotein analysis was used for the first time to characterise the 
disturbances of lipid metabolism associated with systemic disease. The results 
indicate that diabetes mellitus and hypothyroidism are associated with defects 
in the metabolism of both cholesterol-carrying and triglyceride-rich 
lipoproteins, while hyperadrenocorticism, extrahepatic bile duct obstruction 
and protein-losing nephropathy are accompanied solely by increases in plasma 
cholesterol and LDL concentrations. These observations provided clues to the 
origin of the underlying defects in lipoprotein metabolism. The identity of 
these defects was investigated as far as possible, given that the cases were client 
owned, by the measurement of lipoprotein and hepatic lipase activities, and the 
use of the intravenous fat tolerance test to assess plasma triglyceride clearance. 
These methods demonstrated impaired triglyceride clearance associated 
with a decreased lipoprotein lipase activity in obese dogs and dogs with thyroid 
dysfunction. Furthermore, the plasma triglyceride clearance curves in obese 
dogs suggested that the hyperlipidaemia may be complicated by the poor 
regulation of hepatic triglyceride synthesis. These abnormalities of triglyceride 
metabolism may predispose obese dogs to acute pancreatitis. The restriction of 
caloric intake and subsequent weight reduction was shown to improve the 
abnormalities in lipid kinetics associated with obesity and have an important 
role in the prevention of acute pancreatic disease. 
Further understanding of lipid abnormalities could only have been 
gained from measurement of other intravascular enzymes, namely, LeA T and 
the investigation of apoE and receptor function. 
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3. IDIOPATHIC HYPERLIPIDAEMIA 
This study identified a number of dogs with defects of lipoprotein metabolism 
which cannot be attributed to underlying disease processes. Gastrointestinal 
clinical signs were associated wi-h hypertriglyceridaemia and were observed to 
regress in parallel with the lipid abnormalities. Hyperlipidaemia per se, should 
therefore, be considered detrimental to the health of individual dogs. 
The nature of the underlying defects in lipoprotein metabolism could 
not be established. It was unlikely that genetic variations/defects in the 
regulatory elements of the plasma lipoproteins e.g., lipoprotein lipase or 
receptor deficiencies, were solely responsible as the dogs were generally mid- to 
old-aged rather than puppies. However, it is possible that acquired or 
environmental factors such as age or diet, may have further compromised a 
lipoprotein system impaired by an inherited defect. 
Dogs related to those presented with hyperlipidaemia were not available 
for study and therefore the investigation of familial trends in lipoprotein 
disturbances could not be pursued. However, the techniques validated in thi3 
study for the investigation of idiopathic and secondary hyperlipidaemia will 
allow a rational approach to the investigation of the proposed familial 
hyperlipidaemias of the miniature schnauzer and the Briard. 
The measurement of the plasma lipoprotein cholesterol concentrations 
and lipoprotein lipase activity allows a rational approach to the therapy of 
idiopathic hyperlipidaemia which should include dietary fat restriction as the 
first measure. In cases that respond poorly to this action, additional therapy 
with omega-3 fatty acids may be considered. The data regarding 
supplementation with marine oils is still sparse but the results show potential 
and future work should be aimed at targeting suitable cases for therapy and 
closely monitoring the response of both fasting and postprandial lipaemia, as 
well as any side effects. 
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Suppliers of reagents and equipment. 
Amersham International pIc., 
Amersham Place, Little Chalfont, Amersham, Bucks., HP7 9NA 
Beckman Instruments Inc., 
Beckman Instruments (UK) Ltd., Analytical Sales and Service 
Operation, Progress Road, Sands Industrial Estate, High Wycombe, 
Bucks., HP12 4JL. 
Boehringer Mannheim GmbH, 
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd., 
Bell Lane, Lewes, East Sussex, BN7 lLG. 
Ciba Laboratories, 
Horsham, England. 
Hoefer Scientific Instruments, 
Scottish Biotechnology Instrumentation, 
Blairgowrie Business Centre, 60 High Street, Blairgowrie, PHI0 6AF. 
Idexx Laboratories Inc. 
1 Idexx Drive, Westbrook, Portland, Maine, U.S.A. 
ImmunoAG, 
Immuno Ltd., 
Arctic House, Rye Lane, Dunton Green, Nr. Sevenoaks, Kent. 
Joyce-Loebl, 
Dukesway, Team Valley, Gateshead, Tyne & Wear, NEll OPZ. 
Kabi Pharmacia Ltd., 
Davy Avenue, Knowlhill, Milton Keynes, MKS 8PH, Bucks., 
Leo Laboratories Ltd., 
Longwick Road, Princes Risborough, Aylesbury, Bucks., HP17 9RR. 
LKBBromma 
Pharmacia Ltd., Pharmacia LKB Biotechnology Division 
Midsummer Boulevard, Central Milton Keynes, Bucks., MK9 3HP. 
Packard Instrument Co., 
Canberra Packard Ltd., 
Brook House, 14 Station Road, Pangbourne, Berks., RG8 7DT. 
Pharmacia AB, 
Pharmacia Ltd., Pharmacia LKB Biotechnology Division 
Midsummer Boulevard, Central Milton Keynes, Bucks., MK9 3HP. 
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Suppliers of reagents and equipment (continued). 
Randox Laboratories Ltd., 
Ardmore, Diamond Road, Crtlmlin, Co. Antrim BT29 4QY. 
Roche 
Roche Products Ltd., 
P.O. Box 8, Welwyn Garden City, Herts., AL73AY. 
Scottish Quality Assessment Scheme 
Biochemistry Department, Victoria Infirmary, Glasgow. 
SCL Bioscience Services Ltd., 
211 Cambridge Science Park, Milton Road, Cambridge CB4 4ZA. 
Sigma 
Sigma Chemical Company Ltd., 
Fancy Road, Poole, Dorset, BH17 7TG. 
Technicon Instruments Corporation 
Tarrytown, New York 10591, U.S.A. 
U.K. External Quality Assessment Scheme, 
Department of Clinical Chemistry, 
Queen Elizabeth Medical Centre, Edgbaston, Birmingham. 
Wako Chemicals GmbH, 
Alpha Laboratories Ltd., 
40 Paman Drive, Eastleigh, Hampshire S05 4NU. 
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The derivation of the equation for the calculation of post-heparin plasma 
lipolytic activity. 
Activity (,umolFA/ml/hr) = (Sample cpm - Blank cpm) x 755.1 
Total cpm - background cpm 
where 755.1 = 1.5059a x 3b x lOoe x 2.45 d 
2.05 e x If x O.715g 
a is ,umol triolein/assay tube 
b three fatty acids are released from one molecule of triolein 
c to correct 10,u1 sample to 1ml 
d volume of upper phase after extraction 
e volume of lower phase after extraction 
f incubation time in hours 
g % oleic acid extracted into upper phase from Belfrage and Vaughan 
(1969) 
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Performance characteristics of a method for the quantitative analysis of canine 
plasma lipoproteins. 
Intra-assay (Within batch) performance 
Cholesterol concentration (mmoljl) 
---------------------------------------------------------------------------
Aliquot Plasma VLDL LDL HDL 
Low cholesterol pool 
A 2.58 0.02 0.77 1.79 
B 2.63 0.03 0.75 1.85 
C 2.71 0.18 0.73 1.80 
D 2.72 0.19 0.67 1.86 
E 2.71 0.21 0.74 1.76 
F 2.58 0.04 0.65 1.89 
G 2.75 0.12 0.79 1.84 
H 2.61 0.11 0.62 1.88 
I 2.64 0.23 0.71 1.70 
J 2.70 0.12 0.72 1.86 
K 2.71 0.20 0.71 1.80 
L 2.64 0.11 0.72 1.81 
High cholesterol pool 
A 8.20 0.28 3.64 3.54 
B 8.20 0.29 3.47 3.61 
C 8.19 0.26 3.39 3.70 
D 8.32 0.29 3.53 3.67 
F 7.85 0.32 3.76 3.39 
H 8.06 0.30 3.97 3.29 
APPENDIX 4 
The plasma and lipoprotein cholesterol concentrations after storage for two 
and eight weeks. 
Cholesterol concentration (mmol/l) 
----------------------------------------------------------------------------------
Aliquot Plasma Infranatant VLDL LDL HDL 
Two weeks 
A 2.82 2.42 0.39 0.65 1.76 
B 2.88 2.63 0.25 0.80 1.83 
C 2.87 2.50 0.37 0.84 1.67 
D 2.82 2.31 0.51 0.83 1.48 
E 2.90 2.48 0.42 0.87 1.61 
F 2.94 2.03 0.91 0.36 1.67 
Eight weeks 
A 2.81 2.41 0.39 0.65 1.76 
B 2.88 2.63 0.25 0.80 1.83 
C 2.87 2.50 0.37 0.83 1.67 
D 2.82 2.31 0.51 0.83 1.48 
F 2.90 2.43 0.47 0.84 1.59 
H 2.83 2.41 0.42 0.77 1.64 
156 
appendix 5 
The calculated and measured VLDL-C concentration in 28 samples of canine 
plasma. 
Calculated VLDL-C Measured VLDL-C 
(mmol/l) (mmol/l) 
3.28 2.15 
0.63 0.04 
0.47 0.02 
1.54 0.93 
18.64 20.56 
20.26 23.58 
1.02 0.28 
3.27 2.37 
0.76 0.04 
0.99 0.05 
0.64 0.10 
1.85 0.68 
0.79 0.02 
2.71 2.26 
0.40 0.17 
0.54 0.10 
1.28 0.91 
0.65 0.13 
2.02 0.93 
1.33 0.75 
0.62 0.03 
0.52 0.13 
1.22 0.97 
0.54 1.22 
1.10 0.94 
5.89 6.20 
2.17 2.61 
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HDL-C concentrations measured by a combined 
ultracentrifugation/precipitation technique and commercial precipitation 
reagents. 
HDL-C (mmol/l) HDL-C (mmol/l) 
Method A MethodB Method A Method C 
Method A: 
Method B: 
3.54 3.66 3.54 
2.97 3.00 2.97 
4.51 4.59 4.51 
4.13 3.60 4.13 
1.90 1.11 1.90 
4.20* 1.26 4.20* 
3.53 3.87 3.53 
5.97 4.35 5.43 
5.55 3.06 5.55 
2.29* 6.06 1.61 
1.61 0.96 5.26 
5.26 5.70 2.60 
2.60 1.11 5.71 
Ultracentrifugation/precipitation technique. 
HDL-cholesterol precipitant (Randox Laboratories). 
3.69 
3.06 
4.59 
5.79 
1.14 
0.81 
3.45 
5.28 
3.72 
1.80 
4.89 
2.46 
4.56 
Method C: Quantolip HDL-cholesterol precipitation reagent (Immuno Ltd.). 
* plasma triglyceride> 5.00mmol/1. 
158 
APPENDIX 7 
LDL-C concentrations measured by a combined 
ultracentrifugation/precipitation technique and commercial precipitation 
reagents. 
LDL-C (mmol/l) LDL-C (mmol/l) 
Method A Method B Method A 
Method A: 
Method B: 
2.82 2.06 2.82 
4.02 2.84 4.02 
18.63 18.51 23.65* 
23.65* 41.09 1.47 
1.47 2.72 1.14 
1.14 1.43 5.71 
5.71 2.21 1.59 
1.59 1.57 3.86 
10.23* 3.94 10.23* 
1.44 2.96 1.62 
1.62 1.72 7.59 
7.59 2.10 2.46 
2.46 2.04 3.22 
Ultracentrifugation/precipitation technique. 
LDL-cholesterol precipitant (Randox Laboratories). 
Method C 
1.84 
2.07 
6.22 
3.33 
1.54 
1.88 
1.57 
2.29 
9.00 
1.83 
2.10 
2.15 
3.17 
Method C: Quantolip LDL-cholesterol precipitation reagent (Immuno Ltd.). 
* plasma triglyceride> 5.00mmol/1. 
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LDL-C concentrations measured by a combined 
ultracentrifugation/precipitation technique and commercial precipitation 
reagents (continued). 
Method A: 
Method D: 
LDL-C (mmol/l) 
Method A MethodD 
2.82 0.38 
4.02 1.28 
1.47 0.80 
1.14 0.73 
5.71 0.59 
1.59 0.51 
1.99 1.16 
1.62 1.08 
7.59 0.72 
2.46 2.08 
3.22 0.96 
0.85 0.29 
Ultracentrifugation/precipitation technique. 
LDL-cholesterol precipitation reagent (Boehringer Mannheim 
GmbH Diagnositics). 
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The performance characteristics of the precipitation reagents for the 
measurement ofHDL and LDL cholesterol concentrations. 
HDL-C (mmoljl) LDL-C (mmol/I) 
Method A Method B Method C Method D Method E 
5.10 
5.25 
5.13 
5.25 
5.13 
5.07 
5.28 
5.10 
Method A: 
Method B: 
Method C: 
Method D: 
Method E: 
5.28 2.09 0.30 1.54 
5.52 1.65 0.09 1.76 
5.31 1.65 0.18 2.09 
5.31 1.43 0.12 1.76 
5.07 1.98 1.40 1.54 
5.25 1.32 1.29 1.54 
5.22 1.54 1.16 1.76 
5.13 1.54 2.06 1.43 
HDL-choiesterol precipitant (Randox Laboratories). 
Quantolip HDL-cholesterol precipitation reagent (Immuno Ltd.). 
LDL-choiesterol precipitant (Randox Laboratories). 
LDL-cholesterol precipitation reagent (Boehringer Mannheim 
GmbH). 
Quantolip LDL-cholesterol precipitation reagent (Immuno Ltd.). 
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The LDL-cholesterol concentration measured by a combined 
ultracentrifugation/precipitation technique and calculated by the Friedewald 
formula in 81 canine plasma samples. 
Plasma 
triglyceride 
(mmol/l) 
0.95 
0.66 
0.81 
2.34 
1.44 
1.66 
0.82 
2.16 
0.96 
0.49 
1.15 
5.92 
0.98 
0.55 
0.95 
0.43 
1.73 
0.57 
1.42 
0.40 
0.46 
1.35 
0.65 
0.90 
0.41 
Plasma 
cholesterol 
(mmol/l) 
11.36 
6.36 
10.28 
9.35 
7.93 
8.25 
9.23 
11.73 
7.19 
6.17 
9.08 
13.76 
9.10 
3.27 
4.47 
6.32 
7.58 
5.86 
6.65 
5.82 
7.82 
7.59 
7.57 
6.55 
6.01 
HDL-C 
(mmol/I) 
2.77 
2.68 
4.39 
4.91 
4.46 
3.79 
2.58 
2.43 
4.43 
2.40 
6.36 
5.19 
3.31 
1.89 
1.92 
2.71 
3.85 
1.03 
4.36 
1.60 
1.32 
1.02 
2.13 
3.46 
3.25 
Friedewald 
LDL-C LDL-C 
(mmol/l) (mmol/l) 
8.13 8.16 
3.03 3.38 
5.05 5.52 
4.24 3.38 
2.92 2.82 
3.36 3.71 
5.95 6.28 
7.37 8.32 
2.06 2.32 
2.85 3.55 
1.44 2.20 
5.86 5.88 
5.27 5.34 
0.61 1.13 
2.08 2.12 
3.52 3.41 
2.96 2.99 
3.99 4.57 
1.45 1.64 
3.59 4.04 
5.76 6.29 
6.11 5.96 
4.55 8.14 
2.55 2.68 
2.59 2.57 
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The LDL-cholesterol concentration measured by a combined 
ultracentrifugation/precipitation technique and calculated by the Friedewald 
formula in 81 canine plasma samples (continued). 
Plasma Plasma Friedewald 
triglyceride cholesterol HDL-C LDL-C LDL-C 
(mmol/l) (mmol/l) (mmol/l) (mmol/l) (mmol/l) 
0.34 5.34 3.69 1.00 1.50 
1.66 5.89 3.66 1.62 1.48 
0.83 6.67 4.41 1.72 1.88 
0.90 7.29 2.43 4.76 4.48 
0.56 5.60 3.27 1.56 1.59 
2.46 11.59 5.73 4.84 4.74 
0.52 7.00 4.18 2.03 2.58 
5.57 25.57 2.73 16.95 20.31 
3.70 37.85 2.15 29.43 29.47 
4.84 18.04 3.75 11.84 12.09 
1.41 11.53 2.30 8.60 8.59 
1.06 11.90 3.88 6.86 7.54 
2.81 17.67 1.65 13.85 14.74 
0.69 8.72 3.70 4.65 4.71 
0.47 6.89 2.46 3.66 4.22 
1.59 3.87 0.78 2.81 1.50 
0.42 6.97 2.86 3.62 3.43 
0.70 6.61 3.40 2.18 2.89 
0.82 15.02 2.73 11.50 11.92 
0.28 12.43 4.20 7.85 8.10 
0.72 10.55 4.78 5.30 5.44 
1.42 12.70 5.36 6.76 6.69 
0.68 9.69 5.31 3.43 4.07 
1.25 10.10 3.26 6.44 6.28 
1.57 8.76 4.73 3.63 3.32 
1.13 6.74 5.14 1.06 1.09 
1.97 6.30 3.02 1.59 2.40 
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APPENDIX 9 
Plasma Plasma Friedewald 
triglyceride cholesterol HDL-C LDL-C LDL-C 
(mmol/l) (mmol/l) (mmolj1) (mmoljl) (mmol/l) 
0.53 8.12 4.46 3.27 3.42 
0.60 7.91 3.73 2.97 3.91 
1.08 8.98 1.37 6.31 6.72 
0.40 4.20 1.83 2.08 2.19 
0.59 5.35 3.44 1.45 1.64 
0.85 5.83 3.69 1.57 1.74 
1.01 5.60 3.14 1.80 2.00 
0.56 3.99 2.47 1.10 1.27 
1.30 6.48 2.46 3.55 3.43 
0.50 3.20 2.19 0.42 0.78 
0.74 4.91 1.77 2.38 2.81 
0.63 4.34 1.95 2.34 2.10 
0.93 6.05 2.71 2.83 2.92 
0.68 3.51 1.24 1.82 1.96 
0.57 4.81 2.63 1.97 1.92 
0.54 3.99 1.87 1.55 1.87 
0.56 4.24 1.90 1.55 2.09 
0.44 2.95 1.98 0.72 0.77 
0.49 0.49 1.98 0.62 0.77 
0.49 0.49 2.12 0.73 0.63 
0.46 0.46 2.13 1.33 1.22 
0.45 0.45 1.99 0.94 0.98 
0.44 0.44 1.88 0.62 0.57 
0.47 0.47 2.16 0.48 0.55 
1.69 14.62 3.90 10.08 9.95 
4.86 9,80 3.62 4.33 3.26 
1.40 5.37 2.49 1.69 2.24 
1.59 8.51 2.78 5.57 5.01 
1.30 9.01 2.95 5.63 5.47 
APPENDIX 10 
The lipoprotein cholesterol concentration measured by an 
ultracentrifugation/precipitation technique and the relative distribution of 
plasma lipoproteins on agarose gel electrophoresis for 14 samples of canine 
jJiasma. 
Cholesterol concentration (mmol/l) 
Plasma VLDL LDL HDL 
3.52 0.34 0.53 2.65 
8.32 0.96 1.43 5.93 
7.21 0.25 1.51 5.45 
3.65 0.48 0.50 2.67 
2.95 0.45 0.24 2.26 
6.03 0.25 0.95 4.83 
7.50 0.85 1.74 4.91 
15.00 7.72 2.31 4.97 
4.73 0.15 1.14 3.28 
2.72 0.41 0.56 1.75 
4.20 0.47 0.87 2.86 
9.92 1.34 3.75 4.83 
4.00 0.60 0.43 2.97 
4.83 0.63 1.51 2.67 
electrophoretic distribution (%) 
pre-beta beta alpha 
3.32 17.79 72.79 
14.53 83.53 
25.01 66.25 
21.92 75.61 
14.96 81.80 
8.05 90.44 
20.39 78.40 
35.44 23.72 39.14 
40.76 36.54 
11.54 78.73 
12.58 86.64 
36.30 41.35 
29.85 70.15 
20.86 84.52 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs. 
Cholesterol concentration (mmol/l) 
Plasma VLDL LDL HDL 
Control 
4.20 0.29 2.08 1.83 
5.35 0.46 1.45 3.44 
5.83 0.57 1.57 3.69 
5.60 0.60 1.80 3.14 
3.99 0.42 1.10 2.47 
6.48 0.47 3.55 2.46 
3.10 1.00 0.69 1.31 
3.20 0.60 0.42 2.19 
4.91 0.76 2.38 1.77 
4.34 0.06 2.34 1.95 
6.05 0.51 2.83 2.71 
3.51 0.45 1.82 1.24 
4.81 0.21 1.97 2.63 
6.72 1.59 3.43 1.70 
7.00 1.17 3.78 2.05 
3.99 0.57 1.55 1.87 
4.24 0.79 1.55 1.90 
4.93 0.38 1.21 3.34 
3.77 0.18 1.25 2.34 
4.92 0.12 2.60 2.20 
2.95 0.25 0.72 1.98 
2.97 0.39 0.62 1.98 
2.97 0.05 0.73 2.12 
2.93 0.14 0.60 2.18 
3.56 0.08 1.33 2.13 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs (continued). 
Cholesterol concentration emmol/l) 
Plasma VLDL LDL HDL 
Control 
2.65 0.15 0.62 1.88 
2.92 0.27 0.48 2.16 
4.73 0.31 1.14 3.28 
7.00 0.79 2.03 4.18 
4.83 0.63 1.51 2.69 
4.24 0.79 1.55 1.90 
7.57 0.89 4.55 2.13 
6.01 0.96 2.44 2.61 
Obesity 
3.27 0.77 0.61 1.89 
4.47 0.47 2.08 1.92 
6.32 0.09 3.52 2.71 
7.58 0.82 2.03 4.70 
5.86 0.84 3.99 1.03 
6.65 0.84 1.45 4.36 
7.72 1.44 1.62 4.66 
5.74 0.50 1.41 3.83 
5.44 0.52 1.24 3.68 
7.23 1.10 1.94 4.17 
4.20 0.47 0.87 2.86 
3.35 0.41 0.78 2.16 
5.83 0.69 2.02 3.12 
7.50 0.85 1.74 4.91 
4.50 0.76 0.52 3.23 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs (continued). 
Cholesterol concentration (mmol/l) 
Plasma VLDL LDL HDL 
Obesity 
9.96 1.20 5.02 3.74 
9.49 0.36 2.91 6.22 
5.84 0.66 2.10 3.08 
4.81 0.50 0.98 3.33 
5.28 0.68 0.73 3.87 
Diabetes mellitus 
8.76 0.40 3.63 4.73 
6.74 0.54 1.06 5.14 
6.30 1.68 1.59 3.02 
14.62 0.64 10.08 3.90 
9.80 1.85 3.62 4.33 
17.77 8.30 7.32 2.08 
5.37 1.19 1.69 2.49 
9.15 0.50 4.52 4.13 
9.61 1.01 3.83 4.77 
7.01 2.01 1.47 3.53 
7.23 0.64 1.55 5.04 
Hyperadrenocorticism 
5.70 0.44 2.66 2.60 
11.36 0.46 8.13 2.77 
6.36 0.29 3.03 2.68 
10.28 0.64 5.25 4.39 
9.35 0.20 4.24 4.91 
7.93 0.55 2.92 4.46 
8.25 1.00 3.36 3.79 
9.23 0.70 5.95 2.58 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs (continued). 
Cholesterol concentration (mmoljl) 
Plasma VLDL LDL HDL 
Hyperadrenocorticism 
11.73 1.93 7.37 2.43 
7.19 0.70 2.06 4.43 
6.17 0.92 2.85 2.40 
9.18 1.28 1.44 6.36 
13.76 2.71 5.86 5.19 
7.62 0.33 2.82 4A7 
Hypothyroidism 
25.57 5.89 16.95 2.73 
6.71 OA3 3.07 3.21 
37.85 6.30 29A3 2.15 
18.04 1.82 11.84 3.75 
7.86 0.18 4.24 3.44 
10.93 0.63 8.60 2.03 
11.90 1.16 6.86 3.88 
14A1 0.92 9.60 3.89 
15.23 0.89 9.69 4.65 
11.47 1.16 5.13 4.18 
Protein-losing nephropathy 
9.69 0.95 3.43 5.31 
12A3 0.38 7.85 4.20 
10.5 0.47 1A5 4.36 
10.10 OAO 6.44 3.26 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs (continued). 
Cholesterol concentration (mmol/I) 
Plasma VLDL LDL HDL 
Hepatic disease 
8.71 1.16 2.30 5.25 
8.72 0.37 4.65 3.70 
6.89 0.28 3.66 3.14 
3.87 0.28 2.81 0.78 
6.97 0.49 3.62 2.86 
3.59 0.36 1.62 1.61 
Obstructive Jaundice 
15.02 0.79 11.50 2.73 
21.42 0.89 18.63 1.90 
Idiopathic Hyperlipidaemia 
7.82 0.74 5.76 1.32 
7.59 0.46 6.11 1.02 
7.57 1.59 4.55 2.13 
6.55 0.54 2.55 3.46 
6.67 0.54 1.72 4.41 
7.29 0.10 7.37 2.43 
11.59 1.02 4.84 5.73 
7.00 0.79 2.03 4.18 
10.82 1.70 3.20 5.92 
9.96 1.20 5.02 3.74 
9.10 0.52 5.27 3.31 
7.71 1.61 3.61 2.82 
7.23 1.10 1.93 4.17 
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APPENDIX 11 
Plasma cholesterol and lipoprotein cholesterol concentrations in control, obese 
and diseased dogs (continued). 
Cholesterol concentration (mmol/l) 
Plasma VLDL LDL HDL 
Idiopathic hyperlipidaemia 
7.00 0.09 3.78 2.05 
7.22 0.17 2.97 3.76 
6.70 0.82 2.20 3.68 
6.93 0.70 3.52 2.71 
7.72 1.44 1.62 4.66 
6.67 0.54 1.72 4.41 
18.02 5.32 10.38 1.62 
6.72 0.02 2.10 3.20 
6.65 0.84 1.45 4.36 
7.58 0.14 2.96 3.80 
8.81 0.86 3.79 4.16 
8.81 1.31 4.51 2.99 
7.50 0.85 1.74 4.91 
8.56 0.64 4.58 3.34 
9.49 0.36 2.90 6.22 
8.15 0.62 2.24 5.29 
8.49 0.99 2.11 5.39 
14.88 1.18 7.11 6.59 
16.48 3.96 10.23 2.29 
7.58 0.68 2.50 4.40 
8.08 0.42 2.66 5.00 
15.11 7.07 7.07 5.04 
171 
APPENDIX 12 
The plasma lipid and lipoprotein cholesterol concentrations of 13 obese dogs 
on initial presentation. 
Plasma Cholesterol concentration (mmol/l) 
triglyceride --------------------------------------------------------------
Case (mmoljl) Plasma VLDL LDL HDL 
1 0.81 5.44 0.52 1.24 3.68 
2 1.15 4.50 0.76 0.52 3.23 
3 1.93 7.23 1.10 1.96 4.17 
4 1.52 9.96 1.20 5.02 3.74 
5 0.54 4.20 0.47 0.87 2.86 
6 0.74 5.74 0.50 1.41 3.83 
7 1.10 5.83 0.69 2.02 3.12 
8 1.20 5.28 0.68 0.73 3.87 
9 1.00 3.35 0.41 0.78 2.16 
10 0.41 5.84 0.18 2.58 3.08 
11 0.56 9.49 0.36 2.91 6.22 
12 0.73 4.81 0.50 0.98 3.33 
13 1.16 7.50 0.85 1.74 4.91 
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APPENDIX 12 
The plasma lipid and lipoprotein cholesterol concentrations of 12 obese dogs 
after calorie restriction for six weeks. 
Plasma Cholesterol concentration (mmol/l) 
triglyceride -------------------------------------------------------------
Case (mmol/l) Plasma VLDL LDL HDL 
1 0.72 5.32 0.38 1.40 3.54 
2 0.77 4.92 0.62 0.40 3.90 
3 0.60 5.26 0.56 0.66 4.04 
4 0.88 7.55 0.71 1.87 4.97 
5 0.59 5.49 0.73 1.14 3.62 
6 0.69 5.24 0.39 1.24 3.41 
7 1.15 3.24 0.87 1.20 3.17 
8 0.63 5.57 0.28 1.60 3.69 
9 1.18 3.94 0.66 0.56 2.72 
10 0.52 5.76 0.23 1.43 4.10 
11 0.55 7.46 0.25 2.12 5.09 
12 1.50 4.46 0.45 0.85 3.16 
The plasma lipid and lipoprotein cholesterol concentrations of six adult beagle 
dogs. 
Plasma Cholesterol concentration (mmol/l) 
triglyceride --------------------------------------------------------------
Case (mmol/l) Plasma VLDL LDL HDL 
1915 0.44 7.21 0.25 1.51 5.45 
2108 0.42 3.19 0.16 0.43 2.60 
2132 0.68 3.52 0.34 0.53 2.65 
9022 n.d. 6.03 0.25 0.95 4.83 
3004 0.60 3.65 0.48 0.50 2.67 
2519 0.51 2.95 0.45 0.24 2.26 
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APPENDIX 13 
The body measurements and weight reduction performance of 13 obese dogs. 
Circumference (em) 
Weight % over % weight ------------------------------------
Case (kg) ideal reduction* Neck Girth Stifle 
1 42 24 63 49 90 37 
2 35 28 50 42 85 36 
3 23 18 40 73 
4 71 42 24 69 105 52 
5 38 23 7 49 88 44 
6 76 15 63 99 49 
7 38 27 0 50 87 38 
8 28 16 78 56 82 34 
9 13 33 17 36 64 26 
10 11 33 67 31 57 28 
11 12 46 46 31 63 24 
12 17 31 58 38 64 28 
13 22 22 40 71 34 
* weight loss expressed as a percentage of the target weight loss. 
APPENDIX 14 
The postheparin plasma lipolytic, lipoprotein lipase and hepatic lipase 
activities in 13 obese dogs and six beagle dogs. 
Case 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
1915 
2108 
9022 
2132 
2519 
2809 
PHP: Postheparin plasma. 
LPL: Lipoprotein lipase. 
HL: Hepatic lipase. 
Lipolytic activity (ILmolF AI ml/hr) 
PHP LPL HL 
6.83 1.41 5.42 
8.50 1.80 6.70 
12.39 9.11 3.28 
7.50 1.12 6.38 
8.64 4.84 3.80 
3.05 2.09 0.96 
7.05 4.93 2.12 
2.86 0.97 1.89 
7.27 1.21 6.06 
17.10 9.30 7.80 
28.14 17.24 10.90 
9.96 6.25 3.71 
10.74 6.21 4.53 
16.20 7.00 9.20 
15.80 8.10 7.70 
19.10 12.30 6.80 
19.00 12.50 6.50 
17.20 10.80 6.40 
18.60 13.70 4.90 
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APPENDIX 15 
The postheparin plasma lipolytic, lipoprotein lipase and hepatic lipase 
activities in S obese dogs after calorie restriction for six weeks. 
Case 
1 
2 
4 
5 
8 
10 
11 
12 
PHP: Postheparin plasma. 
LPL: Lipoprotein lipase. 
HL: Hepatic lipase. 
Lipolytic activity (,umolF A/ml/hr) 
PHP LPL HL 
13.80 5.70 8.10 
6.35 1.22 5.13 
6.92 2.17 4.75 
7.46 2.84 4.62 
5.72 1.34 4.38 
19.60 5.90 13.70 
10.43 6.21 4.22 
16.40 7.60 8.80 
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APPENDIX 16 
Plasma triglyceride concentration at serial time points after the intravenous 
administration of Intralipid* to 8 obese dogs before and after calorie 
restriction. 
Time (minutes) 
----------------------------------------------------------------------------------------
Case 0 5 10 20 30 40 90 120 
Before 
1 0.33 1.42 1.43 1.35 0.98 1.15 n.d. 0.14 
2 0.56 2.48 1.71 1.38 1.49 n.d. n.d. 0.88 
4 1.93 2.26 2.31 2.80 2.46 2.34 n.d. 1.96 
5 0.11 1.57 1.64 1.55 1.08 1.04 0.36 0.34 
7 0.83 2.17 1.71 1.77 1.53 n.d. 1.23 1.00 
8 0.17 1.08 0.84 0.84 0.49 0.41 0.28 0.18 
9 0.26 1.80 1.80 1.74 1.26 1.06 0.38 0.24 
12 0.27 1.16 0.93 0.71 0.44 0.31 0.28 0.23 
After 
1 0.24 1.34 1.25 1.08 0.94 0.69 0.23 0.23 
2 0.18 0.92 0.82 n.d. 0.64 0.61 0.33 0.24 
4 0.69 1.83 1.73 1.45 1.43 1.24 0.72 0.74 
5 0.43 1.51 1.39 1.34 1.41 1.18 0.72 0.56 
7 0.31 1.41 1.11 0.90 0.74 0.64 0.41 0.45 
8 0.23 0.94 0.59 0.28 0.13 0.16 0.23 0.20 
9 0.85 2.01 2.07 1.64 1.52 1.70 1.24 1.14 
12 0.41 1.17 0.91 0.94 0.85 0.72 0.25 0.18 
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APPENDIX 16 
Plasma triglyceride concentr2ltion at serial time points after the intravenous 
administration of Intralipid* to six beagle dogs. 
Time (minutes) 
----------------------------------------------------------------------------------------
Case 0 5 10 15 30 45 90 120 
2519 0.16 1.98 1.21 0.78 0.20 0.21 0.16 0.18 
1915 0.25 2.03 1.44 0.82 0.29 0.23 0.22 0.23 
2108 0.14 1.11 0.55 0.29 0.15 0.11 0.11 0.10 
3004 0.19 1.49 0.97 0.60 0.27 0.21 0.13 0.15 
2132 0.15 0.91 0.41 0.27 0.14 0.13 0.12 0.11 
9023 0.29 1.74 0.94 0.58 0.29 0.28 0.29 0.29 
The r2 value, AVC, AUMC and MRT for the triglyceride clearance curves of six 
beagle dogs. 
Case [2 AUC AUMC MRT 
(mmol.min/1) (mmol.min 2/1) (min) 
2519 0.91 27.63 281.7 10.19 
1915 0.85 33.44 267.6 8.00 
2108 1.00 14.68 101.9 6.94 
3004 0.74 24.07 207.8 8.63 
2132 0.99 10.60 69.3 6.53 
9023 1.00 21.14 147.4 6.97 
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APPENDIX 16 
The r2 value, AUC, AUMC and MRT for the triglyceride clearance curves of 
eight obese dogs before and after calorie restriction. 
Case r2 AUC AUMC MRT 
(mmol.min/l) (mmol.min 2/1) (min) 
Before 
1 0.68 104.10 2376.1 22.83 
2 0.68 115.80 7279.0 62.86 
4 0.02 41.26 1441.1 34.93 
5 0.95 101.09 5902.0 58.38 
7 0.89 82.04 3728.5 45.45 
8 0.95 34.24 1048.6 30.63 
9 0.81 80.74 2369.8 29.35 
12 0.91 19.52 311.13 15.94 
After 
1 0.96 44.98 1487.5 33.07 
2 0.91 42.70 1838.4 43.05 
4 0.62 51.24 1299.5 25.36 
5 0.88 78.07 3549.9 45.47 
7 0.95 40.45 1268.8 31.37 
8 0.97 11.55 79.2 6.86 
9 0.88 102.25 6920.3 67.68 
12 0.80 35.64 985.9 27.66 
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APPENDIX 16 
The intravenous fat tolerance test curves before and after calorie restriction in 
four obese dogs which lost weight. 
Triglyceride (mmol/I) Triglyceride (mmol/I) 
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1.6r-----------------------------------~ 3r------------------------------------, 
0.6 
0.4 
0.2 
o OL-----------------------------------~ 
o 10 20 30 40 50 60 70 80 90 100 110 120 0 10 20 30 40 50 60 70 80 90 100 110 120 
Time (minutes) Time (minutes) 
Triglyceride (mmol/l) Triglyceride (mmol/l) 
1.2r-----------------------------------~ 1.4 ~------------------------------~ 
O. 
0.2 
OL-----------------------------------~ 
o 10 20 30 40 50 60 70 80 90 1 00 110 120 
oL-------------------------------~ 
o 1 0 20 30 40 50 60 70 80 90 1 00 11 0 1 20 
Time (minutes) Time (minutes) 
~Before 
+ After 
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APPENDIX 16 
The intravenous fat tolerance test curves before and after calorie restriction in 
four 0 bese dogs which lost minimal quantities of weight. 
Triglyceride (mmol/I) Triglyceride (mmol/I) 
3r-------------------------------------~ 2r---------------------------------, 
2.5 
0.5 - - - .. - . - - - - -
0.5 
o~------------------------------------~ oL-----------------------------------~ 
o 10 20 30 40 50 60 70 80 90 100 110 120 o 10 20 30 40 50 60 70 80 90 100 110 120 
Time (minutes) Time (minutes) 
Triglyceride (mmol/I) Triglyceride (mmol/I) 
2.5,-----------------------------------~ 2.5 r------------------------------------, 
2 
0.5 -- 0.5 -
oL------------------------------------- oL-------------------------------__ 
o 1 0 20 30 40 50 60 70 80 90 100 110 120 o 10 20 30 40 50 60 70 80 90 100 110 120 
Time (minutes) Time (minutes) 
-Before 
+ After 
APPENDIX 17 
Pharmacokinetic analysis and terms. 
The Fortran IV curve stripping programme generates up to 3 y-axis intercepts 
(AI, A2 and A3) and exponents (Bl, B2 and B3) (first to last) for the equations 
best describing the data. The area under the plasma concentration versus time 
curve for observed values (AUCobs), in mmol.min/l, from time 0 to infinity was 
determined for observed concentrations using the trapezoidal rule. The area of 
the triangle between time 0 and the first sample was calculated by taking the 
average of the CpO and the first observed concentration multiplied by the first 
time point, and the area of the triangle between the last sample and 0 
concentration was calculated by dividing the final concentration with the 
terminal slope, Bl. The area under the first moment curve for observed values 
(AUMC obs) from time 0 to infinity, i.e. the plasma concentration time versus 
time curve in mmol.min 2/1, and the area between time 0 and the first sample 
were calculated in a similar fashion. The area (AUMC) of the triangle between 
the last sample and concentration 0 was calculated using the product of time 
and the last plasma concentration divided by Bl. 
AUC 
AUMC 
Cmax 
Total area under the triglyceride concentration versus time or zero 
moment curve (mmol.min/l) from time 0 to time infinity 
calculated using the trapezoidal rule. 
Total area under the triglyceride concentration time versus time or 
first moment curve (mmol.min2/l) from time 0 to time infinity 
calculated using the trapezoidal rule. 
Maximum plasma triglyceride concentration following Intralipid * 
administration. 
CpO Initial concentration of triglyceride in plasma following 
administration of an intravenous bolus of Intralipid * . 
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APPENDIX 18 
Postheparin plasma lipolytic, lipoprotein lipase and hepatic lipase activity in 
dogs with diabetes mellitus and hypothyroidism. 
Lipolytic activity (fLmolFA/mljhr) 
Case PHP LPL 
Hypothyroidism 
1 6.49 2.47 
2 4.59 2.92 
3 4.64 3.09 
4 3.78 1.78 
5 6.30 5.73 
Hyothyroidisim (after therapy) 
1 15.60 
4 11.20 
Diabetes mellitus 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
PHP: Postheparin plasma. 
LPL: Lipoprotein lipase. 
HL: Hepatic lipase. 
29.40 
16.43 
22.96 
17.60 
19.08 
17.37 
13.34 
26.86 
20.44 
40.46 
5.90 
4.42 
18.50 
8.47 
12.75 
6.41 
5.43 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
HL 
4.02 
1.67 
1.55 
2.00 
0.57 
13.70 
6.78 
10.90 
7.96 
10.21 
11.19 
13.65 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
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APPENDIX 19 
Plasma lipid and lipoprotein concentrations in 16 dogs. 
Case 112714 
Tibetan terrier, 5.5 years, iemale (N), diabetes mellitus and 
hypothyroidism. 
Biochemical parameters: 
Cholesterol 17.51 mmo/l 
Trigyceride 14.15" 
VLDL-C 
LDL-C 
HDL-C 
Amylase 
Case 122074 
8.41 
6.97 
2.13 
5294 
" 
" 
" 
IU/I 
Golden retriever, 12 years, female (N). 
Biochemical parameters: 
Cholesterol 14.88 mmo/l 
Triglyceride 4.37 " 
VLDL-C 1.18" 
LDL-C 7.11 " 
HDL-C 6.59 " 
Amylase > 3000 IU/l 
Lipase > 1000 IU/l 
Case 119993 
X-bred, 7 years, male(N). 
Biochemical parameters: 
Cholesterol 16.48 mmo/l 
Triglyceride 39.00" 
VLDL-C 3.96 II 
LDL-C 
HDL-C 
Amylase 
Lipase 
10.23 " 
2.29 " 
2763 IU/I 
308 IU/I 
184 
APPENDIX 19 
Plasma lipid and lipoprotein concentrations in 16 dogs (continued). 
Case 120360 
Yorkshire terrier, 8 years, female (N). 
Biochemical parameters: 
Cholesterol 6.23 mmo /1 
Triglyceride 11.30" 
Amylase 1860 IU /1 
Lipase 480 IU /1 
Case 116313 
Cocker spaniel, 3 years, female. 
Biochemical parameters (24.10.91): 
Cholesterol 7.13 mmo/l 
Triglyceride 0.74" 
VLDL-C 0.08 II 
LDL-C 
HDL-C 
Case 112876 
2.71 
3.69 
" 
" 
Dobermann, 8 years, male, hypothyroidism. 
Biochemical parameters: 
Cholesterol 17.67 mmo/l 
Triglyceride 2.61" 
VLDL-C 2.17 11 
LDL-C 
HDL-C 
13.85 
1.65 
" 
" 
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Plasma lipid and lipoprotein concentrations in 16 dogs (continued). 
Case 114522 
Whippet, 9 years, male, hy~othyroidism. 
Biochemical parameters: 
Cholesterol 47.80 mmoll 
Triglyceride 5.60" 
VLDL-C 22.31" 
LDL-C 23.74" 
HDL-C 1.75 " 
Case 1 
Golden retriever, 10 years, female. 
Biochemical parameters: 
Cholesterol 14.41 mmoll 
Triglyceride 2.04 11 
VLDL-C 0.92" 
LDL-C 9.60 11 
HDL-C 3.89 " 
Case 2 
German shepherd dog, 3 years, female (N). 
Biochemical parameters: 
Cholesterol 5.13 mmoll 
Triglyceride 0.60" 
VLDL-C 0.51" 
LDL-C 1.99" 
HDL-C 2.63 " 
APPENDIX 19 
Plasma lipid and lipoprotein concentrations in 16 dogs (continued). 
Case 3 
Case 4 
Case 5 
German shepherd dog, 7 years, female. 
Biochemical parameters: 
Cholesterol 5.88 mmoll 
Triglyceride 0.90 II 
VLDL-C 0.85 II 
LDL-C 2.20" 
HDL-C 2.83" 
German shepherd dog, 3 years, female. 
Biochemical parameters: 
Cholesterol 4.37 mmoll 
Triglyceride 0.99" 
VLDL-C 0.59 II 
LDL-C 
HDL-C 
1.42 
2.36 
" 
" 
Rottweiller, 3 years, female. 
Biochemical parameters: 
Cholesterol 11.35 mmo II 
Triglyceride 1.20" 
VLDL-C 1.05" 
LDL-C 
HDL-C 
4.81 
5.49 
" 
" 
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Plasma lipid and lipoprotein concentrations in 16 dogs (continued). 
Case 6 
Case 7 
Case 8 
X-bred, 3 years, female. 
Biochemical parameters: 
Cholesterol 6.93 mmo /1 
Triglyceride 0.83 11 
VLDL-C 0.73 It 
LDL-C 1.99 11 
HDL-C 4.21 11 
X collie, 7 years, female. 
Biochemical parameters: 
Cholesterol 8.15 mmo /1 
Triglyceride 0.76 11 
VLDL-C 0.65 11 
LDL-C 
HDL-C 
2.84 
4.66 
11 
" 
Labrador retriever, 3 years, female. 
Biochemical parameters: 
Cholesterol 6.16 mmo/l 
Triglyceride 1.84" 
VLDL-C 1.51 II 
LDL-C 
HDL-C 
1.20 
3.45 
11 
11 
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Plasma lipid and lipoprotein concentrations in 16 dogs (continued). 
Case 9 
Alaskan Malamute, 5 yean.., female. 
Biochemical parameters: 
Cholesterol 6.16 mmo/l 
Triglyceride 1.84 11 
VLDL-C 1.51" 
LDL-C 
HDL-C 
1.20 
3.45 
11 
11 
Case 120848 
Cavalier King Charles spaniel, 9 years, male. 
Biochemical parameters: 
Cholesterol 15.11 mmo/l 
Triglyceride 2.46 11 
VLDL-C 0.58" 
LDL-C 
HDL-C 
9.49 
5.04 
11 
11 
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APPENDIX 20 
The plasma lipid and lipoprotein concentrations and hepatic enzyme activities 
of 20 dogs with idiopathic hyperlipidaemia. 
Plasma Cholesterol concentration (mmol/l) 
triglyceride -------------------------------------------------------------
Case (mmol/l) Plasma VLDL LDL HDL 
1 1.52 9.96 1.20 5.02 3.74 
2 0.88 7.71 1.61 3.61 2.82 
3 1.93 7.23 1.10 1.93 4.17 
4 0.68 7.00 0.09 3.78 2.05 
5 0.50 6.70 0.82 2.20 3.68 
6 0.43 6.93 0.09 3.52 2.71 
7 2.34 7.72 1.44 1.62 4.66 
8 0.83 6.67 0.54 1.72 4.41 
9 n.d. 18.02 5.32 10.38 1.62 
10 n.d. 6.72 0.02 2.10 3.20 
11 1.42 6.65 0.84 1.45 4.36 
12 1.73 7.58 0.14 2.96 3.80 
13 0.34 8.81 0.86 3.79 4.16 
14 n.d. 8.81 1.31 4.51 2.99 
15 0.56 9.49 0.36 2.91 6.22 
16 0.78 8.15 0.62 2.24 5.29 
17 1.55 8.49 0.99 2.11 5.39 
18 39.00 16.48 3.96 10.23 2.29 
19 2.46 15.11 0.58 7.07 5.04 
20 4.37 14.88 1.18 7.11 6.59 
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The plasma lipid and lipoprotein concentrations and hepatic enzyme activities 
of 20 dogs with idiopathic hyperlipidaemia. 
Case No. ALP AST ALT 
1 966 23 33 
2 78 19 24 
3 64 24 37 
4 154 31 72 
5 49 29 68 
6 168 29 37 
7 277 18 21 
8 109 14 76 
9 409 77 135 
10 132 81 50 
11 448 18 23 
12 1130 11 40 
13 55 28 23 
14 67 20 30 
15 60 31 22 
16 480 12 104 
17 892 21 48 
18 1289 16 98 
19 356 106 53 
20 901 28 52 
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The plasma lipid concentrations before and after dietary fat restriction in 10 
dogs. 
Cholesterol (mmol/l) Triglyceride (mmol/l) 
Before After Before After 
8.41 3.99 0.59 0.75 
11.44 5.78 10.83 1.96 
17.51 15.14 17.20 23.57 
11.35 9.35 1.20 1.15 
14.88 11.67 4.37 1.16 
6.23 4.49 11.30 6.77 
16.13 15.38 2.62 2.13 
7.23 5.26 1.93 0.60 
9.96 7.55 1.52 0.88 
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apo 
ACAT 
ALP 
ALT 
AST 
(3 
CETP 
Ci 
cm 
cpm 
Da 
EDTA 
FA 
g 
h 
HDL 
HDL-C 
HL 
IDL 
kg 
I 
LCAT 
LDL 
LDL-C 
LPL 
mg 
mIll 
ml 
mM 
mmol 
Mr 
N 
n.d. 
NEFA 
n.s. 
GLOSSARY 
alpha 
apolipoprotein 
acyl coA cholesterol acyl transferase 
alkaline phosphatase 
alanine aminotransferase 
aspartate aminotransferase 
beta 
cholesteryl ester transfer protein 
curie 
centimetre 
counts per minute 
Dalton 
ethylenediaminetetra-acetate 
fatty acids 
gram 
hour 
high density lipoprotein(s) 
high density lipoprotein cholesterol 
hepatic lipase 
intermediate density lipoprotein( s) 
kilogram 
litre 
lecithin:cholesterol acyl transferase 
low density lipoprotein(s) 
low density lipoprotein cholesterol 
lipoprotein lipase 
milligram 
minute 
millilitre 
millimolar 
millimole 
relative molecular mass 
normality 
not determined 
non-esterified fatty acids 
not significant 
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PVS 
PHP 
Rf 
rpm 
sd 
SDS 
SDSPAGE 
TEMED 
ILl 
VLDL 
VLDL-C 
GLOSSARY 
polyvinylsulphate 
postheparin plasma 
relative band speed 
revolutions per minute 
standard deviation 
sodium dodecyl sulphate 
sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
N,N,N',N',-tetramethylethylenediamine 
microlitre 
very low density lipoprotein(s) 
very low density lipoprotein cholesterol 
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